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The link between mind and biology is intuitively known: We notice changes in our mood and 
behavior when hungry, in pain, or under the influence of substances. Yet, the specifics of this 
link—for example, how changes in biology affect directly apprehended conscious experience—
are not well known. The present study was an exploratory attempt toward filling that gap by 
using a state-of-the-art, beeper-driven method for exploring directly apprehended conscious 
experience (Descriptive Experience Sampling; DES) across one of the most predictable and well-
known biological cycles: menstruation. We screened approximately 300 college women to 
identify those who reported clinically significant symptoms of premenstrual distress but were 
otherwise generally healthy, and ultimately engaged five of those women in approximately 20 
days each of DES sampling. Menstrual cycle status was tracked using an at-home ovulation 
microscope test kit, and sampling days were distributed across each participant’s menstrual 
cycle, thereby allowing for experiential changes across cycle phases (if any) to emerge. All DES 
sampling and the review, captioning, and coding of samples was completed largely blind to the 
menstrual cycle phase associated with the samples. Then, sampling days were separated by 
menstrual cycle phase to explore any differences in experience across cycle phases. All five 
participants showed some experiential differences (some subtle, some obvious) across cycle 
phases. For all but one of the participants, experiences differed primarily around the time of 
ovulation, an important finding given that the literature on premenstrual distress assumes that the 
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 The link between mind and biology is well-known in modern psychology and commonly 
championed in modern psychotherapies. For example, the mental practice of mindfulness has 
been found to impact the processes of inflammation and aging (Fountain-Zaragoza & Prakash, 
2017; Laneri et al., 2016). The link between mind and biology is also intuitively known: We 
notice changes in our mood and behavior when hungry, in pain, or under the influence of 
substances. Yet, the specifics of this link—the directly apprehended conscious experiences 
corresponding to biological states and fluctuations—have arguably been explored more often in 
psychedelic memoirs than in systematic psychological research. This study took a step toward 
filling that gap in psychology’s understanding. To study experience, we used a state-of-the-art 
method for exploring directly apprehended conscious experience—Descriptive Experience 
Sampling (DES). To provide access to variations in biological state, we took advantage of one of 
the most predictable and well-known biological cycles: the hormonal changes surrounding 
menstruation. Our interest was in exploring whether there were changes in experience 
corresponding to changes in biological (hormonal) state. That is, our interest was not particularly 
in exploring the nature of premenstrual distress. However, we focused specifically on women 
who reported premenstrual distress because if premenstrual distress is caused largely by 
menstrual cycle-related changes in biology, as is generally accepted, it seemed likely that the 
inner experiences of such women would be sensitive to biological fluctuations.     
The idea that women can experience physical and psychological changes in accord with 
their menstrual cycles dates back at least to Hippocrates (460 B.C. – 370 B.C.), who observed 
that “the blood of females is subject to intermittent ‘agitation’…” (quoted in Malik & Bhat, 
2016, p. 17). We now know that as many as 80-85% (di Scalea & Pearlstein, 2017; Pearlstein & 
2 
 
Steiner, 2008) of women notice physical (breast tenderness, bloating, headaches, muscle, or joint 
pain), mood (lability, irritability, depression, and anxiety), and/or behavior changes (decreased 
interest in typically enjoyable activities, difficulty concentrating, low energy, changes in appetite 
or food cravings, and insomnia or hypersomnia) in the week or so before menses (Epperson & 
Hantsoo, 2014). [Hereafter, the “week or so before menses” will be referred to as the “late 
luteal” or “premenstrual” phase as is consistent with the literature in this area]. A subset of 
women notice these symptoms begin around the time of ovulation (Yonkers et al., 2008). Most 
women are not clinically distressed by the cycle-related changes in their mood, body, and 
behavior; however, 20 to 25% do experience distress, at which point the condition is known 
broadly as premenstrual syndrome or “PMS” (Pearlstein & Steiner, 2008). An even smaller 
subset, approximately 5-8% of women, experience symptoms so severe and impairing as to meet 
diagnostic criteria for premenstrual dysphoric disorder (PMDD; Angst et al., 2001; APA, 2013; 
Wittchen et al., 2002). PMDD can be considered a severe and restrictive form of PMS.  
The earliest diagnostic categorization of PMDD, called then “late luteal phase dysphoric 
disorder,” appeared in the appendix of the third edition of the Diagnostic and Statistical Manual 
for Mental Disorders (DSM-III; APA, 1980). The category was renamed PMDD in the fourth 
edition of the DSM (DSM-IV; APA, 1994) but was still relegated to the appendix pending more 
careful research. PMDD was officially adopted as a diagnosis within the Depressive Disorders 
section of the fifth (and most recent) edition of the DSM (DSM-5; APA, 2013). A diagnosis of 
PMDD requires that, for the majority of menstrual cycles, there be at least five of eleven total 
symptoms present in the final week before the onset of menses and that those symptoms start to 
improve within a few days after the onset of menses such that they are minimal or absent in the 
week post menses (APA, 2013, p. 171). At least one of the five symptoms must be one of the 
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four core mood symptoms of PMDD: (1) marked affective lability; (2) marked irritability or 
anger or increased interpersonal conflicts; (3) marked depressed mood, feelings of hopelessness, 
or self-deprecating thoughts; and (4) marked anxiety, tension, and/or feelings of being keyed up 
or on edge. Additionally, the symptoms must be associated with “clinically significant distress or 
interference” in one or more domains of daily functioning (e.g., work, school, social activities, or 
interpersonal relationships) (APA, 2013, pp. 171-2). Finally, the DSM-5 requires that a diagnosis 
of PMDD be confirmed by “prospective daily ratings” (i.e., filling out daily questionnaires/scales 
of symptoms) during at least two symptomatic cycles. 
The exact etiology of PMDD is unknown; however, research has long pointed to sex 
hormones as a major factor. Two key hormones, estrogen and progesterone, rise and fall 
predictably during the menstrual cycle: Estrogen levels increase early in the cycle (between 
menses and ovulation), peaking at ovulation to prepare the uterus to accept a fertilized egg, and 
then rise and decline rapidly in the second half of the cycle if pregnancy does not occur. 
Progesterone levels increase only later in the cycle (following ovulation) and then decline rapidly 
if pregnancy does not occur (see Marshall, 2016 for an overview of the menstrual cycle).  
Given that PMDD occurs only in women in their reproductive years, ovarian sex 
hormones have long been suspected in the etiology of PMDD (Rapkin & Mikacich, 2013). 
Halbreich (2003) showed that ovulation processes trigger the onset of PMS symptoms and 
Schmidt et al. (1998) showed that PMS symptoms recur with the reintroduction of estradiol (the 
predominant naturally occurring form of estrogen) and progesterone.  
Direct evidence for the link between sex hormones and premenstrual symptoms has 
emerged in the last several years. In a landmark finding, Schmidt et al. (2017) showed that 
women with PMDD have an atypical reaction to changes in sex hormone levels by comparison 
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to women without PMDD. They found that the onset of premenstrual symptoms was due not to 
an excess or deficit in the absolute levels of sex hormones but rather to a reaction to changes in 
the levels of sex hormones.  
The progesterone metabolite allopregnanolone (ALLO) has been at the center of the 
recent research in this area; findings suggest that women with PMDD have an abnormal response 
to changes in ALLO levels (Timby et al., 2016; Yonkers & Simoni, 2018) and that blocking 
ALLO production reduces premenstrual symptoms (Schmidt et al., 1991; Chan et al., 1994). 
ALLO is a neurosteroid that is synthesized from progesterone in the brain, ovary, and adrenal 
glands. It acts upon the GABAA receptor—the major inhibitory system of the central nervous 
system—which is usually associated with calming effects, but, in women with PMS/PMDD, can 
trigger a severe mood response when at high levels such as in the luteal phase of the menstrual 
cycle (Placzek, 2016).  
In sum, it is well-accepted that, for women with premenstrual distress or PMDD, 
psychological and behavioral symptoms (e.g., affective lability, irritability, interpersonal 
conflicts, hopelessness) are associated with, and probably in some way caused by, cycle-related 
changes in biology (especially, in hormones). It would be clinically and theoretically useful to 
understand the details of that psychological/behavioral/hormonal association. However, the 
psychological/behavioral symptoms are generally cumulative aggregates rather than particular 
experiences, making exploration of symptom/hormone link difficult if not impossible. For 
example, “interpersonal conflicts” are not caused directly by hormonal shifts but by some not-
well-understood combination of potentially important but diverse variables such as interpersonal 
history, perceptual narrowing, skin tenderness, altered focus on hopes and expectations, fatigue, 
and so on. Linking such an agglomeration (which importantly spans previous months and years 
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and future months and years) to a hormonal shift whose time scale is measured in minutes or 
hours presents perhaps substantial—perhaps insurmountable—challenges. 
It therefore might be useful to examine psychological events that occur at precisely 
definable moments, that is, to investigate what Hurlburt (2011; Hurlburt & Akhter, 2006) has 
called “pristine inner experience.” Pristine inner experience refers to directly apprehended 
conscious experiences—thoughts, feelings, images, sensations, and so on—as they are in their 
natural state, disturbed as minimally as possible by the act of introspection or experimentation. 
Here is an example from a previous study by Hurlburt and colleagues of what is meant by 
pristine inner experience:  
Ashley (not her real name) is watching a sad video. Her chest feels tight in a circular-
shaped region, about palm-sized on her upper chest/sternum area. Separately but 
simultaneously, she feels pressure and warmth inside the bridge of her nose just between 
her eyes as if she is about to cry.  
In the interview to discuss this sample of experience, Ashley acknowledged that this was a sad 
moment (spawned by the video) and, had someone interrupted her watching the video to ask, 
“How’s your mood right now?” she likely would have answered, “sad.” “How’s your mood right 
now?” typifies the way PMDD research typically proceeds—a focus on aggregate experiences 
that involve not-well-understood combinations of variables. In contrast, the video-watching 
example above is of a particular moment of Ashley’s experience. In this example, her experience 
was not of feeling sad; it was of two separate but simultaneous bodily sensations; she felt her 
chest tight and warm pressure between her eyes. Those bodily sensations, directly apprehended 
“before-the-footlights” (James, 1890) of Ashley’s naturally evolving consciousness, are an 
example of what is meant by “pristine inner experience.” 
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To date, most studies that have examined the phenomenology of PMS and PMDD have 
done so using self-report symptom rating scales. For example, the widely used Daily Record of 
Severity of Problems (DRSP; Endicott et al., 2006) asks respondents to rate on a scale from 1 
(Not at all) to 6 (Extreme) the degree to which they “felt anxious, tense, ‘keyed up,’ or ‘on 
edge,’” “felt out of control,” and “had mood swings (e.g., suddenly felt sad or tearful)” 
throughout the day. Whereas such questions might seem on their face to inquire about pristine 
inner experience, they very likely do not do so (Hurlburt & Heavey, 2015). Because people 
generally do not know well the characteristics of their inner experience (Hurlburt et al., in press; 
Hurlburt 2011), they often conflate their actual experience with presuppositions (assumptions, 
worldviews, self-theories, self-presentations biases, and other heuristics that skew, suppress, or 
exaggerate observations; Hurlburt, 2011) about their experience. Therefore, Hurlburt and Heavey 
(2015) argued, responses on a symptom rating scale likely do not reflect one’s genuine 
experience but rather, presuppositions about one’s experience. Indeed, McFarland et al. (1989) 
found that a woman’s theory of her menstrual cycle symptoms influenced her recall of 
symptoms, such that the more a woman believed in the phenomenon of menstrual distress, the 
more she reported, in recall, the negativity of symptoms during her last cycle. 
Moreover, though prospective daily reports are preferred and now required for diagnosis 
(APA, 2013), an estimated 90% of researchers continue to use retrospective rating scales 
(Eisenlohr-Moul et al., 2017), which ask a woman to reflect over her last one, two, three, or more 
menstrual cycles. Even “prospective” daily rating scales require respondents to reflect over, 
potentially, 24 hours, which is a substantial and probably impossible demand. Any level of 
retrospection renders the results susceptible to memory errors, faulty recall, and false positives 
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(Craner et al., 2014), and even if minimal (i.e., daily report) retrospection were successful, 
averaging over 24 hours may well mask important shorter-duration psychological events.  
The present study examined the inner experience of women who self-reported clinically 
significant PMDD symptoms across their menstrual cycles using a method, Descriptive 
Experience Sampling (DES; Hurlburt, 1990, 1993, 2011; Hurlburt & Heavey, 2006), that 
attempts to overcome these and other shortcomings of self-report rating scales. DES aims to 
capture and describe pristine inner experience in high fidelity. Briefly, DES participants wear a 
random-interval beeper while going about their everyday activities. When the beeper sounds, 
their sole task is to grasp whatever was ongoing in experience at the “microsecond before,” or 
was “ongoing at” the onset of the beep or was “at the moment of the beep” (all are equivalent 
metaphors for the experience to be examined; Hurlburt & Heavey, 2006), and immediately to jot 
down notes about that experience. Then, within 24 hours, the participant meets with a team of 
DES investigators for an “expositional interview” during which all parties work collaboratively 
to arrive at a high-fidelity apprehension of each beeped experience. This sampling-interview 
procedure is repeated over several sampling days with the goals (a) of iteratively building the 
participant’s skill in apprehending and describing experience and (b) of collecting and describing 
samples of experience. Decades of DES research has shown that, using random, natural-
environment sampling, one can arrive at a high-fidelity ‘sketch’ of a person’s characteristic inner 
experience. The present study attempted to capitalize on this fidelity: If experience is closely tied 
to some biological events (such as a change in hormone levels), then strategic DES sampling 
across the phases of the menstrual cycle might illuminate experiential patterns associated with 
those biological changes. 
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Participants were college-aged women from a large urban university. We screened more 
than 300 women to identify those who self-reported significant premenstrual symptoms and who 
were otherwise generally healthy. Eligible women were invited to participate in DES sampling 
across at least two and preferably three or more menstrual cycles. We aimed for a targeted eight 
sampling days per cycle, therefore, a total of 24 sampling days across three cycles. Due to the 
time intensive nature of the procedure (several dozen hours of wearing the beeper plus 24 hour-
long, face-to-face interviews for each participant), our target sample was between six and eight 
women; ultimately, five women completed the study. This sample size is small but typical of 
other qualitative research studies, especially those with an idiographic aim (Rennie, 2012; 
Robinson, 2014).  
To explore whether experience-level changes accompany the biological fluctuations of 
the menstrual cycle, we ensured that DES sampling occurred across all phases of the menstrual 
cycle, with care taken to sample most frequently at times of rapid biological (hormonal) change. 
The progesterone withdrawal and high levels of ALLO of the late luteal/premenstrual phase have 
historically garnered the most research attention (hence, Premenstrual Dysphoric Disorder); 
however, we were equally, if not more, interested in inner experience that might occur along 
with the rapid estrogen spike that accompanies ovulation (but which has garnered surprisingly 
little attention from PMS/PMDD researchers). Therefore, when possible, we increased the 
“density” of DES sampling around times where we could (cautiously) infer such biological 
changes were occurring. To identify menstrual cycle phases and the key moment of ovulation, 
we needed to monitor each participant’s menstrual cycle. We did so using daily at-home saliva 
ovulation test kits. These test kits have been shown to detect ovulation with approximately 
93.3% accuracy (95% Confidence Interval = 85.5 to 99.9; Melnick & Goudas, 2015), which is 
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important for the present study given that the ovulation window is short (1-2 days 
conservatively) and that we wanted to schedule DES sampling during each ovulatory phase to 
capture an adequate sample of experiences during ovulation.  
Ultimately, the present study resulted in idiographic characterizations of the pristine inner 
experience of five women with significant premenstrual distress. As is typical of DES studies, 
the salient phenomena of each woman’s experience were described in detail; however, for this 
study, we paid special attention to how those phenomena and/or other experiential characteristics 
might differ across menstrual cycle phases. Perhaps experience in the traditionally symptomatic 
(late luteal/premenstrual) phase would differ from experience in the other phases; perhaps 
experience when hormone levels were changing most rapidly (ovulation) would differ from 




Chapter 2: Review of Literature 
Overview of the Menstrual Cycle 
The menstrual cycle refers to the female body’s cyclic pattern of reproductive function. It 
begins at a menarche, a woman’s first menses, typically around ages 12 and 13 (Campbell et al., 
2013), and lasts until menopause, or the cessation of menstruation, which typically begins 
between ages 45 and 55 (National Institute on Aging, 2017). The absence of menstruation is 
known as amenorrhea, which can occur naturally, such as during pregnancy or breastfeeding, or 
can be a sign of another health problem, such as a genetic abnormality or dysfunction of the 
hypothalamus. Hypothalamic amenorrhea can be caused by excessive exercise, anorexia nervosa, 
extreme stress, or as a medication side effect (Hormone Health Network, 2011).  
The typical female menstrual cycle lasts approximately 28 days with most cycle lengths 
between 25 and 30 days (Reed & Carr, 2018). A given menstrual cycle begins (“day 1”) on the 
first day of menses, or menstrual bleeding, and ends on the first day of menses of the next cycle. 
The menstrual cycle is typically divided into three phases: follicular phase (approximately days 
1-14), ovulation (approximately day 14), and luteal phase (approximately days 14-28). Ovulation 
and the luteal phase are typically relatively constant in duration; therefore, variability in cycle 
length is usually due to varying lengths of the follicular phase. Each phase is marked by 
predictable changes in pituitary hormones (FSH and LH) and ovarian hormones (progesterone 
and estrogen), which are depicted in Figure 1. Note especially the red line (“estradiol,” the 







Hormonal fluctuations across the menstrual cycle 
 





The follicular phase begins on day 1 of the cycle and lasts until ovulation. As we have 
seen, day 1 of the menstrual cycle is the onset of menstruation, or the sloughing of degraded 
endometrial tissue (the tissue lining the uterus) in the form of menstrual fluid. Menstrual fluid 
flow typically lasts between four and six days but can range from as few as two to as many as 
eight days (Reed & Carr, 2018).  
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The key event of the follicular phase is the preparation of a dominant ovarian follicle that 
will release an ovum (egg) at ovulation. During menstruation (approximately days 1 through 4), 
an increase in levels of follicle-stimulating hormone (FSH) leads to recruitment of a group of 
ovarian follicles. Then, between days five and seven of the cycle, one follicle is selected from 
among that group; this follicle will release an egg (ovulate) whereas the others will degenerate. 
By day eight of the cycle, one follicle will be established as the dominant follicle and will 
promote its own growth while suppressing the growth and maturation of all other ovarian 
follicles (Reed & Carr, 2018). 
During the follicular phase, estrogen (a female sex hormone) levels rise in parallel to the 
size of the maturing follicle (Reed & Carr, 2018), eventually resulting in peak levels of estrogen 
near the end of the follicular phase (just before ovulation). Three forms of estrogen are produced 
by the ovary: estradiol, estrone, and estriol. Of the three, estradiol is the most predominant and 
has been the subject of the most research regarding hormones and mood (Amin et al., 2005). 
Rising estrogen during this phase also causes a thickening of the uterine lining which creates a 
hospitable environment for the egg to implant (Epperson & Hantsoo, 2014).  
Ovulation 
At approximately day 14 of the cycle, ovulation occurs. Ovulation is triggered by rising 
levels of FSH and luteinizing hormone (LH). Both hormones are secreted by the pituitary gland, 
which cause the dominant follicle to release an egg. An “LH surge” begins approximately 34 to 
36 hours prior to ovulation, and ovulation occurs approximately 10-12 hours after LH reaches its 
peak. The LH surge, therefore, is a relatively precise predictor of ovulation (Reed & Carr, 2018). 




Ovulation is the fertile phase, the most likely opportunity for fertilization if intercourse 
occurs. The “fertile window” has generally been considered to include the five days before 
ovulation and the day of ovulation itself or, more broadly, days 10 through 17 of the cycle 
(Beckmann et al., 1998), though Wilcox and colleagues (2000) argued that such guidelines are 
“outdated” given that timing of the fertile window is highly variable, even among women who 
report regular menstrual cycles (p. 1260). Anovulation, or the failure to ovulate, can result from 
normal processes, such as aging and lifestyle factors, or another medical condition, such as 
ovarian and gynecological conditions and endocrine disorders (Jose-Miller et al., 2007).  
The ovulatory period may be a time of mood change. For example, a subset of women 
notices premenstrual distress symptoms begin around the time of ovulation as opposed to the 
more common report that symptoms begin the week or so before a menstrual period (Yonkers et 
al., 2008). Conversely, Rebollar and colleagues (2017) showed that, compared to women using 
hormonal contraceptives, naturally cycling women who were not using hormonal contraceptives 
reported significantly higher positive affect corresponding to the LH surge that precedes 
ovulation.  
Given its relevance for reproduction and that it is the theoretical midpoint of the cycle, 
there are several methods available for determining the timing of Ovulation. These methods 
include: ultrasound (where an egg, if released, can be visualized), the calendar method (that 
determines a woman’s fertile period based on the length of her past six or more menstrual 
cycles), urine test strips or sticks (that detect the presence of hormones indicative of impending 
or resolved ovulation), basal (upon waking) body temperature (where several consecutive 
“spikes” in basal body temperature indicate ovulation has occurred), cervical mucus (where 
patterns in mucus quality indicate fertility), actigraphy watches (that estimate ovulation based on 
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several physiological readings, including heart rate and basal body temperature), and ovulation 
microscopes (where a “ferning” pattern in dried saliva indicates ovulation).  
Each ovulation detection method has advantages and disadvantages. For example, basal 
body temperature and cervical mucus methods are inexpensive (or free) but require substantial 
training and compliance for desired outcomes. Urine test strips and sticks have high rates of 
accuracy for detecting ovulation (FDA, 2018) but can be expensive (as strips/sticks can only be 
used once and some systems require a digital device to read the test) and require substantial 
compliance for desired outcomes. Early studies of actigraphy watches suggest they attain 
similarly high rates of accuracy for predicting ovulation (Stein et al., 2016) but are expensive and 
research is in its infancy. For the present study, we chose to use the KNOWHEN ® ovulation 
microscope which detects a fern-like crystallization pattern in dried saliva that has been shown to 
be indicative of ovulation. KNOWHEN ® is inexpensive, can be re-used daily for years, requires 
little training for participants, and affords the level of accuracy needed for this exploratory study. 
In brief, KNOWHEN ® users remove the lens from the microscope each morning, place a drop 
of saliva on the center of the lens, allow 15 minutes for the saliva to dry, and then return the lens 
to the microscope and peer through it to observe whether the ferning pattern is present.  
Casals (1968) first described how salivary ferning crystallization patterns could be read 
as biological markers of impending ovulation. According to Johannes (2014, paragraph 6), “the 
idea behind ferning is simple. When estrogen rises in the body, so does its salt content—resulting 
in the fern-like pattern in saliva.” Since that time, correlational studies comparing salivary 
ferning with ultrasound-detected ovulation (the “gold standard”) have reported mixed results 
ranging from 36.8% (Guida et al., 1999) to 92% (Guida et al., 1993). Guida (1999) concluded 
that low correlations were likely due to frequently uninterpretable ferning results produced by 
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lower-quality device designs. More recent designs appear to have overcome this limitation; for 
example, Salmassi and colleagues (2013) found 78% specificity and 80% sensitivity using a 
microscope system to detect salivary ferning.  
In an open label prospective study of the KNOWHEN system, Melnick and Goudas 
(2015) examined 22 women across a total of 41 menstrual cycles. The women assessed for 
ovulation daily using the KNOWHEN system and, at the midpoint of their cycle, underwent a 
transvaginal ultrasound examination to determine whether the cycle was ovulatory. Ultrasound 
results were then compared to results from the KNOWHEN testing. Results supported use of the 
KNOWHEN device, which had a positive predictive value of 93.3% (95% CI = 85.5-99.9%) and 
a sensitivity of 96.5% (95% CI = 90.9-99.9%) and a negative predictive value of 90.9% (95% CI 
= 82.1-99.7%) and specificity of 83.3% (95% CI not provided).  
Luteal (premenstrual) phase 
Immediately following ovulation, approximately days 14-28, is the luteal phase, which is 
marked by rising levels of progesterone produced by the corpus luteum. The corpus luteum is a 
“transient endocrine organ that predominantly secretes progesterone” (Reed & Carr, 2018, 
paragraph 12). Progesterone further prepares the uterine lining (endometrium) on which the 
potentially fertilized egg can implant. If fertilization has not occurred, the corpus luteum 
disintegrates, which triggers rapid decreases in progesterone and estrogen and results in the 
shedding of the uterine lining as the next cycle’s menstruation begins (Epperson & Hantsoo, 
2014; Marshall, 2016).  
Premenstrual Dysphoric Disorder 
Premenstrual disorders are characterized by physical, mood, and behavioral symptoms 
that begin the week or so before menses (late luteal/premenstrual phase), resolve during menses, 
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and are absent for at least one week after menses. Premenstrual disorders are generally grouped 
into three classes: one clinically diagnosable disorder (Premenstrual Dysphoric Disorder, or 
PMDD), another milder subclinical disorder (Premenstrual Syndrome, usually termed “PMS”), 
and “variant” disorders (O’Brien et al., 2011). The most-discussed variant disorder is known as 
premenstrual exacerbation (PME), or the worsening of symptoms of another psychiatric disorder, 
such as major depressive disorder, during the premenstrual phase. That is, women with PME do 
not have a distinct premenstrual disorder but rather experience an exacerbation of another 
underlying disorder during the premenstruum (Epperson & Hantsoo, 2014). The subclinical form 
of premenstrual disorders is generally known as premenstrual syndrome (PMS), which affects an 
estimated 20-25% of women (Pearlstein & Steiner, 2008), and is characterized by mild 
symptoms that, though they cause some distress, are manageable (Epperson & Hantsoo, 2014).  
Premenstrual dysphoric disorder (PMDD) is the lone clinically diagnosable condition 
among the premenstrual disorders. PMDD, essentially a severe form of PMS, affects between 5 
and 8% of women (Angst et al., 2001; APA, 2013; Wittchen et al., 2002). Women with PMDD 
experience premenstrual physical, mood, and behavioral symptoms that are so severe they impair 
one’s everyday functioning. The burden of illness of PMDD is significant, with impairments 
noted in interpersonal and work functioning as well as effects on daily living comparable to 
depression, migraine headaches, and irritable bowel syndrome (Rapkin & Winer, 2009). See 






Common Symptoms of PMS and PMDD 





Mood lability 76.9 
Sadness/Depression 58.5 
Feeling insecure 46.2 
Low self-esteem 46.2 





Physical discomfort 53.8 
Breast tenderness 47.7 




Social withdrawal/isolation 55.4 
Appetite changes (i.e.., food cravings) 46.2 
Poor concentration c 
Decreased interest c 
Sleep disturbance c 
Note. PMS = Premenstrual Syndrome; PMDD = Premenstrual Dysphoric Disorder 
a Symptoms are derived from Freeman (2003) and Bloch, Schmidt, & Rubinow (1997) 
b Percentage of cycles in which the severity of the symptom was at least 30% greater in the premenstrual 
week than in the postmenstrual week based on prospective daily symptom ratings of N = 16 women with 
PMS (Bloch et al., 1997) 
c Data not available for this symptom 
 
 
Assuming they are sensitive to biological fluctuations, the present study focused on 
women who reported significant premenstrual distress. Among premenstrual disorders, PMDD is 
the most well-defined and well-researched in the literature; therefore, the review that follows will 
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focus primarily on PMDD. However, it should be noted that the PMDD diagnosis is sometimes 
viewed as unnecessarily restrictive:  
Many women with clinically significant premenstrual symptoms do not meet full 
diagnostic criteria; they might not have a prominent mood symptom, or the five different 
symptoms required as a minimum by the DSM-IV [and now the DSM-5]. (Yonkers et al., 
2008, p. 2) 
In a large-sample (N = 1251) prospective-longitudinal community survey, Wittchen and 
colleagues (2002) reported that whereas 5.3% of respondents met DSM-IV criteria for PMDD, 
another 18.6% had “near-threshold” symptoms, typically meeting requirements for the number, 
nature, and timing of symptoms but without the corresponding levels of impairment. To rectify 
this, the American College of Obstetrics and Gynecology (ACOG) uses a more inclusive 
definition of “moderate to severe PMS” (which includes PMDD) that requires at least one 
psychological or physical symptom that causes significant impairment and is confirmed by 
means of prospective ratings (ACOG, 2014). Additionally, the International Classification of 
Diseases (ICD), the other major diagnostic classification system alongside the DSM, uses a 
different diagnosis entirely: Premenstrual tension syndrome (WHO, 1992). Fortunately, these 
differences in diagnostic classification appear not to restrict the generalizability of research on 
PMDD. Yonkers et al. (2008) found that the descriptions of symptoms correspond well between 
PMS, PMDD, premenstrual tension syndrome, and the ACOG definition, and, therefore, research 
on PMDD is expected to be informative across the range of premenstrual disorders.  
History of the Diagnosis 
Hippocrates (460 – 370 B.C.), in his text, Diseases of Women, is typically cited as 
making the first known reference to premenstrual distress in his text, Diseases of Women: “the 
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blood of females is subject to intermittent agitation” and the “agitated blood makes its way from 
the head to the uterus from which it is expelled” (qtd in Hanson, 1975). Malik and Bhat (2016) 
reviewed historical references to premenstrual disorders, finding that many of the physical 
symptoms that define PMS today were described as early as 900 A.D., including increased body 
weight, food cravings, abdominal bloating, and headache. The temporal relationship between 
symptoms and the onset of menses appeared in academic writings as early as 1100 A.D. 
Descriptions of the psychological symptoms of premenstrual disorders, however, did not appear 
until the 17th and 18th centuries when the following were noted: mood change, irritability, 
insomnia, nervous attacks/nervous excitement, morbid dispositions of mind, a wayward and 
capricious temper, proneness to quarrel with their dearest relatives, and melancholy (Prichard, 
1835). In 1902, von Krafft-Ebing provided a description of premenstrual distress that 
emphasized the interpersonal impairment associated with premenstrual symptoms, including 
difficulty getting along with other members of the household, including otherwise tenderly loved 
children, emotional explosions, libelous acts, and breaches of peace.  
The cause of premenstrual symptoms remained largely unknown until the late 19th and 
early 20th centuries. Before that time, symptoms were variously attributed to hysteria, the uterus 
(“strangulation of the uterus”; Dubois, 1478-1555; in Stolberg, 2000), and the systemic effects of 
excess blood. Henry Maudsley (1873) was first to connect premenstrual symptoms to cyclical 
ovarian activity, which is still considered the leading explanatory cause of premenstrual 
disorders.  
In 1931, Robert Frank created the first clinical description of premenstrual symptoms: 
intense personal suffering, restlessness, irritability, feeling like “jumping out of their skin,” and 
various physical complaints seven to 10 days before the onset of menses. Frank (1931) attributed 
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the cause of premenstrual symptoms to an excess of circulating “female hormone.” Green and 
Dalton (1953) built upon Frank’s speculation, attributing premenstrual symptoms more 
specifically to dysfunctions in estrogen and progesterone. Dalton is considered a highly 
influential figure in the history of premenstrual disorders; among her many contributions is the 
coining of the term “premenstrual syndrome,” which, by using the term “syndrome,” helped 
legitimize the experience as a medical disorder.  
“Late luteal phase dysphoric disorder” (LLPDD) was the first premenstrual disorder to 
appear in a formal diagnostic manual—Appendix A of the third edition of the DSM (DSM-III-R; 
APA, 1987). A diagnosis of LLPDD required a minimum of five symptoms with predictable 
onset in the late luteal phase and offset in the early follicular phase. In preparation for the fourth 
edition of the DSM (DSM-IV; APA, 1994), a work group cited the wide-ranging prevalence 
estimates of LLPDD (from 7-54%; Yonkers, 2012) as evidence that the disorder was not 
sufficiently understood to be classified as an official diagnosis. The work group recommended 
additional research using prospective daily rating scales to estimate the true prevalence of the 
disorder Though LLPDD was renamed “Premenstrual Dysphoric Disorder” (PMDD) in the 
DSM-IV, it was still listed only in the appendix as a provisional diagnosis pending additional 
research (Epperson et al., 2012). The DSM-IV PMDD diagnosis required the presence of five of 
11 symptoms that occur premenstrually, involve disruption in day-to-day functioning, and abate 
after the menstrual period (Freeman, 2003).  
In preparation for the fifth edition of the DSM (DSM-5; APA, 2013), a work group was 
tasked with determining whether research showed that PMDD: was a diagnosis distinct from 
similar diagnoses (e.g., Major Depressive Disorder); had antecedent validators, such as family 
history and environment risk factors; had concurrent validators, such as cognitive, biological and 
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temperamental correlates; and had predictive validity with respect to diagnostic stability, 
predictability in trajectory, and response to treatment (Epperson et al., 2012). The work group 
confirmed that PMDD met each of these requirements, and it was officially recognized as a 
diagnostic entity in the DSM-5 among the category “Depressive Disorders.”  
Slight changes were made to the criteria between DSM-IV and DSM-5. First, the timing 
criterion was altered such that symptoms need only be present in the final week before menses 
(as opposed to “most of the week” before menses) and symptoms need only improve (as opposed 
to “remit”) within a few days of menses. Second, mood lability and irritability were made more 
prominent by moving them to first and second position in the symptom list (formerly depressed 
mood and marked anxiety). Third, “clinically significant distress” was included as a component 
of functional impairment and the “home” was now considered as a potential place of impact for 
that distress/impairment. Fourth, a final criterion was added to ensure that the symptoms are not 
due to the direct physiological effects of a substance or another medical condition.  
The DSM-5 diagnostic criteria for PMDD are presented in their entirety in Table 2. Five 
of 11 symptoms are required, at least one of which must be a mood symptom (Table 2, Criterion 
B, e.g., depression, irritability, etc.) and one a cognitive/behavioral/physical symptom (Table 2, 





DSM-5 Diagnostic Criteria for Premenstrual Dysphoric Disorder  
Criterion Relevance   
A Timing 
In the majority of 
menstrual cycles, at least 
five symptoms must be 
present in the final week 
before the onset of 
menses, start to improve 
within a few days after 
the onset of menses, and 
become minimal or 
absent in the week 
postmenses. 
 
B Core mood 
symptoms 
One (or more) of the 
following symptoms must 
be present: 
1.  Marked affective lability (e.g., mood 
swings; feeling suddenly sad or tearful, or 
increased sensitivity to rejection 
2.  Marked irritability or anger or increased 
interpersonal conflicts 
3.  Marked depressed mood, feelings of 
hopelessness, or self-deprecating thoughts 
4.  Marked anxiety, tension, and/or feelings 
of being keyed up or on edge 
 
C  Additional symptoms 
One (or more) of the 
following symptoms must 
additionally be present, to 
reach a total of five 
symptoms when 
combined with symptoms 
from Criterion B. 
1.  Decreased interest in usual activities 
(e.g., work, school, friends, hobbies) 
2.  Subjective difficulty in concentration 
3.  Lethargy, easy fatigability, or marked 
lack of energy 
4.  Marked change in appetite; overeating; 
or specific food cravings 
5.  Hypersomnia or insomnia 
6.  A sense of being overwhelmed or out of 
control 
7.  Physical symptoms such as breast 
tenderness or swelling, joint or muscle 




The symptoms are 
associated with clinically 
significant distress or 
interference with work, 
school, usual social 
activities, or relationships 
with others (e.g., 






efficiency at work, school 





or other primary 
diagnoses 
The disturbance is not 
merely an exacerbation of 
the symptoms of another 
disorder, such as major 
depressive disorder, panic 
disorder, persistent 
depressive disorder 
(dysthymia), or a 
personality disorder 
(although it may co-occur 
with any of these 
disorders). 
 
F Required prospective 
assessment 
Criterion A should be 
confirmed by prospective 
daily ratings during at 
least two symptomatic 
cycles (Note: The 
diagnosis may be made 
provisionally prior to this 
confirmation).  
 
G Rule out confounding substance or medical 
causes 
The symptoms are not 
attributable to the 
physiological effects of a 
substance (e.g., a drug of 
abuse, a medication, other 
treatment) or another 
medical condition (e.g., 
hyperthyroidism) 
 
Note. See APA (2013), pp. 171-172 
 
 
Research suggests there may be clinically meaningful subtypes of PMS/PMDD 
characterized by different mood symptoms—specifically a subtype dominated by depressed 
mood and a subtype dominated by other psychiatric symptoms—however, such subtypes are not 
yet defined or routinely used (Landén & Eriksson, 2003).   
Feminist Perspectives on PMDD 
Feminist scholars have long criticized (in some cases) the PMS/PMDD diagnosis itself 
and (in many cases) elements and language within the diagnosis. Arguably the most salient 
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criticism from the feminist camp is that classifying PMDD as a disorder pathologizes female 
biology and underemphasizes the influence of individual, cultural, and political factors in 
shaping women’s experiences of premenstrual symptoms (Cosgrove & Riddle, 2003; Gurevich, 
1995; Ussher, 2003, 2004; King & Ussher, 2012). Gurevich (1995) argued that there are at least 
three faulty assumptions inherent in the biology-forward approach to PMDD. First, it is assumed 
that biology operates within a woman without influence from external factors. Second, it 
assumes that fluctuations in mood and behavior are signs of illness instead of assuming that what 
women naturally experience (including fluctuation) is healthy. Third, it favors positivistic 
methods that must reduce complex psychological and/or social phenomena into objective, 
presumably value-free variables (e.g., hormone levels).  
A corollary of the “biologization” (Slife et al., 2010) of PMDD is that female biology is 
now viewed as inherently faulty, unpredictable, and inferior to the relatively more stable male 
biology (Gurevich, 1995), which, in turn, perpetuates the “good woman” ideal (Rodii, 1992). In 
feminist discourses, the “good woman” ideal explains how women tend to view themselves as 
“split,” as being either “good” (self-sacrificing, compassionate, coping, calm) or “bad” 
(aggressive, impatient, anxious) (Ussher, 2004, p. 261). When interviewed about their experience 
of premenstrual symptoms, women allude to this split by describing their premenstrual 
experiences in such ways as “I’m just stressed and anxious—not a pleasant person to be around. 
Its [sic] like Dr. Jekyll and Mr. Hyde” (Ussher, 2004, p. 261). Notably, the hallmark symptoms 
of PMDD—anger, irritability, aggression, feeling out-of-control, and so on—are inconsistent 
with the “good woman” ideal. Some have speculated that women freely express these otherwise 
unacceptable emotions and behaviors during the premenstrual phase because they can do so for a 
medically acceptable reason (PMDD) without losing their “feminine allure” (Gottlieb, 1988, p. 
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13) or being labeled as neurotic (Gurevich, 1995). Ussher (2004, p. 262) theorized that the good-
bad tension associated with PMDD forces women to “self-silence”: 
By attributing transgressive emotions or behavior to an outside thing, ‘PMS’, women are 
able to keep a core sense of self as ‘good’ intact. However, in doing so, they are not 
addressing the needs or issues that lead to the emotions that emerge in the premenstrual 
phase of the cycle.  
Feminist scholars have also criticized the male-dominated early history of PMDD, 
especially given that it is a uniquely female disorder. Gurevich (1995), for example, argued that 
Robert Frank’s motivation in defining “premenstrual tension” (Frank, 1931) was to identify a 
deficit in women that would make them appear less desirable to employers. Chrisler and Caplan 
(2002) saw Frank’s definition as adding a “modern veneer to the cult of invalidism and Victorian 
era concerns” about the potential effects of women exerting themselves in intellectual and 
workforce activities (p. 283). At the time, women were entering the workforce in greater 
numbers to account for male employees serving overseas in World War I, and Martin (1987) 
viewed this as a trend in PMDD’s history: “When women’s participation in the labor force [is 
viewed] as a threat, menstruation [becomes] a liability” (p. 121). These ideas may persist into the 
modern day where many women with PMS symptoms are advised to treat their symptoms by 
resting and slowing the pace of their lives (including, especially, work demands), which may, in 
turn, threaten their potential for successful careers (Chrisler, 2001). Like Chrisler and Caplan, 
Gurevich noted the similarities between PMDD and the Victorian era concept of “hysteria”: both 
were overwhelmingly applied to women; both were blamed on female physiology (the uterus); 
and, ultimately, both dictated:  
26 
 
that a woman’s most natural functions lie in the realm of childbearing and caretaking. 
Therefore, when women transgress by stepping out of or, worse yet, by completely 
abandoning their ‘natural’ sphere of domesticity, they are inevitably subject to 
psychological disturbances, such as PMS. (1995, p. 76) 
Overall, feminist scholarship hopes to affect the future of PMDD by calling for an understanding 
of premenstrual symptoms that: is in women’s own words; values but does not overemphasize 
biology; integrates constructivist views, including the influence of social and political factors; 
and considers the possibility that premenstrual fluctuations are normal and healthy (and that 
some women actually experience positive changes in the premenstruum; King & Ussher, 2012).  
Epidemiology 
Most reproductive-age women—an estimated 80-85%—experience mild, non-clinical 
premenstrual characteristics (di Scalea & Pearlstein, 2017; Pearlstein & Steiner, 2008). Twenty 
to 25% experience mild to moderate distress consistent with descriptions of PMS premenstrual 
syndrome or PMS (Freeman, 2003; Pearlstein & Steiner, 2008). Approximately 5-8% of women 
experience symptoms severe and disabling enough to meet diagnostic criteria for premenstrual 
dysphoric disorder (PMDD) (Angst et al., 2001; APA, 2013; Wittchen et al., 2002). Estimates of 
PMDD have hovered consistently around 5% since the time of the DSM-III-R when it was 
termed “late luteal phase dysphoric disorder” (Rivera-Tovar & Frank, 1990; Soares et al., 2001). 
Alevizou and colleagues (2018) noted that women who display four severe PMDD symptoms are 
double or even triple the number of those who report five severe symptoms as required for a 
DSM-5 diagnosis of PMDD. For this reason, PMDD has been criticized for being too stringent 
and failing to capture a substantial number of women who also experience distressing symptoms 
(Yonkers et al., 2008).  
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PMDD is present across disparate cultures, as confirmed by epidemiological studies in 
the United States, Canada, Europe, India, and Japan (Epperson et al., 2012). Di Scalea and 
Pearlstein (2017) concluded that the rates and symptoms of PMDD are consistent across several 
continents. However, one study of tribal cultures (Paige & Paige, 1981) found that 0% of 
individuals reported premenstrual problems, and others (Gurevich, 1995) have argued that only 
the physical symptoms of PMDD are consistent cross-culturally whereas the mood symptoms of 
PMDD are specific to the United States and other westernized cultures. A cross-sectional 
analysis of community-based studies from 14 different countries (N = 7,226 women) found that, 
across all countries, physical symptoms were the most prevalent and that irritability was the most 
common among the four mood complaints (Dennerstein et al., 2011).  
Rates of PMDD are comparable among White and African American women in the 
United States (Epperson et al., 2012). However, Pilver and colleagues (2011) found that rates of 
PMDD among ethnic minority women may be influenced by exposure to American culture. In 
their study of nearly 4,000 English-speaking Asian, Latina, and Black women, they found that 
nativity status, duration of residence, and age at immigration were significantly associated with 
PMDD. U.S.-born women and women who immigrated to the U.S. before age six were more 
likely to have PMDD than those who arrived after age six. Additionally, the likelihood of PMDD 
increased with one’s duration of residence in the U.S.  
Relation to other Disorders 
The exact taxonomy and nomenclature of PMDD remains hotly debated (Alevizou et al., 
2018), and there has been question as to whether PMDD should be considered a variant of 
depression, a variant of anxiety, or a disorder (gynecological or psychological) of its own. At 
present, there appears to be consensus that PMDD should be considered distinct from depression 
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and anxiety, as reflected in the inclusion of PMDD as its own disorder in DSM-5 (Epperson et 
al., 2012; Landén & Eriksson, 2003). 
Depression. PMDD has historically been criticized for its similarity to major depressive 
disorder (MDD), which, especially in preparation for the DSM-5, led to increased research into 
the distinctions between the two disorders, five of which will be considered here. First, the 
timing of symptoms in proximity to menstruation is unique to PMDD. MDD symptoms must 
occur consistently for at least two weeks but need not have any temporal relationship to the 
menstrual cycle. Second, though PMDD and MDD share symptoms, they are emphasized 
differently. Specifically, irritability and mood lability are key components of PMDD, whereas 
they are less common in individuals with MDD (Yonkers et al., 2008). Third, there are several 
physical symptoms (e.g., bloating, breast tenderness) that are unique to PMDD. Fourth, PMS 
does not share substantial genetic variance with MDD or with broadband personality traits like 
neuroticisms (Kendler et al., 1998; Epperson et al., 2012). Fifth, selective serotonin reuptake 
inhibitors (SSRIs), a form of antidepressant, act differently upon PMDD. Whereas patients with 
MDD may wait weeks to experience symptom improvement from an SSRI, patients with PMDD 
can begin taking SSRIs in the luteal phase and experience nearly immediate alleviation in 
symptoms, suggesting a different mechanism of action (Dimmock et al., 2000; Epperson et al., 
2012).  
Premenstrual disorders do frequently co-occur with depressive disorders both over the 
lifetime and concurrently. Other depressive disorders occur concurrently in approximately 12-
25% of PMS/PMDD patients, though this is perhaps an underestimate due to the symptom 
overlap mentioned above (Kim et al., 2004; Yonkers & McCunn, 2007). Lifetime co-occurrence 
rates are much higher: Women with PMDD are more likely to have major depressive disorder 
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and/or postpartum depression in the future (Bloch et al., 2000; Hartlage et al, 2001). At least 
30% of women with PMS will have a minor or major depressive episode at some point in their 
lives (Yonkers et al., 2008) and between 30 and 70% of women with PMDD have had an episode 
of major depression in the past (Yonkers & McCullen, 2007).  
Anxiety. Women with PMDD frequently report premenstrual anxiety symptoms, 
including nervousness (27.1% prevalence), anxiety (4.9% prevalence), and tension (27.1% 
prevalence) (Landén & Eriksson, 2003). Women with severe premenstrual complaints are 
believed to be at greater risk for anxiety disorders including panic disorder and generalized 
anxiety disorder (Angst et al., 2001). However, as with depression, these figures may be inflated 
by the fact that individuals who retrospectively report premenstrual anxiety symptoms are 
actually experiencing premenstrual exacerbation of a chronic anxiety disorder and would not 
meet diagnostic criteria for PMDD using prospective daily ratings. Unfortunately, rates of 
premenstrual exacerbation of anxiety are unknown (Kim & Freeman, 2010). 
Between four and 38% of women with PMS/PMDD (as confirmed by prospective report) 
were found to have comorbid generalized anxiety disorder (Kim et al., 2004). Estimates of 
concurrent PMS/PMDD and panic attacks/panic disorder are generally higher and much more 
consistent than of concurrent PMS/PMDD and generalized anxiety disorder, at about 25% when 
using prospective reports (Kim et al., 2004). Estimates of concurrent PMS/PMDD and phobic 
disorders are also fairly consistent, ranging from 16-30% for simple phobia and 19-23% for 
social phobia (Kim et al., 2004). Estimates of concurrent PMS/PMDD and obsessive-compulsive 
disorder are lowest among anxiety disorders, ranging from 1-2.26% (Kim et al., 2004).  
Bipolar disorder. Data on the comorbidity of PMDD and bipolar disorder is sparse (Kim 
et al., 2004) and may overestimate the true prevalence if retrospective or other flawed methods 
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of diagnosis are used (Kim et al., 2011). An early study of women with late luteal phase 
dysphoric disorder (confirmed by prospective reports), found no relationship (0%) with bipolar 
disorder (Fava et al., 1992). More recent estimates of concurrent PMS/PMDD and bipolar 
disorder (inclusive of both bipolar I and bipolar II disorder) based on retrospective reporting 
range from 11-20% (Kim et al., 2004). Wittchen et al. (2002) distinguished between bipolar I 
and bipolar II disorder, finding similar rates of comorbidity for each with PMS/PMDD—5.7% 
and 4.9%, respectively. Payne et al. (2007) also distinguished between bipolar I and bipolar II 
disorder but examined premenstrual symptoms broadly (as opposed to official diagnoses), 
finding high rates among both groups—65.1% and 70.5%, respectively. Premenstrual 
exacerbation of underlying bipolar disorder symptoms is common, reported by 60-70% of 
women (Kim et al., 2011).  
Seasonal affective disorder. Estimates of concurrent PMS/PMDD and seasonal affective 
disorder range from 38-46% when using prospective reports (Kim et al., 2004). The two 
disorders share unique features—namely, cyclicity and a combination of somatic and psychiatric 
symptoms—suggesting similar biological mechanisms or vulnerabilities; however, additional 
research is needed. 
Etiology 
Raffi and Freeman (2017) produced an etiological model that they call “the 5 interwoven 
pieces of the PMDD puzzle.” The model is shown in Figure 2 and is a useful summary of the 
most recent and robust research in this area. Each of the five factors (among others) will be 






The five interwoven pieces of the PMDD puzzle (Raffi & Freeman, 2017, p. 24) 
 









Table 3  
Summary of Studies of PMS and PMDD Etiological Factors 
Source Finding Cycle days affected 
In General 
Backström et al. (2014) PMDD is associated with 
increased negative mood 
(depression, irritability) during 
the luteal phase reaching a 
maximum during the last days 
of the menstrual cycle or first 
days of menstrual bleeding 
21-28 
Hormones 
Backström et al. (2011) In animal models, premenstrual 
anxiety and depression during 
progesterone withdrawal can be 
mitigated by preventing the 
conversion of progesterone into 
ALLO 
Not specified; can infer 
approximately days 21-28 
Epperson et al. (2002) Cortical GABA levels increased 
across menstrual cycle for 
women with PMDD (opposite 
pattern of “healthy” controls), 
suggesting a luteal-phase 
specific decrease in cortical 
inhibition 
Late luteal phase (1-5 days 
before menses) 
Girdler et al. (2001) Women with PMDD with 
greater levels of premenstrual 
anxiety and irritability had 
significantly reduced ALLO 
levels in the luteal phase as 
compared to less symptomatic 
PMDD women 
Luteal phase (days not 
specified); can infer 
approximately days 15-28 
Lovick (2013) Rapid withdrawal from ALLO 
when progesterone drops in the 
late luteal phase precipitates 
premenstrual symptoms 
Late luteal phase (days not 
specified); can infer 
approximately days 21-28 
Martinez et al. (2015) Blocking conversion of 
progesterone to ALLO led to a 
reduction in PMDD symptoms 
Week 4 of menstrual cycle; can 
infer days 21-28 
Schmidt et al. (2017) PMDD is associated with 
changes from low to high levels 
of estradiol/progesterone 
Luteal phase (days not 
specified); can infer 
approximately days 20-25 
Timby et al. (2016) PMDD is associated with 




at GABAA receptors in luteal 
phase 
Yen et al. (2018) Women with PMDD who had 
lower levels of estrogen had 
high anxiety and perceived 
stress in the premenstrual phase 
7 days before menstruation 
(predicted based on the last 
menstruation cycle) 
Neurotransmitters 
Inoue et al. (2007) Compared to “healthy” controls 
and women with PMS, those 
with PMDD had highest 
serotonergic function during 
follicular phase and lowest 
during luteal phase (which has 
been associated with cognitive-
affective PMDD symptoms)  
Late luteal phase (days not 
specified); can infer 
approximately days 21-28  
Oral et al. (2015) PMDD is associated with higher 
luteal serum BDNF levels and 
serum BDNF levels were 
significantly higher in the luteal 
phase than in the follicular 
phase for women with PMDD  
21-25 
Sue et al. (1997)a; Steinberg et 
al. (2012)b 
Fluoxetine, an SSRI, 
administered continuouslya or 
only during luteal phaseb 
improved self-reported 
emotional and physical PMDD 
symptoms in luteal phase 
7 days before mensesa/Luteal 
phase (days not specified)b 
Brain function 
Gingnell et al. (2013) 
PMDD is associated with an 
exaggerated response in 
prefrontal cortex when 
anticipating negative stimuli in 
late luteal phase 
8-13 days after ovulation 
Protopopescu et al. (2008) 
PMDD is associated with an 
increased emotional response to 
negative stimuli in the 
premenstrual phase 
1-5 days before menses 
Other 
Bannbers et al. (2011)  Compared to “healthy” controls, 
women with PMDD display a 
heightened startle response to 
both positive and negative 
stimuli in the luteal phase  
1-7 days before menses 
Bertone- Johnson et al. (2014) Premenstrual symptoms were 
associated with inflammatory 
markers in blood during mid-
luteal phase 





Neuroendocrine explanations. Given that PMDD occurs only in women in their 
reproductive years, ovarian sex hormones have long been suspected in the etiology of PMDD. As 
Timby et al. (2016) wrote, “The pathophysiology of PMDD is not yet fully understood, but the 
temporal association with circulating ovarian steroids, in particular progesterone, produced by 
the corpus luteum after ovulation, is obvious” (p. 2019). Estrogen and progesterone are key 
ovarian sex hormones, both of which can directly or indirectly affect central nervous system 
functioning including mood (Reid & Soares, 2018; for a review, see Table 1 in Soares & Zitek, 
2008).  
Recall from Figure 1 that progesterone levels are low during menses and the follicular 
phase, increase in the luteal phase, and then decrease rapidly before the next menses. This pattern 
of chronic exposure followed by rapid withdrawal of progesterone is associated with anxiety and 
alterations to one of the central nervous system’s major inhibitory systems, the gamma-
aminobutyric acid (GABA) system (Hantsoo & Epperson, 2015). Recall also from Figure 1 that 
estrogen levels are low during menses and rise gradually during the follicular phase, peaking just 
before ovulation. Estrogen levels then decrease rapidly after ovulation, rise gradually in the 
luteal phase, and then decrease rapidly again around the next menses. Estrogen—mostly through 
an interaction with the serotonergic system—has been shown to have broadly beneficial effects 
on mood, cognition, appetite, sleep, and behavior (Hantsoo & Epperson, 2015). Low levels of 
estrogen in the luteal phase are associated with serotonin abnormalities, which can result in the 
PMDD symptoms of low mood, craving of specific foods, and impaired cognitive performance 
(Hantsoo & Epperson, 2015).  
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Emphasizing these patterns in estrogen and progesterone, Rafi and Freeman (2017) 
suggested that PMDD may be best conceptualized as a disorder of withdrawal caused by 
mechanisms similar to those demonstrated in substance use withdrawal. They theorized that the 
intersecting withdrawal from serotonin (caused by an interaction with estrogen) and GABAergic 
activity (caused by the decline in progesterone) may explain PMDD.  
Abnormal response to normal fluctuations of ovarian sex hormones. Research indicates 
that PMDD is not caused by an excess or deficit in sex hormones (Yonkers & Simoni, 2018); 
instead, research shows that women with PMDD are more vulnerable than others to changes in 
hormone levels (Schmidt et al., 2017). Schmidt and colleagues examined 22 women 
prospectively diagnosed with PMDD who were given a gonadotropin-releasing hormone 
(GnRH) agonist to suppress ovarian activity (including hormone production). After 2-3 months 
of the GnRH alone, the women whose self-reported PMDD symptoms were in remission 
(“responders”) were selected to continue in the study. Responders continued to receive monthly 
GnRH for another four months followed by one month of single-blind (participant only) placebo 
(a patch which they believed to be a hormone patch) and finally, three months of hormone 
(combined estradiol and progesterone) replacement. Results showed that self- and observer 
ratings of PMDD symptoms increased significantly during the first month of hormone 
replacement as compared to the last month of GnRH, the placebo month, and the second and 
third months of estradiol/progesterone. This suggested that the onset of PMDD is associated with 
changes from low to high levels of estradiol/progesterone as opposed to any differences in 
steady-state levels.  
Newhouse and Albert (2015) speculated that decreased estradiol may attenuate emotion 
regulation such that, when levels of estradiol drop, women experience altered reactivity to 
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negative emotional information which may explain the mood disturbance observed in PMDD. 
Yen et al. (2018) tested this hypothesis in a sample of 240 university students, 137 of whom met 
diagnostic criteria for PMDD. For three menstrual cycles, participants were assessed one week 
before menstruation and then again during the pre-ovulatory follicular phase. The assessments 
included blood samples (to measure estrogen levels) and questionnaires measuring PMDD 
symptoms, affective style, depression, anxiety, and perceived stress. Results showed that women 
with PMDD who had lower levels of estrogen had high anxiety and perceived stress in the 
premenstrual phase, suggesting that estrogen plays a role in the stress response for women with 
PMDD but not for those without. Additionally, women with PMDD had more unhealthy emotion 
regulation qualities in the premenstrual phase than in the follicular phase, though there was no 
association with estrogen levels. Therefore, in line with Schmidt et al. (2017), the authors 
concluded that emotion regulation is affected by a decline in estrogen levels but not by 
differences in steady-state estrogen levels.  
Decreased sensitivity of the GABAA receptor to allopregnanolone (ALLO). Recent 
research has narrowed in on ALLO and its effect on GABA receptors. ALLO is a neurosteroid 
metabolized by progesterone and produced by the corpus luteum; circulating levels of ALLO are 
found in the brain (Raffi & Freeman, 2017). ALLO is also a strong positive modulator of 
GABAA receptor with calming and sedative effects similar to those of benzodiazepines and 
alcohol. ALLO is known to provide relief in times of acute distress (Raffi & Freeman, 2017) and 
has been implicated in the pathophysiology of mood disorders (Schule et al., 2014). Animal 
models show that the effects of premenstrual progesterone withdrawal (e.g., anxiety and 
depression) can be mitigated by preventing the conversion of progesterone into ALLO 
(Backström et al., 2011). Similarly, in an important randomized controlled trial, Martinez et al. 
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(2015) showed that blocking the conversion of progesterone to ALLO led to a reduction in 
several symptoms (irritability, sadness, anxiety, food cravings, and bloating) for women with 
PMDD. There was no such effect on symptoms for women without PMDD or for women with 
PMDD who were given a low dose of the ALLO-blocker. 
Monteleone et al. (2000) examined basal levels of ALLO and progesterone in the 
follicular and luteal phases over three months in patients with prospectively diagnosed PMS and 
a non-PMS control group. They also performed a GnRH challenge test during the luteal phase of 
the third month to identify any difference in ALLO response. Results showed that, compared to 
women without PMS, women with PMS had lower basal levels of ALLO and exhibited a lesser 
ALLO response to GnRH ovarian suppression. Similarly, Timby et al. (2016) demonstrated that 
women with PMDD had a decreased response to ALLO in the follicular phase as compared to 
the luteal phase (i.e., women with PMDD exhibited lower levels of ALLO in the luteal phase), 
whereas the opposite pattern was observed in a control group of women without PMDD. 
Severity of symptoms, especially anxiety and irritability, may be negatively associated with 
ALLO levels, such that women with the most severe symptoms have the lowest ALLO levels 
(Girdler et al., 2001). Research also suggests that a small subset of women react to increases in 
ALLO (e.g., in the midluteal phase) paradoxically: Instead of experiencing calm and a return to 
homeostasis, they experience more or worsened mood and anxiety symptoms (Bäckstrom et al., 
2014).  
It is thus believed that women with PMDD have an altered sensitivity at the ALLO site of 
the GABAA receptor and do not experience the expected calming and inhibitory effects in 
response to stress in the luteal phase (diScalea & Pearlstein, 2017). Indeed, Girdler et al. (2001) 
showed that, whereas 83% of women without PMDD showed a stress-induced increase in 
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ALLO, only 42% of women with PMDD showed the same response. It is possible that part of the 
reason selective serotonin reuptake inhibitors (SSRIs) are effective in treating PMDD is that 
SSRIs enhance the sensitivity of GABAA receptors, thus increasing the ALLO response (Raffi & 
Freeman, 2017).  
Neurochemical explanations. Neurotransmitters, or chemical messengers in the brain, 
have been implicated in the etiology of PMDD, usually in complex connections with other 
systems and chemicals such as hormones.  
Alterations in the serotonergic system. The etiological impact of serotonin on PMDD 
has been demonstrated by many studies using primarily indirect measures of central serotonin 
levels and serotonin transmission (diScalea & Pearlstein, 2017). Rapkin et al. (1987) were the 
first to report whole-blood serotonin abnormalities in women with PMS. Brain imaging studies 
have since shown associations between PMS symptoms and serotonergic transmission (Eriksson 
et al., 2006; Jovanovic et al., 2006). Inoue et al. (2007) reported that women with PMDD had the 
highest levels of serotonergic functioning during the follicular phase and the lowest levels during 
the luteal phase compared to women with PMS and asymptomatic controls. Low serotonergic 
function is associated with many of the cognitive-affective symptoms seen in PMDD, such as 
low mood, food cravings, and decreased cognitive performance (Hantsoo & Epperson, 2015). 
Estrogen appears to interact with serotonin to produce the mood symptoms observed in 
PMDD. Brain imaging studies have found increased serotonin binding with the addition of 
estrogen and even higher potential for binding with the addition of combined estrogen and 
progesterone (Amin et al., 2005; Moses-Kolko et al., 2003). As Hantsoo and Epperson (2015, p. 
87) summarized: “It is possible that women with PMDD are more sensitive to these effects of 
estrogens on serotonergic function. Women with PMDD or PMS exhibit specific serotonin (5-
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HT) abnormalities that are particularly apparent in the late luteal phase when estrogen levels 
have declined.” 
The influence of brain-derived neurotrophic factor (BDNF). BDNF is a  
Neurotransmitter found throughout the brain; it promotes neuronal growth and survival and is 
critical for learning and memory (Bathina & Das, 2015). Though research in this area is just 
beginning, preliminary results suggest that BDNF may play a role in the etiology of PMDD 
through its link to estrogen (BDNF levels are influenced by estradiol and have been shown to 
cycle predictably with the menstrual cycle; Carbone & Handa, 2013) and specific gene 
polymorphisms (Hantsoo & Epperson, 2015). Oral and colleagues (2015) showed that women 
with PMDD had significantly higher luteal serum BDNF levels than women without PMDD and 
that BDNF levels were significantly higher in the luteal phase than in the follicular phase among 
women with PMDD. The authors speculated that higher levels of BDNF in the luteal phase may 
reflect the brain’s attempt to respond to distress and prevent neuronal damage from the 
depressive and other mood symptoms associated with PMDD.  
Genetics. Twin studies find the heritability of PMDD to range from 30-80%, suggesting 
a genetic component to the disorder (Condon, 1993; Kendler et al., 1992; Kendler et al., 1998; 
Treloar et al., 2002). Polymorphisms in the human estrogen receptor 1 (ESR-1), also known as 
human estrogen receptor alpha (ESRα), gene has been implicated in the heritability of 
PMS/PMDD (Huo et al., 2007). Yen et al. (2018) found negative associations between stress, 
depression, and estrogen level for those with the G genotype of ESRα, but not for those with the 
AA genotype, suggesting a potential stratifying effect of ESRα. The human serotonin gene and 
serotonin transporter genotype have also been considered in the heritability of PMDD, though 
results are mixed (Raffi & Freeman, 2017).  
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Neuroanatomical explanations. Neuroimaging studies have shed light on differences in 
brain structure and function between women with PMDD and women without.   
Differences in brain structure. Women with PMDD have evidenced atypical brain 
structure in brain regions associated with emotional processing. Jeong and colleagues (2012) 
were the first to employ structural magnetic resonance imaging (MRI) in the study of PMDD; 
structural MRI allows for comparison of between-group differences in gray matter volume. Gray 
matter refers to the tissue (composed of neuronal cell bodies, glial cells, synapses, capillaries, 
and more) found in various brain regions that is said to be involved in information processing; 
higher gray matter volume (if in the ‘right’ regions) is generally positive, indicative of higher 
performance or intellect. Jeong et al. (2012) scanned 15 women with PMDD and 15 women 
without during the luteal phases of their menstrual cycles, finding that women with PMDD 
showed lesser gray matter density in the left parahippocampal gyrus and greater gray matter 
density in the right parahippocampal gyrus. As the parahippocampal gyrus is involved in the 
formation of emotional memories and detection of emotional stimuli, the authors speculated that 
the atypical structure in these areas may lead to increased sensitivity to negative emotional 
stimuli and an exaggerated emotional response in the luteal phase of the menstrual cycle.  
Conversely, Berman and colleagues (2013) observed the MRI scans of 12 women with 
PMDD compared to 13 women without, finding that women with PMDD had greater gray matter 
volume in the posterior cerebellum, another region involved in emotional processing, as 
compared to women without. These results suggested that PMDD may be associated with a 
protection against age-related grey matter loss in this region, and the authors speculated that the 
apparent protection may result from “effortful mental exercises” that afflicted women must 
employ to compensate for and emotionally cope with their PMDD symptoms each month (p. 
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270). Overall, PMDD appears to be associated with atypical volume of gray matter of brain 
regions known to be involved with emotions.  
Differences in brain function. Studies using functional magnetic resonance imaging 
(fMRI) have found that women with PMDD exhibit an increased emotional response to negative 
stimuli and a diminished emotional response to positive stimuli during the late luteal 
(symptomatic) phase of their menstrual cycles (Protopopescu et al., 2008). Gingnell and 
colleagues (2012) found no difference in luteal phase emotional response between women with 
and without PMDD, but they did find that trait-level anxiety and progesterone levels seemed to 
modulate menstrual cycle related reactivity in the amygdala, a key emotion processing center in 
the brain.  
While those studies focused on the amygdala, others have focused on the prefrontal 
cortex, the uniquely human brain region that is involved in planning, decision-making, 
inhibition, and other complex cognitive tasks. Atypical functioning of the prefrontal cortex is 
believed to be a risk factor for PMDD (Hantsoo & Epperson, 2015). Gingnell et al. (2013) 
showed that, during the luteal phase, women with PMDD exhibited an exaggerated prefrontal 
cortex reaction when anticipating (but not when exposed to) negative stimuli, which was 
positively correlated with progesterone level. The authors speculated that this increased 
reactivity may help explain why women with PMDD frequently report feeling like they lack 
emotional control. Using two forms of brain imaging technology, fMRI and positron emission 
tomography (PET), Baller et al. (2013) found that women with PMDD displayed atypical 
activation in the prefrontal cortex during a working memory task and that levels of activation 
were positively associated with symptom severity and impairment. Overall, PMDD appears to be 
associated with abnormalities in brain response, especially to negative emotional stimuli. 
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Stress. The brain’s stress response systems are known as the hypothalamic-pituitary-
adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis and these two axes 
interact with respect to hormones (Mastorakaos et al., 2006). For example, reproductive (HPG 
axis) hormones, such as testosterone (male) and estrogen (female), modulate the HPA axis 
response; Estrogen appears to increase serotonin receptor function at presynaptic sites whereas it 
decreases serotonin receptor expression at postsynaptic sites, which may explain why women 
display a heightened HPA axis response to stress compared to males. In the reciprocal direction, 
activation of the stress axes, especially if repeated or chronic, inhibits production of estrogen and 
testosterone (Mastorakaos et al., 2006). Dysregulation of the HPA and HPG axes is suspected to 
contribute to PMDD. For example, HPG axis dysregulation is associated with sleep disruption 
and mood symptoms during menopause, both of which are also common symptoms of PMDD. In 
addition, one study found that women with PMDD who had high levels of ALLO (HPG-related) 
had low, or blunted, levels of cortisol (HPA-related) as compared to women without PMDD who 
had high levels of ALLO (Segebladh et al., 2013).  
Indeed, women with PMDD are shown to experience high levels of stress and trauma. 
Two studies of approximately 3,000 participants each found associations between trauma/abuse 
and PMS/PMDD (Bertone-Johnson et al., 2014a; Pilver et al., 2011). There are several working 
explanations for the relationship between PMDD and stress/trauma, both of which refer to 
ALLO. Recall that, in healthy individuals, ALLO increases in response to stress, triggering 
calming, sedative effects. However, women with PMDD do not have the same response to 
ALLO and therefore, do not experience its sedative effects (Hantsoo & Epperson, 2012), which 
renders them less efficient at responding to and re-stabilizing in times of stress.  
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Inflammation. A relatively newer area of investigation has considered the role of 
immune activation and inflammation in PMDD, thus far focusing mostly on menstrual changes 
in inflammatory markers (e.g., specific proteins and genes that signal inflammation) among 
women with and without premenstrual disorders (Hantsoo & Epperson, 2015). Given that 
inflammatory markers are already associated with depressive symptom severity, Bertone-
Johnson and colleagues (2014b) examined whether inflammatory markers are also associated 
with menstrual symptom severity and PMS. A total of 277 reproductive-age women self-reported 
on menstrual symptoms, lifestyle, diet, and other factors and also provided mid-luteal phase 
blood samples which were examined for markers of chronic inflammation. Results showed that 
participants’ total menstrual symptom score was positively associated with inflammatory 
markers and that, women who met criteria for PMS had increased proinflammatory markers as 
compared to women without PMS.  
Psychological correlates 
Premenstrual disorders are characterized by cycle-dependent changes in one’s 
psychology—particularly with respect to mood and behaviors. Refer to Table 1 for a summary of 
the common symptoms observed in PMS and PMDD. Refer also to Table 2 for the DSM-5 
diagnostic criteria for PMDD, which require the presence of at least one core mood symptom (of 
four possible forms) and at least one additional physical or behavioral symptom (of seven 
possible forms). In addition to the well-defined mood and behavioral symptoms, research has 
focused on personality and neurocognitive correlates of PMDD.   
Personality. Studies of the personality correlates of premenstrual disorders are limited in 
several ways: (1) They tend to use different measures of personality traits or disorders, making 
comparison difficult; (2) They are overwhelmingly correlational, rendering causal arguments 
44 
 
moot; and (3) They are predominantly of women with ill-defined variations of “PMS” as 
opposed to the clinical definition of PMDD, meaning conclusions may not generalize to the 
PMDD population. 
Freeman and colleagues (1995) administered the Tridimensional Personality 
Questionnaire (TPQ; Cloninger et al., 1991), a now well-validated measure of personality 
dimensions, to N = 157 women who met “clearly defined criteria” for PMS, N = 20 age-matched 
women with major depression and N = 24 age-matched women with premenstrual exacerbation 
of major depression. The three dimensions of the TPQ are harm avoidance (tendency to be 
cautious, tense, and apprehensive in new situations), novelty-seeking (tendency to be excitable, 
exploratory, enthusiastic, and impulsive), and reward dependence (tendency to be sensitive and 
dependent). Women with PMS earned higher TPQ scores on all three dimensions as compared to 
normative samples and their harm avoidance and novelty seeking scores were modestly 
correlated with daily premenstrual symptom scores (r = .19 for both). However, women with 
PMS actually scored significantly lower on harm avoidance than did women in either of the two 
depression groups. The authors concluded that there is little support for the idea that personality 
pathology is a central underlying feature of premenstrual disorder that distinguishes it from other 
depressive disorders. Eissa (2010) replicated Freeman et al.’s (1995) finding that women with 
PMS earned higher scores on the TPQ harm avoidance scale compared to those without PMS, 
albeit in a much smaller sample (N = 22 women with “severe PMS” and N = 20 “healthy” 
controls).  
Eissa’s (2010) study also found that women with PMS earned higher scores on a scale 
measuring perfectionism and that this was particularly true for women reporting the highest 
severity of PMS symptoms:  
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High symptom women showed patterns of perfectionism, an emphasis on self-sacrifice 
and unfavorable comparison of self with others. They reported feeling alone, 
overwhelmed by unresolved tensions…A major issue for high symptom women was that 
they struggled to tolerate imperfections, both in their own performance or in their 
relationships with others. (p. 59)  
Berlin and colleagues (2001) used the Personality Diagnostic Questionnaire-Revised 
(PDQ-R; Johnson & Bornstein, 1991), a broadband measure of personality disorder 
symptomatology, with N = 40 women with PMS and N = 20 women with non-menstrual-cycle-
related depression. All participants completed the PDQ-R in both the follicular and luteal phases 
of their menstrual cycles. Results showed a cycle phase effect such that only women with PMS 
evidenced a significant increase in total score (reflecting overall personality pathology) from the 
follicular phase to the luteal phase, which the authors interpreted to mean that, for women with 
PMS, personality dysfunction may occur at both the state and trait levels.  
Sassoon and colleagues (2011) used the Structured Interview for DSM-IV Personality 
Disorders (SID-P; Pfohl et al., 1995) to determine categorical diagnoses of personality disorders 
in N = 33 women with severe PMS and N = 26 matched “healthy” controls. Results showed that, 
in general, women with PMS were more likely to be diagnosed with a personality disorder (27%) 
than were their healthy peers (0%). Additionally, a sizeable portion of women with PMS (18%) 
had obsessive-compulsive personality disorder, a finding consistent with earlier studies showing 
a relationship between obsessive personality traits and PMS symptoms (Critchlow et al., 2001; 
Eissa, 2010) but inconsistent with rates of comorbidity between the two disorders (which are 
low, between one and 3 percent). Unlike Berlin et al. (2001), Sassoon and colleagues (2011) did 
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not find a cycle phase effect; however, participants completed the SCID-IV-PD in either the 
follicular or the luteal phase, not in both as Berlin et al. (2001) had done.   
Gingnell et al. (2010), in contrast, involved participants with valid DSM-IV diagnoses of 
PMDD as confirmed by prospective daily ratings for two menstrual cycles. They administered 
the Swedish universities Scales of Personality (SSP; Schalling et al.,1987) to N = 30 women with 
PMDD and N = 55 “healthy” controls, finding that women with PMDD scored significantly 
higher on neuroticism-related traits, including somatic trait anxiety, psychic trait anxiety, 
embitterment, trait irritability, mistrust, and detachment compared to the “healthy” controls. 
These differences were disproportionately accounted for by those with the most severe 
symptoms (the “high-severity PMDD patients”).  
More recent research has focused on potential interactions between genetics and 
personality. For example, a link between the estrogen receptor 1 gene (ESR-1) and the traits 
neuroticism, emotional stability, abstractedness, impression management, and harm avoidance 
has also been shown to distinguished patients with PMDD from those without (Miller et al., 
2010). Gingnell et al. (2010) compared the genotypes of 27 women with PMDD and 18 
“healthy” controls, finding that individuals with PMDD who carried the short allele for 5-
HTTLPR (a serotonin transporter gene) earned higher scores on psychic trait anxiety and lack of 
assertiveness compared to “healthy” controls, suggesting that “genetic vulnerability factors and 
associated personality traits may, in concert or separately, influence symptom severity in PMDD 
patients” (p. 422).  
Neurocognitive. Women with premenstrual disorders subjectively report problems with 
cognition during the symptomatic phase of their menstrual cycle (Diener et al., 1992). Indeed, 
“subjective difficulty in concentration” is listed as one potential symptom in the DSM-5 criteria 
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for PMDD (APA, 2013). However, studies examining performance on cognitive tasks in women 
with PMDD have produced conflicting results, finding either no (Morgan & Rapkin, 
2002; Rapkin et al., 1989) or only mild impairment (Diener, et al., 1992; Evans et al., 1998; Man 
et al., 1999; Posthuma et al., 1987; Resnick et al., 1998). Souza and colleagues (2012) reviewed 
27 studies that compared neuropsychological performance across the menstrual cycle. They 
concluded that all women (i.e., with and without premenstrual symptoms) evidence mild 
impairments in cognitive performance during the luteal phase for visuospatial and motor skills, 
attention and concentration, verbal memory, visual memory, working memory, and reaction 
time. However, these changes are more pronounced for women with PMS or PMDD, 
specifically, on tasks of visuospatial and motor skills, attention and concentration, verbal 
memory, working memory, reaction time and impulsivity. For a review of neuropsychological 
impairment in PMDD, see Wiklund (2017). 
Working memory. Earlier studies had found that working memory was impaired during 
the luteal phase for both women with PMDD and “healthy” controls (Man et al., 1999). More 
recently, Yen et al. (2012) studied a relatively large sample of women with (N = 64) and without 
(N = 62) PMDD, finding that, on a working memory task, women with PMDD showed a 
decrease in performance during the luteal phase whereas women without PMDD did not show 
this decrease. Similarly, Reed and colleagues (2008) engaged women with (N = 14) and without 
(N = 15) PMDD in cognitive tasks (while also measuring hormone levels and obtaining 
subjective ratings of mood) and found that women with PMDD performed worse than did 
women without PMDD on two working memory tasks—digit recognition after a brief delay and 
word recall after a four-hour delay—during the luteal phase.  
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Executive functioning. Executive functions, broadly, refer to higher-level mental 
activities, such as prioritizing, planning, multitasking, switching attention, and inhibiting 
competing stimuli. Executive functioning is generally measured using neuropsychological tests. 
Yen et al. (2014) engaged 59 women with PMDD and 74 “healthy” controls in a “Go/NoGo 
task” intended to measure cognitive control, or the ability to select and prioritize behavior in 
response to a stimulus while inhibiting competing stimuli, finding that women with PMDD 
showed decreased cognitive control during the late luteal phase. However, this decrease was only 
observed in women with a specific genotype (G/G) on the HTP1A gene which is thought to be 
involved in the inhibition of serotonin neurotransmitter. Bannbers et al. (2012) also engaged 
women with (N = 13) and without (N = 14) PMDD in a Go/NoGo task during the follicular and 
luteal phases of their cycle, but they also measured brain activation during the task using fMRI 
scanning. Results showed no difference in performance on the task, and, therefore, no difference 
in cognitive control between the two groups, though there was a significant difference in brain 
activation. Women with PMDD showed a decrease in activation throughout the menstrual cycle 
(not limited to specific phases) in several brain areas, especially areas within the parietal lobe.   
Diagnosis 
Diagnostic screening tools. Diagnostic screening tools for PMDD are typically grouped 
into one of two camps: retrospective or prospective. Research has shown that retrospective 
PMDD symptom reports can be easily biased by one’s beliefs about premenstrual symptoms 
(Marván & Cortés-Iniestra, 2001; McFarland et al., 1989) and by memory distortions, including, 
for example, the impact of the context in which the memory is retrieved (Bosman et al., 2016). 
Moreover, retrospective reports are discrepant from prospective reports: Retrospective reports 
tend to overestimate symptoms (Haywood et al., 2002) and cases initially diagnosed by 
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retrospective report are only confirmed by follow-up prospective reports only about one-third of 
the time (Endicott & Halbreich, 1982; Rubinow et al., 1984). To rectify this issue, a valid 
diagnosis of PMDD now requires an evaluation of prospective daily symptom ratings for at least 
two, and preferably more, menstrual cycles (APA, 2013; Eisenlohr-Moul et al., 2017).  
Prospective daily rating scales typically require respondents to indicate the presence 
and/or severity of a myriad of physical and psychological symptoms. In practice, diagnosis is 
typically made by visual inspection of the rating charts, though due to the complexity of the 
information and potential for diagnostician error, computerized models have recently been 
developed (Eisenlohr-Moul et al., 2017). In the research literature, a 30% increase in the severity 
of the symptom from the follicular phase to the luteal phase is typically required to consider a 
diagnostic criterion met (e.g., Yen et al., 2018), though others have required changes as high as 
50% or 75% (Freeman et al., 2000; Yonkers et al., 1997).  
For a recent review of available diagnostic screening tools, including prospective daily 
rating scales, see Hall and Steiner (2015). For the present purposes, consider, as an example, the 
Daily Record of Severity of Problems (DRSP; Endicott et al., 2006), the most commonly used 
prospective measure of premenstrual symptoms (Bosman et al., 2016). The DRSP is a self-report 
measure that consists of 21 items inquiring about physical and psychological symptoms and 
three items inquiring about impairment caused by those symptoms. The DRSP items adhere to 
the DSM-IV definition of PMDD and, to my knowledge, have not been updated to reflect the 
DSM-5. Respondents indicate “the degree to which you experienced each of the problems” on a 
six-point severity scale ranging from 1 (Not at all) to 6 (Extreme). See Figure 3 for an example 





Example item from the Daily Record of Severity of Problems (© 1997, Jean Endicott, Ph.D. and 
Wilma Harrison, M.D) 
 




In a large sample (N = 243) of women who met criteria for PMDD, Endicott et al. (2006) 
demonstrated high internal consistency for DRSP total and summary (depressive symptoms, 
physical symptoms, and anger/irritability) scores (Cronbach’s alphas ranging from .76 to .95) as 
well as high test-retest reliability for total score (intraclass correlation coefficients ranging from 
.73 to .83). The authors found moderate correlations between DRSP total and summary scores 
and other measures of depressive symptoms (rs ranging from .36 to .39), problems of social 
adjustment (rs ranging from .37 to .45), and quality of life (rs ranging from -.36 to -.44). With 
respect to validity, Endicott et al. (2006) found that the individual items and summary scores 
were sensitive to change with treatment and capable of detecting the differential effects of two 
treatment modalities. Borenstein et al. (2007) examined whether the DRSP, which is typically 
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analyzed after one month of ratings, could be made more efficient. They administered the DRSP 
to N = 697 women, more than half of whom continued to complete the record for two full cycles, 
and then compared DRSP first day (i.e., first day of menses) scores to prospectively confirmed 
PMS diagnoses. First-day scores were calculated using the sum of all 21 items (standard) or the 
sum of the highest rated items within each of the 11 scale domains (alternative), finding positive 
and negative predictive values of 53.8% and 83.4% respectively (standard) and 52.7% and 
84.0% respectively (alternative). The authors thus concluded that administering the DRSP on the 
first day of menses is an acceptable and potentially much more efficient screening method to 
identify women with PMS or PMDD.  
Bosman and colleagues (2016) reviewed 75 studies to assess how prospective symptom 
rating scales have been used in research on PMDD. They identified several methodological 
problems inherent in research studies that have used such measures. First, there is little overlap 
in the choice of measure, which limits the ability to compare results across studies. Second, few 
studies specified the time of day that reports should be completed, which is problematic given 
that prior research suggests PMDD symptom severity may vary within a day. Third, most studies 
looked only at reports during the premenstrual phase, thus eliminating any opportunity to 
observe within-person processes or other phasic changes. Fourth, there does not appear to be 
agreement as to which days constitute the premenstrual phase; some authors used the seven days 
before menses, others the ten days before menses, and still others, the five worst days out of the 
seven before menses. Bosman et al. (2016) noted that mean symptom severity will be artificially 
lowered if the chosen period includes days without symptoms. Fifth, most studies have examined 
between-group differences (i.e., women with PMDD compared to women without PMDD) which 
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is problematic because group-level differences are difficult to generalize at the individual level 
(Molenaar, 2004). Truly idiographic approaches are needed. 
Even though prospective rating tools are preferred, and several psychometrically valid 
versions are now available, Eisenlohr-Moul et al. (2017) estimated that approximately 90% of 
practicing clinicians continue to use retrospective measures. This is not, however, entirely the 
result of ignorance or sloth: The International Society for Premenstrual Disorders encourages use 
of retrospective measures to avoid delaying treatment (Hall & Steiner, 2015). Again, consider 
one example, in this case the most widely used retrospective measure, known as the 
Premenstrual Symptoms Screening Tool (PSST; Steiner et al., 2003). The PSST is a self-report 
measure that consists of 19 items inquiring about physical and psychological symptoms and 
another five items inquiring about functional impairment. Respondents answer, “Do you 
experience some or any of the following premenstrual symptoms which start before your period 
and stop within a few days of bleeding” on a four-point severity scale ranging from not at all to 
severe. Like the DRSP, the PSST is based on DSM-IV criteria for PMDD and, to my knowledge, 
has not been updated to reflect the DSM-5. The psychometric properties of the PSST have been 
validated (Hall & Steiner, 2015). Ozdel (2014) reported high item internal consistency 
(Cronbach’s alpha = .93), adequate concurrent validity with another measure of psychiatric 
problems, and the ability to discriminate between groups (PMS versus sub-threshold PMDD 
versus PMDD).  
Differential diagnosis. Perhaps the most common difficulty in distinguishing PMDD 
from related disorders is the necessity of ruling out premenstrual exacerbation (PME). Many 
women who have an underlying chronic mood or anxiety disorder experience worsening 
symptoms during the late luteal phase, which is characteristic of PME but can be easily 
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misdiagnosed as PMDD (Raffi & Freeman, 2017). Indeed, women themselves often misattribute 
worsened symptoms as menstrual cycle-related: Research suggests that women who 
retrospectively report PMS or PMDD symptoms but for whom those symptoms are not 
confirmed by prospective daily report are likely to suffer from a chronic underlying depressive 
disorder, such as MDD, which they misperceive as related to their menstrual cycle (Yonkers & 
McCunn, 2007). Gynecological and other medical conditions must also be ruled out in the 
differential diagnosis of PMDD, including dysmenorrhea, menopausal transition, 
endocrinological diseases (e.g., hypo- or hyperthyroidism), and hormonal treatments (e.g., use of 
some hormonal contraceptives) (Sánchez Blanco et al., 2017). 
Treatment 
Pharmacological.  
Antidepressants. According to the American College of Obstetrics and Gynecology 
(ACOG; 2001), pharmacological treatments are considered first line for PMDD, with selective 
serotonin reuptake inhibitors, or SSRIs, considered the “gold-standard” (Hantsoo & Epperson, 
2015). A 2013 systematic review of 31 randomized controlled trials comparing SSRIs to placebo 
for a total of N = 4372 women diagnosed with “clinical PMS” concluded that SSRIs are effective 
for reducing symptoms of PMS overall (Marjoribanks et al., 2013). However, effect sizes have 
generally been small to moderate (Cohen’s ds ranging from .29 to .58; Kleinstäuber et al., 2012) 
with response rates ranging from 12 to 50% after accounting for placebo effects (Halbreich, 
2008). Halbreich (2008) thus concluded that “it should be acknowledged that, even though 




Results are mixed as to whether continuous (medication administered across the entire 
cycle) or intermittent (medication administered in only the luteal phase) dosing is more effective 
(di Scalea & Pearlstein, 2017). Typically, when SSRIs are prescribed to treat mood-related 
conditions, intermittent dosing is not possible because the therapeutic effects of the medication 
take weeks to appear. In PMDD, SSRIs have been shown to have a much faster therapeutic effect 
on the order of days or even hours (Landén & Thase, 2006; Steinberg et al., 2012). This 
difference is apparently due to SSRIs ability to increase metabolization of progesterone into 
ALLO (Hantsoo & Epperson, 2015). Landén and colleagues (2007) showed that intermittent 
dosing may be particularly helpful for treating irritability and mood lability, though longer-term 
treatment appears to be required to treat depression and physical symptoms.  
Oral contraceptives. Given the relationship between PMDD symptoms and ovulatory 
processes, clinicians have long prescribed oral contraceptives as treatment for PMDD albeit with 
little research support to substantiate that choice (di Scalea & Pearlstein, 2017). To date, there is 
scant research support for the use of oral contraceptives in treating PMDD (Cunningham, 
Yonkers et al., 2009). A systematic review concluded that treating PMDD with single hormones 
(e.g., progesterone or estrogen) is not effective (Ford et al., 2012), though the oral contraceptive 
Yasmin (“Yas” or “Yaz”) has shown promising results and was approved by the FDA as a 
treatment for PMDD in 2006 (di Scalea & Pearlstein, 2017). Yaz contains drospinerone, a 
synthetic form of progesterone, and estradiol, and was shown to perform better than placebo in 
reducing PMDD symptoms and improving quality of life (di Scalea & Pearlstein, 2017; 
Pearlstein et al., 2005; Yonkers et al., 2005).  
Ovulation-suppressants. The administration of gonadotropin releasing hormone (GnRH) 
agonists suppresses ovulation and, with it, the secretion of ovulatory hormones, thus inducing 
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postmenopausal levels of estradiol, progesterone, and ALLO (di Scalea & Pearlstein, 2017; 
Hantsoo & Epperson, 2015). There is some research support for the use of GnRH agonists as 
compared to placebo (Wyatt et al., 2004) and this method is often recommended after women 
have not experienced relief following a trial of SSRI treatment (Hantsoo & Epperson, 2015). 
However, ovarian suppression also leads to the sudden onset of menopausal symptoms and, 
therefore, hormone replacement, or “add-back,” therapy is often needed (Reid & Soares, 
2018).Ovulation can also be suppressed through administration of estrogen (in gel, patch, or 
implant form), which is more common in Europe, or, as a last-resort, by oophorectomy (surgical 
removal of the ovaries) or hysterectomy (surgical removal of the uterus) (di Scalea & Pearlstein, 
2017; Reid & Soares, 2018). Reid and Soares (2018) noted that surgical treatment is usually 
preferred by women who have attempted other forms of treatment without avail, who are 
burdened by the cost of continued medical procedures, and who have other gynecological 
concerns for which surgery may be beneficial.   
Psychotherapeutic.  
Cognitive behavioral therapy (CBT). CBT is the most studied psychotherapeutic 
intervention for PMDD, though findings are of mostly small effects (di Scalea & Pearlstein, 
2017; Hantsoo & Epperson, 2015). Lustyk and colleagues (2009) reviewed seven trials of CBT, 
including five randomized controlled trials, and concluded that “it is clear that the cognitively 
focused therapies do not outperform pharmacotherapy, and, in some instances, they do not 
outperform forms of basic behavioral intervention alone (e.g., relaxation)” (pp. 94-95). However, 
compared to pharmacotherapy, CBT has been found to be uniquely helpful in altering negative 
thoughts and increasing one’s ability to cope with the distress associated with PMDD (Reid & 
Soares, 2018). For instance, a 2012 systematic review concluded that CBT was not more 
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effective than SSRIs in treating anxiety symptoms but was associated with better use of coping 
skills and a shift in understanding of symptoms (Kleinstäuber et al., 2012).  
Lifestyle modification. According to ACOG (2001), lifestyle modification may be 
appropriate for those with mild PMS but is not recommended as the primary treatment for 
individuals with PMDD. Exercise may help alleviate premenstrual symptoms, though studies are 
rare and have yet to evaluate efficacy in women with prospectively diagnosed PMS or PMDD 
(Daley, 2009). Dietary changes may also be beneficial, and common recommendations include 
decreased caffeine, frequent snacks or meals, reduction of sugar intake, and an increase in 
complex carbohydrate consumption (di Scalea & Pearlstein, 2017). Freeman, Stout, Endicott, 
and Spiers (2002) showed that consumption of a carbohydrate-rich beverage led to a reduction in 
symptoms for approximately 30% of women (compared to 5% of women consuming a placebo 
beverage) likely by increasing the availability of tryptophan which increases serotonin 
production and, in so doing, improves mood. Calcium supplementation has demonstrated small 
benefits, not superior to SSRIs but better than placebo (Yonkers et al., 2013).  
Prognosis 
Symptoms of PMDD can begin any time after menarche and occur only during her 
reproductive years, thus ceasing after menopause. Symptoms tend to be chronic and stable across 
cycles; that is, women with PMDD typically experience the same, severe symptoms with each 
menstrual cycle, and this stability appears to be especially true for mood symptoms (Bloch et al., 
1997; Wittchen et al., 2002). According to Landén and Eriksson (2003), clinicians commonly 
believe that symptoms worsen with age until menopause; however, Ramcharan and colleagues 
(1991) reported that, in a large (N = 6232) population-based sample, PMS symptoms appeared to 
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be the most severe among women in their twenties to mid-thirties and actually tended to improve 
as women approached menopause. 
Exactly what percentage of women with PMDD receive treatment is not known, but 
Freeman (2003) reported that, on average, women notice symptoms for approximately 10 years 
before seeking treatment. Pearlstein et al. (2000) and Yonkers et al. (1996) found that women 
who seek treatment for PMDD tend to be those who experience impairments in functioning and 
social adjustment. Robinson and Swindle (2004) extended that finding in a large (N = 1022) 
nationally representative sample of reproductive-age women, showing that treatment-seeking for 
PMS was associated with symptom severity, symptom chronicity, older age, greater overall use 
of healthcare services, and less negative attitudes towards PMS.   
Impact 
In an important 2009 paper, Rapkin and Winer reported on PMDD’s burden of illness 
and impact on quality of life. They assessed burden of illness in the standard way by examining 
direct medical costs, occupational productivity, and quality of life. Summarizing across several 
studies, the authors reported that women with PMDD experience adverse effects on their 
schoolwork, emotional well-being, social life, and work activity. They cited a large (N = 1045 
general population women) cross-sectional study that found the greatest premenstrual-related 
impairment was experienced in the home followed by social situations, school and the workplace 
(Hylan et al., 1999). In addition, Rapkin and Winer (2009) found that a diagnosis of PMS or 
PMDD was associated with greater utilization of healthcare services, a relationship that 
strengthened as symptom severity increased.  
Quantitative data on work-related impairments due to PMDD are mixed; some studies 
report significant rates of work absenteeism whereas others do not. More consistently, PMDD 
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symptomatic phases are related to lower quality and efficiency of work. Qualitative interview 
studies of PMS and PMDD have helped clarify the impact of the disorder on a woman’s work 
life. Jurvanen’s (2017) thesis is a classic example: 11 women with PMDD were interviewed 
according to a “phenomenological approach,” which the author described as an attempt “to 
overlook her [the researcher’s] preunderstanding (assumptions) and instead try to see the world 
through the participant [sic] perspective” (p. 14). The author interviewed each woman 
independently following an “interview guide” that was provided to the participants during the 
interview and was arranged into four topic areas with potential subtopics and questions. For 
example, topic area two was titled “Work related – subjective experiences about PMDD in 
relation to working,” which included the bulleted section “Demands (psychological experience)” 
and the potential questions “What is expected of you?” and “How do you cope?” (p. 51). The 
interviews were transcribed verbatim, read several times, summarized, and then analyzed for 
patterns, or “themes,” according to Braun and Clarke’s (2006) guidelines for thematic analysis.  
The final product, according to Jurvanen, was a “map of themes that accurately correlated 
with the full data, meaning that the essence of participant’s experiences were [sic] represented 
and the plan gave a good summarizing overview” (p. 19). Interviewees reported that their work 
quality is lower and that they socially isolate or otherwise struggle in work relationships when 
they are symptomatic; the vast majority indicated that they can continue to work despite these 
difficulties, but perhaps at some psychological cost; many reported that they have required sick 
leave or changes in their schedule to accommodate symptoms. Also using a semi-structured 
interview approach, Hardy and Hardie (2017) arrived at similar conclusions. In their sample of 
15 women with PMDD, respondents indicated that symptoms interfered with their work 
(specifically, difficulty concentrating, self-doubt, paranoia, fatigue, tearfulness, a heightened 
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sensitivity to the environment and people, outbursts, and finding social interaction difficult), and 
that those symptoms led to greater absences and lesser quality of work. Notably, Hardy and 
Hardie (2017) also found that, after symptoms improved, many women felt significant guilt for 
the premenstrual changes in their work behavior and would subsequently attempt to 
overcompensate by working longer hours, taking work home, or doing extra work, all of which 
contributed to negative long-term outcomes including leaving their jobs.   
The social impact of PMDD is also well-documented by qualitative interview studies 
(Jurvanen, 2017; Siahbazi et al., 2018). Women report increased relationship conflict, difficulty 
managing social interaction, increased social isolation, and lack of emotional experience, all of 
which have a negative impact on their significant relationships. Women with romantic partners 
expressed distress about decreased sexual desire and reduced sexual pleasure; parents reported 
feeling inadequate in their roles, for example stating things like “Even in the morning, it’s hard 
for me to wake up and handle family members. I hardly prepare my child to go to school” 
(Siahbazi et al., 2018, p. 289). Yet, women also frequently endorse the need for social support 
and connection during symptomatic phases (Jurvanen, 2017).  
Critique of Methods for Exploring Premenstrual-related Inner Experience  
Premenstrual symptoms are understood to be inner experiences—private to the external 
observer but directly appended by the woman herself. For example, whereas the external 
observer may notice a sullen look or slow speech (both potential signs of depression), only the 
woman herself experiences “depressed mood.” At present, what we know about the inner 
experiential world of PMDD comes mostly from questionnaires, diary-type studies—the 
repeated, daily administration of questionnaires or symptom rating scales—and, to a lesser 
extent, from single-occasion semi-structured interviews guided by broad interests and questions. 
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Such methods have important limitations, some of which were mentioned before, and which will 
be elaborated in this section.  
First, questionnaires typically require substantial retrospection. For example, the cycle 
version of the Moos Menstrual Distress Questionnaire (MDQ; Moos, 1968) and the Premenstrual 
Assessment Form (PAF: Allen et al., 1991) ask respondents to rate the presence of symptoms 
“during your last cycle” (therefore, requiring them to retrospect over approximately an entire 
month). The Premenstrual Symptoms Screening Tool (PSST: Steiner et al., 2003) does not 
specify a time frame or specific menstrual cycle, but rather implies that respondents are to report 
on their menstrual cycles in general (therefore, requiring them to retrospect and summarize over, 
potentially, several months or years).  
The diary-type administration of questionnaires or symptom rating scales (for example, 
the DRSP; Endicott et al., 2006) limit the amount of retrospection required. For example, the 
DRSP asks respondents “each evening” to rate the severity of a list of possible symptoms (recall 
Figure 3), therefore requiring them to retrospect over, potentially, an entire day. The memory 
errors (Tourangeau, 2000) and biases (Tversky & Khaneman, 1974) associated with 
retrospection are well-known, including, specific to the PMS/PMDD population, a tendency for 
over-reporting (Endicott & Halbreich, 1982).  
Second, prior research has shown that, on questionnaires and rating scales, women tend 
to misattribute symptoms to their menstrual cycle based on self-theories of menstruation. In an 
important early study in this area, Ruble (1977) deceptively informed N = 44 college-aged 
women that the researchers could predict whether they were in the premenstrual phase of their 
cycle using electroencephalography (EEG). Each participant underwent an EEG simulation, after 
which she was told that she was either “premenstrual” (expected to begin her period within 1 or 
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2 days) or “intermenstrual” (not expected to begin her period for at least one week to 10 days). 
Fifteen women were also assigned to a control group and were not given any information about 
their menstrual cycles. Immediately after learning this information, all participants completed the 
MDQ (Moos, 1968) which asked them to rate the severity of 48 symptoms they may have 
experienced over the last two days. Results showed that women who were led to believe they 
were in the premenstrual phase earned significantly higher symptom scores than did women in 
the “intermenstrual” or control groups, suggesting that symptom reporting is influenced by the 
cycle phase a woman perceives herself to be in, regardless of the actual phase of her cycle 
(Veeninga & Kraaimaat, 1995).  
McFarland et al. (1989) showed that the more a woman believed in the phenomenon of 
menstrual distress, the more she reported, in recall, the negativity of symptoms during her last 
cycle. Similarly, Marván and Cortes-Iniestra (2001) showed that the more prevalent a woman 
believed premenstrual syndrome to be, the more premenstrual changes she recalled in her own 
cycles. Veeninga and Kraaimaat (1995) examined the ways women with and without 
premenstrual symptom histories explained their physical and psychological complaints across 
two (cycles) months. They found that women with a history of PMS reported significantly more 
physical and psychological symptoms than did those without PMS, both during the premenstrual 
phase and during the intermenstrual (traditionally non-symptomatic) phase. And while women 
with PMS were, indeed, more likely to attribute their complaints to the menstrual cycle, they also 
more commonly used non-medical explanations, such as psychological distress, physical 
exertion, and even the weather.   
Third, both questionnaires/rating scales and qualitative interviews rely on pre-determined 
questions and prompts that bias the responses in favor of existing cultural and scientific theories 
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and unnecessarily constrain the phenomena that can be explored. Rating scales are typically 
aligned with diagnostic criteria, which makes them useful for establishing diagnosis, but may 
also lead respondents to overreport symptoms they do not truly experience (but that are listed on 
the form) and entirely neglect other symptoms they do truly experience (but that are not listed on 
the form). Attempting to overcome the confinement of questionnaires/rating scales and to 
consider the experience of PMS/PMDD in terms beyond merely symptomatology, some have 
turned to qualitative interview approaches. For example, Siahbazi and colleagues (2018) 
conducted semi-structured interviews with 21 high school and college-aged Iranian women. 
Their goal was to assess the effects of PMS on women’s quality of life and, to that end, each 
interview began with the question, “What has been premenstrual syndrome’s effect on your 
quality of life?” This question appears to be open-ended, though closer examination shows that 
both the beginning and end of the question are specified: The beginning specifies that the 
interviewer presumes a connection between premenstrual syndrome and quality of life. 
Questions that are both open-ended and open-beginninged are needed. An open-ended prompt 
(such as those used in qualitative interviews) is of the form: “I am interested in X; tell me about 
how X is included in your experience.” An open-beginninged prompt is of the form: “I am 
interested in your experience, whatever that experience might be (including nothing); tell me 
about your experience in as complete details as possible” (Hurlburt & Heavey, 2006a). 
Fourth, most questionnaire and interview prompts (including “premenstrual syndrome” 
and “quality of life” in the example before; Sizbazhi et al., 2018) are ambiguous, referring to 
constructs that are typically not adequately defined for participants and therefore, are likely 
interpreted in disparate ways. The failure to clarify prompt language implies that constructs such 
as “quality of life” are believed to be easily identifiable and universally understood experiential 
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phenomena. However, there is no reason to believe that people could reliably say, Aha, yes, now 
I am experiencing “quality of life = 7.” One cannot directly apprehend one’s own “quality of 
life”; instead, an impression of quality of life is undoubtedly derived from some combination of 
directly apprehended experiences, heuristics, self-presentation and other biases, self-theories, 
cultural and scientific theories, and so on. On questionnaires and rating scales, not only is the 
content of a question ambiguous, but the response options are also often ambiguous, typically 
asking participants to rate potential symptoms on a range of severity. For example, the PSST 
(Steiner et al., 2003) asks respondents to rate the severity of symptoms during the premenstrual 
phase as either not at all, mild, moderate, or severe. The authors do not define any of these 
response options; thus, respondents are left to make their own judgments of what qualifies as, for 
example, mild, or how much more distress must be present for a symptom to be rated as severe 
as opposed to moderate.   
Despite their limitations, it is from these commonly used methods that science has 
derived its understanding of the everyday lived inner experience of women with PMDD. 
Hurlburt (2011; Hurlburt & Akhter, 2006) has called everyday lived inner experience “pristine 
inner experience”—the thoughts, feelings, images, sensations, and so on that are directly 
apprehended (“before the footlights of consciousness”), undisturbed by experimentation, 
manipulation, or reflection. Commonly used methods seem on their face to inquire about pristine 
inner experience. For example, if women with PMDD report frequent and severe irritability on 
symptom rating scales, we assume they must feel highly irritable in their direct inner experience 
much of the time. However, as we have seen, such methods are inadequate for exploring pristine 
inner experience because they invite the influence of presuppositions (assumptions, worldviews, 
self-theories, self-presentations biases, and other heuristics that skew, suppress, or exaggerate 
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observations; Hurlburt, 2011) about inner experience. Hurlburt and Heavey (2015) argued that, 
unless methods make systematic efforts to “bracket” (limit the influence of) presuppositions, 
results will reflect some “ill-defined mixture of presuppositions, judgments about experience, 
and pristine experience itself” (p. 148). Descriptive Experience Sampling is one result of the 
sincere effort to bracket the influence of presuppositions. 
Descriptive Experience Sampling 
Descriptive experience sampling (DES; Hurlburt, 1990, 1993, 2011; & Heavey, 2006a) is 
a method that aims at exploring pristine inner experience with fidelity.  DES was originated by 
Hurlburt in the 1970s after he created the beeper that made what is today known as “experience 
sampling” (then, “thought sampling,” or “random sampling of cognitions,” Hurlburt, 1979) 
possible. In DES, participants are given a random-interval beeper (shown in Figure 4) and asked 
to wear the beeper for approximately three hours while going about their everyday activities. The 
beeper emits a 700 Hz tone at random intervals (average = 30 minutes, minimum = a few 
seconds, maximum = one hour). Therefore, three or four hours is typically long enough to collect 
approximately half-a-dozen “beeped” experience samples. When the beeper sounds, participants’ 
sole task is to attend to whatever was ongoing in their inner experience at the “microsecond just 
before your awareness was disturbed by the beep” (Hurlburt & Heavey, 2006a, p. 84), that is, to 
apprehend that which was “caught in flight” by the beep (Hurlburt & Heavey, 2006a, p. 15). 
They are instructed to immediately jot down notes about the experience in a small notebook 







The standard DES beeper (“v.3.x Random Interval Generator”) 
 
Note. Re-printed with permission from hurlburt.faculty.unlv.edu/beeper.html. 
 
Within 24 hours of collecting a half-dozen or so sampled experiences, participants meet 
with a team of DES investigators (at least 2, usually more) for an in-person “expositional 
interview,” during which all parties work together to understand and describe each beeped 
experience. The interview is always guided by some form of the question, “What, if anything, 
was ongoing in your experience at the moment the beep interrupted you?” (Hurlburt & Heavey, 
2006, p. viii) with disambiguating follow-up questions. Expositional interviews are videotaped 
for investigator training and/or to review and discuss differences in understanding. Within 24 
hours of each expositional interview, the investigators collaboratively complete written 
descriptions of each beeped experience. Consensus is not the object; all descriptions are 
circulated among investigators for tracked-changes editing and commentary and are left “messy” 
with disagreements/differences in understandings explicitly noted (Hurlburt, 2017).  
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Participants repeat this natural-environment-sampling-followed-by-expositional-
interview process several times (usually at least four, sometimes dozens), each time iteratively 
building skill through “on-the-job” training (Hurlburt, 2017). DES finds that iteration is 
absolutely essential, allowing for participant and investigators to confront their potentially 
disparate understandings of what is meant by pristine inner experience and the specificity of “the 
moment of the beep” as well as clarifying language for describing inner experiences, for which, 
by their private nature, there is no common language (Heavey et al., 2010). Iterative interviews 
also allow for opportunities to identify and practice bracketing presuppositions for both 
participant and investigator.  
Ultimately, the DES procedure results in a collection of randomly sampled moments of 
one’s naturally occurring inner experience and from this, a “sketch” of characteristics of his or 
her inner experience can be created. Some DES studies engage several individuals who belong to 
some group (e.g., individuals with the same psychiatric diagnosis) and, after following the 
typical DES procedure for each participant, compare those several or many characterizations to 
identify experiential characteristics that emerge as highly salient for the group as a whole or for 
some subset of individuals. When it seems virtuous, DES beeps can be coded for the presence of 
experiential phenomena and those codings can be used to derive estimates of frequency in the 
standard way (total number of samples containing the phenomena ÷ total number of samples) 
within individuals or across a group of individuals.   
Throughout the characterization process, DES investigators remind each other that the 
experiences themselves are the meaningful data—not the interviews, the written descriptions, the 
coding of the descriptions, or anything else—and that the goal of any characterization is to bring 
to life these individual experiences in all their rich detail (or lack thereof), and, often, messiness. 
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Thus, wherever the characterization process involves some reduction (e.g., coding), investigators 
explicitly resist the temptation to ascribe more meaning to those reduced categories than is given 
to the individual experiences themselves. 
Distinguishing Features 
DES is distinguished from questionnaire and interview-based methods in that it 
maximizes ecological validity (by sampling experience in one’s natural environment) and 
minimizes retrospection (by asking participants to describe, only, the experience ongoing at the 
last undisturbed moment before the beep). Other experience sampling methods, such as 
ecological momentary assessment (EMA; Stone & Shiffman, 1994) and the experience sampling 
method (ESM; Csikszentmihalyi & Larson, 1987), also seek to maximize ecological validity and 
minimize retrospection by randomly or quasi-randomly cuing participants to respond to 
questionnaire-like items multiple times throughout a day. These can be called “questionnaire-
based experience sampling methods” (Hurlburt et al., in press).  
However, whereas questionnaire-based experience sampling methods typically provide 
one-shot instructions and training specific to compliance (i.e., monitoring and providing 
feedback on whether participants complete the prompts when they are cued to do so), DES 
provides repeated training (through expositional interviews) that is iterative, in-person, and 
confrontational (in the front-to-front etymological essence, not negative but actually supportive; 
Hurlburt, 2011). Additionally, whereas interviews and questionnaire-based studies rely on pre-
determined prompts (and, usually, hypotheses), DES has no pre-determined interest beyond 
experience itself and therefore asks the “open-beginninged” question, “What, if anything, was 
ongoing in your experience at the moment the beep interrupted you?” (Hurlburt & Heavey, 
2006a, p. viii). Additionally, whereas the questionnaires used in questionnaire-based (including 
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experience sampling) studies are developed and validated for groups of people, DES is truly 
idiographic in that its fundamental purpose is to describe one person’s experience one randomly 
selected moment at a time. This is especially salient to the present study given feminist critiques 
of the PMDD literature; a truly idiographic approach like DES aims at one woman’s experience, 
as she experienced it, in her own words, with explicit efforts to set aside biological, 
psychological, and sociocultural ideas or theories that may influence her experience or 
descriptions of experience. Though the present study’s participants will know they are taking 
part in a study of women with premenstrual symptoms, DES investigators will emphasize 
repeatedly that the interest is in their experience one randomly selected microsecond at a time—
regardless of whether that experience has any connection to the menstrual cycle.  
Perhaps most importantly, DES makes substantial principled efforts to bracket 
presuppositions. Recall that presuppositions are assumptions, worldviews, self-theories, self-
presentations biases, and other heuristics that skew, suppress, or exaggerate apprehensions of 
experience (Hurlburt, 2011). A presupposition is, therefore, a blind spot—a taken-for granted 
“notion about the world that is so fundamental that it exists prior to critical examination” 
(Hurlburt & Heavey, 2006a, p. 151). A presupposition is more than just a mistaken 
preconception; it’s a mistaken presupposition bolstered by unquestioned and powerful 
assumptions (Hurlburt & Schwitzgebel, 2011a), and is therefore difficult to escape from and 
highly likely to influence what one reports. Presuppositions about experience are rampant within 
individuals (e.g., “I’m a verbal person who mostly thinks in words”) and within psychology (e.g., 
“Human beings talk to themselves every moment of the waking day”; Baars, 2003, p. 106). 
 Hurlburt (2011; Hurlburt & Schwitzgebel, 2007, 2011a, p. 225) has argued that 
presuppositions must be actively battled, that it is possible for “the bracketing skill” to 
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overpower the “presupposition skill” within an individual at least so that experience can be 
described with some fidelity in its pristine state. There is no single act or procedure that could be 
called “bracketing presuppositions”; rather, it is a spirit that infuses the entire DES process, from 
the instructions to the participant to the random sampling to the open-beginning prompts to the 
final pen stroke characterizing the experience. Hurlburt (2011) discusses a hundred “constraints” 
inherent in the exploration of inner experience, most if not all of which can be thought of as 
aiming at bracketing presuppositions. 
Consider the self-characterization presupposition mentioned before: “I’m a verbal 
person.” DES attempts to bracket such presuppositions, sometimes explicitly: for example, when 
a participant says in an expositional interview something like, “I was saying to myself, ‘Don’t go 
there.’ That’s how I pretty much always think—I talk to myself a lot,” DES investigators will 
respond with something like, “We accept that you may talk to yourself a lot. But we don’t know 
that yet, so let’s set that self-theory aside for now and focus on this experience, regardless of how 
you usually are. If you do, in fact, talk to yourself frequently, then we will find many examples 
of self-talk over several days of sampling. But sometimes people are surprised to find that their 
experience is quite different from how they thought prior to DES sampling, and we want to be 
open to that possibility, too.” In other ways, the bracketing of participant’s presuppositions is 
more implicit: For example, randomly selecting moments of experience prevents participant’s 
from wittingly or unwittingly choosing moments that they think would be the most interesting or 
avoiding moments that they think would be difficult or boring (both forms of self-presentation 
bias).  
DES investigators, too, have presuppositions. Sometimes those are addressed explicitly, 
such as through discussing the value of presuppositions (so that that valuing is kept front and 
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center) and encouraging disagreement among investigators (so that presuppositions can be 
questioned and exposed). Sometimes they are addressed more implicitly, such as through 
including multiple investigators (so that one investigator’s individual presuppositions might be 
balanced by another investigator’s). 
Decades of DES research have concluded that people are often mistaken (sometimes 
dramatically so) about the characteristics of their inner experience and are often surprised to find 
that their experience as captured by DES is barely (or not at all) reflective of their pre-sampling 
presuppositional views of their experience (Hurlburt, 2011; Hurlburt et al., in press). Hurlburt 
and Heavey (2015) argued that what people report on questionnaires and in questionnaire-based 
experience sampling is likely littered with, if not totally composed of, one’s presuppositions. If 
that is true, it may explain the huge discrepancies between what DES and other methods find 
about inner experience: For example, Hurlburt et al. (in press) showed that questionnaire-based 
methods produced dramatically higher (from two to four times as high) frequencies of 
experiential phenomena than were discovered by DES with correlations between questionnaire 
reports and sampling frequencies were near zero. Those discrepancies raise several questions 
which future research should address. Whose estimates are accurate: DES or questionnaire-based 
methods? If DES estimates are accurate, is it, as DES proponents have argued, the result of the 
bracketing of presuppositions? And is the tremendous time and skill required to bracket 
presuppositions worth it for psychological science? 
Phenomena 
By comparison to retrospective questionnaires (which are typically interested in 
impressions of psychological constructs), DES is fundamentally interested in directly 
apprehendable phenomena of inner experience. To that end, investigators have described in 
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detail phenomena that commonly emerge across DES studies. For example, Hurlburt et al. 
(2013) described inner speaking (a.k.a. inner speech); Heavey et al. (2017) described feelings 
(the experience of emotion); Hurlburt et al. (2009) described sensory awareness (attending to a 
particular sensory aspect of the internal or external environment without particular regard for 
instrumentality); and Hurlburt and Akhter (2008) described unsymbolized thinking (the direct 
experience of thinking without words, images, or other symbols). Together with inner seeing 
(a.k.a. visual/mental imagery), these phenomena have been dubbed the “five frequent 
phenomena” of inner experience, or the “5FP” (Kühn et al., 2014). McKelvie (2019) observed 
that what DES calls sensory awareness, feeling, inner seeing, and unsymbolized thinking seem to 
respectively resemble theoretical elements identified by the classical introspectionists: 
sensations, feelings, images, and imageless thought.  
To examine if and how frequent the 5FP “truly” are, Heavey and Hurlburt (2008) 
engaged N = 30 college students (stratified by self-reported level of psychological distress) in 
three days each of DES sampling according to the typical procedure. This resulted in a total of 
295 experience samples (approximately 10 samples per participant after discarding the first day 
samples as is typical), which were then coded for the presence of the 5FP. Results showed that 
each of the 5FP occurred in approximately one-quarter of experience samples in this stratified 
college student sample. To establish concurrent validity of the 5FP, Kühn et al. (2014) presented 
the case study of one woman trained in DES and then scanned by functional magnetic resonance 
imaging (fMRI) while intentionally or naturally innerly speaking. Results showed that the 
participant’s inner speaking (intentional or natural) was reliably associated with activation in 
brain areas known to be involved in speech processing. 
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It can be useful to code experience samples for the presence of certain phenomena, 
usually including, because they are so frequent, the 5FP. Codings for the 5FP have been shown 
to be reliable: When two independent raters each coded 60 samples (6 each from N = 10 
participants), Hurlburt and Heavey (2002) reported a median Spearman-Brown estimate of 
interrater reliability as 0.98; Across three studies, when five raters each coded a subset of N = 
997 total samples, Hurlburt et al. (in press) reported an average Spearman-brown split-half 
reliability of .95. Hurlburt et al. (in press) thus concluded, “whatever DES measures, it does so 
reliably” (p. 38). 
Adequacy 
The adequacy of DES has been discussed at length, including in a special issue of the 
Journal of Consciousness Studies (Weisberg, 2011) and through back-and-forth dialogue with a 
“skeptic” of first-person methods (Hurlburt & Schwitzgebel, 2007) and a literary scholar 
(Caracciolo & Hurlburt, 2016). Mostly, DES, which is considered a form of introspection 
(“looking into our own minds and reporting what we there discover”; Boring, 1953, p. 170), has 
been pitted against other introspective methods. In Hurlburt and Schwitzgebel (2011b), Hurlburt 
responded to a series of criticisms of the DES method and argued that DES need not be 
considered the epistemic tribunal against which other methods should be judged, but that DES 
takes seriously constraints inherent in introspection that consciousness science has largely 
ignored. For example, most introspective methods ask participants to simulate a specific 
experience (e.g., “Form a visual image of some familiar object, such as the front of your house”; 
Schwitzgebel, 2002, p. 38); Hurlburt argued that such simulated phenomena (in this case, inner 
seeing, or imagery) may be importantly different from the same phenomena as they occur 
pristinely (due, for example, to the social pressures of the investigator’s asking) and that an 
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open-beginninged approach (such as DES) is therefore better-able to capture pristine inner 
experience (Kühn et al., 2014).  More recently, McKelvie (2019) favorably compared DES to 
“classical introspection” (training participants to report the contents of their ongoing awareness; 
p. 1) based on six criteria: function, training, terminology, reliability, validity, and disputes.   
Prior studies 
DES has been undertaken with clinical populations, including individuals with 
depression, anxiety, posttraumatic stress disorder (PTSD), obsessive-compulsive disorder 
(OCD), schizophrenia, borderline personality disorder, bulimia nervosa, and more. Some of these 
studies have uncovered phenomena that—despite being highly salient across participants—are 
completely unknown or poorly described in the clinical literature. For instance, across several 
studies (N = 24 total) of women with bulimia, Hurlburt and colleagues (Jones-Forrester & 
Hurlburt, 2011; Doucette & Hurlburt, 1993a,b) reported that the inner experience of bulimia is 
overwhelmingly (60% of the time on average, ranging from one-third of the time to nearly all the 
time; Krumm, Jones-Forrester, & Hurlburt, 2019) characterized by fragmented multiplicity—the 
experience of several or many (10 or more) separate, disjointed phenomena occurring 
simultaneously. Fragmented multiplicity is rare among non-clinical participants (Heavey & 
Hurlburt, 2008) and therefore appears to be a hallmark experiential characteristic of bulimia.  
No DES study has systematically examined individuals across a biological process, but 
prior studies have included individuals with cyclical disorders. For example, Hurlburt (1993) 
presented four case studies of individuals who experienced distinct mood periods such as 
normalcy punctuated by periods of depression or a cycling between high-energy euphoria and 
fatigue. Hurlburt (1993) made five observations which, though speculative due to the small 
sample size, could be generalized to all four participants. First, symbolization of experience (i.e., 
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the presence of words and images) decreased as depression increased. Second, inner perceptual 
clarity (e.g., the color and detail of imagery) decreased as depression increased. Third, depressed 
participants had difficulty discriminating an actual perceptual experience (e.g., innerly seeing 
something) from metaphors or conceptual descriptions (e.g., that use visual language but do not 
refer to an actual inner seeing). Fourth, some depressed participants seemed to have distinctly 
different mental states associated with different kinds of thoughts; that is, the experiential 
process (not only the experience) was not constant. Fifth, as participants became more depressed, 
they reported more frequent feelings (emotions present in awareness) and fewer emotional 
processes ongoing outside of awareness (which were common during non-depressed periods).    
A review of “John,” one of Hurlburt’s (1993) case study participants, will help illustrate 
the first two observations. John was a 27-year-old university student at the time of his DES 
sampling. John’s baseline, typical functioning was labeled “slightly hypomanic,” where 
“hypomanic” reflects the clinical definition: a distinct and continuous period of elevated mood 
and increased energy lasting less than one week (APA, 2013). According to John, he generally 
had a great deal of energy, needed little sleep (between three and five hours each night), and was 
highly goal-oriented, jumping from one activity to the next. John’s high energy was obvious to 
the DES investigators as well. According to John, this slightly hypomanic state was persistent 
but punctuated by occasional, brief (a day or so) periods of “fatigue.” John wore the DES beeper 
for four days during his typical, slightly hypomanic, functioning, and collected a total of 42 
experience samples.  
John’s experience during the slightly hypomanic period was marked by near constant 
(95% of those samples) inner seeings that were clear, vivid, colored, richly detailed, and usually 
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in motion. For example, at beep 16 (square brackets separate context and background 
information from direct experience): 
[John was remembering a pigeon he had watched die earlier that day. John had picked up 
the bird to soothe it and, noticing that it did not respond, put the bird on the floor of his 
car to take to a zoological park. On the way to the park, the bird flapped its wings 
vigorously, its eyes became beet red, and it then fell over backwards, dead.] Now, at the 
moment of beep 16, John was innerly seeing the dying bird flapping its wings, exactly as 
he had seen it earlier, viewed from the above left, that is, from the same perspective he 
had seen it in the original incident while driving with the bird on the passenger-side floor. 
Simultaneously, he was feeling a little sad, a bodily feeling that centered around his chest 
area. (Hurlburt, 1993, p. 31) 
Of the four case study participants, John was the most euphoric/least depressed and his 
experience was also the clearest and most symbolized, which suggested that perhaps 
symbolization of experience is inversely related to depression. To examine this possibility within 
John, he was asked to wear the beeper again when he noticed he was feeling fatigued. He did so 
on one occasion and collected a total of 10 experience samples. John’s experience during the 
fatigue period was also frequently of inner seeings (90% of those samples). However, the 
fatigue-period inner seeings were, indeed, less symbolized; they were less clear, less detailed, 
lacked motion, and had atypical features, including abrupt edges and unusual and impossible 
perspectives. For example, at beep 48:  
[John was imagining himself and the two DES investigators in the office where their 
sampling interviews took place.] At the moment of the beep, he was innerly seeing the 
three sitting engaged in conversation. John himself was in the center, holding his 
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sampling notebook, and gesturing with both hands slightly outstretched as if to 
emphasize a point. The inner seeing was frozen; for example, his hands were not moving. 
Moreover, the visual details were somewhat indeterminate; for example, he could not say 
whether he held the notebook at the bottom or top; he could “see” that one of the 
investigators was wearing a dress but could not define its color or style; he could not see 
any of their faces, despite apparently seeing their hands. [John described the inner seeing 
as “blurred” or “fuzzy,” but was not confident about that either.] (Hurlburt, 1993, p. 39) 
Thus, beep 48 during the fatigue period was importantly different from beep 16 during the 
slightly hypomanic period: It was less clear, less detailed, and lacked motion. Overall, it was 
noticeably less symbolized than John’s inner seeings during his typical, slightly hypomanic, 
functioning, further supporting the notion that symbolization of experience may be inversely 
related to depression. 
There were limitations to Hurlburt’s (1993) approach, including the small sample size 
and the fact that participants’ self-reported cyclicity was not confirmed in any bona fide 
diagnostic way (though there were signs visible to the investigators that corroborated 
participants’ self-reports). Despite these limitations, the results suggest that inner and external 
experience may covary. The present study will build on that early finding by examining 
experience across a truly cyclic and biologically well-defined process—the menstrual cycle.  
The Present Study 
Overall, a sizeable portion of women report psychological and behavioral symptoms 
(e.g., mood lability, irritability, interpersonal conflicts, depression) that are associated with, and 
probably in some way caused by, cycle-related changes in biology and, especially, in hormones. 
We were therefore interested in exploring whether there are also changes in one’s directly 
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apprehended pristine inner experience during times of cycle-related biological change. To do so, 
we identified women who (by self-report questionnaire) experienced significant premenstrual 
distress and engaged them in multiple (between 16 and 22) days of Descriptive Experience 
Sampling (DES). DES is a beeper-driven method designed to capture pristine inner experience in 
as high fidelity as the current state of the art allows. We dispersed DES sampling days 
throughout the several phases of each participant’s menstrual cycle, thereby allowing for 
experiential differences (if any) to emerge across cycle phases. We suspected that experiences 
would differ around times of rapid biological change, such as during the popularly studied 
progesterone withdrawal of the Late Luteal/Premenstrual but also during the lesser-studied 




Chapter 3: Method  
 The Present Study proceeded in two steps: (1) Screening and (2) Descriptive Experience 
Sampling. (It might be seen as customary to refer to these as “phases” rather than “steps,” but 
using “phase” to refer to investigation step introduces a substantial conflict with the use of 
“phase” to refer to the segment of the menstrual cycle.) 
Step 1: Screening 
The purpose of Step 1 was to identify women who self-reported clinical or near-clinical 
premenstrual symptoms and to advance approximately six of those women to the second and 
main phase of the study. All study procedures were approved by the University of Nevada, Las 
Vegas (UNLV) institutional review board.  
Participants 
 Participants were recruited from the UNLV psychology subject pool online study 
database. The study was advertised as appropriate for women who have noticed premenstrual 
symptoms. In total, 339 women (Mage = 20.20 years, SDage = 3.72) completed the screening step. 
31.9% identified as White or Caucasian, 30.1% as Hispanic or Latinx, 23.3% as Asian and/or 
Pacific Islander, 8.0% as Black or African American, and 5.9% as Other.   
Measures 
 Health & Eligibility Questionnaire. The Health & Eligibility Questionnaire was 
developed for the present study. It included questions about the participant’s typical menstrual 
cycles, use of hormonal contraceptives, and health conditions/behaviors that may have affected 
hormone activity. It also included questions about basic demographic and contact information. 
Participants could refuse to answer any question except those related to contact information. The 
entire questionnaire is shown in Appendix A. 
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 DSM-5 PMDD Visual Analogue Scales. These visual analogue scales (VAS) were 
adapted from Steiner et al. (2005) to reflect the updated DSM-5 criteria for PMDD. A single-
item VAS was used to assess each of the 11 diagnostic criteria, each consisting of a horizontal 
line ranging from 0 = not at all (“the way you normally feel when you don’t have premenstrual 
symptoms”) to 100 = extreme symptoms (“the way you feel when your premenstrual symptoms 
are their worst”). Respondents drug a bar along the line to select their response, which was 
displayed numerically in a box above the bar and changes in real-time as they did so. Steiner et 
al. (2005) administered the VAS to participants on multiple occasions during different phases of 
their menstrual cycles; however, for the present study, participants completed the VAS only once 
and were thus asked to reflect over “the majority of your menstrual cycles.” In the prompt, the 
premenstrual phase was defined as starting “before your period” and ending “within a few days 
of bleeding.” In keeping with Steiner et al. (2005), VAS scores for the four core symptoms were 
averaged to create a mean “mood symptoms” score and all 11 VAS scores were averaged to 
create a mean “total VAS” score.  
Steiner et al. (2005) showed that VAS mean mood symptoms and total scores correlated 
moderately with observer ratings of PMS symptoms on the Premenstrual Tension Syndrome – 
Observer form (PMTS-O; Steiner et al., 1980) with rs ranging from .41 to .63. Internal 
consistency was high for VAS mood symptoms scores during both the luteal and follicular 
phases (Cronbach’s alpha ranging from .88-.96). The mean VAS mood symptoms score was 41 
(95% CI = 38-44) for participants with mild symptoms, 54 (95% CI = 52-55) for participants 
with moderate symptoms, and 70 (95% CI = 66-73) for participants with severe symptoms.  
 The 10-item Premenstrual Assessment Form (PAF; Allen et al., 1991). The 10-item 
PAF is based on the 10 most endorsed items on the original PAF (Halbreich et al., 1982). 
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Respondents rate the intensity of each of 10 premenstrual symptoms during their last cycle from 
1 (not present or no change from usual) to 6 (extreme change, perhaps noticeable even to casual 
acquaintances). The premenstrual phase is defined as beginning “about seven days prior to 
menstrual bleeding (or seven days before your period)” and ending “about the time bleeding 
starts.” Scores on the 10-item PAF range from 10 to 60, and in the normative sample were 
normally distributed with a mean of approximately 30 (M = 27.4, SD = 10.9).  The PAF was 
normed on a non-PMS-related sample of N = 417 Caucasian women between the ages of 22 and 
65 who reported regular menstrual cycles and were taking part in a smoking cessation treatment 
trial. The 10-item PAF demonstrated high internal consistency (Cronbach’s alpha = .95 at 
baseline) and moderate to high test-retest reliability (rs ranging from .6 to .7).  
 DSM-5 PMDD Checklist of Symptoms. This Checklist of Symptoms was developed for 
the present study and directly mirrors the DSM-5 criteria for PMDD. Participants rated the 
presence (yes/no) of the 11 diagnostic criteria and then rated the extent to which those symptoms 
interfere with their functioning in five life domains (from not at all to severely with the 
possibility of selecting not applicable). The entire questionnaire is shown in Appendix B. 
 Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). The 
HADS is a popular and brief tool used primarily in general medical settings to screen for anxiety 
and depression. It is composed of 14 questions, seven pertaining to anxiety and seven to 
depression, and takes approximately two to five minutes to complete. Respondents are asked to 
choose the response that indicates how they have been feeling over the past week. Each item is 
scored from 0 to 3 with higher scores reflecting greater symptomatology. Total anxiety (HADS-
A) and depression (HADS-D) scores are computed separately and range from 0 to 21 where: 0-7 
= Normal, 8-10 = Borderline, and 11-21 = Abnormal. 
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 The HADS has been studied extensively. Bjelland and colleagues (2002) reviewed N = 
71 studies that have used the HADS finding support for the two-factor structure of the HADS 
and effective cut scores (average sensitivity and specificity of approximately 0.80). They also 
reported that the HADS has demonstrated moderate to high concurrent validity (e.g., HADS-D 
correlations with the Beck Depression Inventory range from .62 to .73; HADS-A correlations 
with the State Trait Anxiety Inventory range from .52 to .81) and adequate internal consistency 
(Cronbach’s alphas .60 or greater across all studies).  
 Nevada Inner Experience Questionnaire (NIEQ; Heavey et al., 2019). The NIEQ 
presents 10 visual analogue scales, two (a Frequently item and a Generally item) for each of the 
“five frequent phenomena” of inner experience (“5FP”; Kühn et al., 2014): inner speaking, inner 
seeing, unsymbolized thinking, feelings, and sensory awareness. The original NIEQ was 
administered with paper and pencil; the present study used a computer presentation where (as 
with the DSM-5 PMDD VAS) respondents drug a bar along a horizontal line ranging from 0 = 
none of the time to 100 = all of the time to select their response, which was displayed 
numerically in a box above the bar, changing in real-time as they did so. In keeping with Heavey 
et al.’s (2019) method, markings for each pair were averaged to produce subscale scores for the 
frequencies of each of the 5FP. The five-factor structure of the NIEQ was confirmed, and the 
complete NIEQ is shown in Heavey et al. (2019). 
Procedure 
 Participants followed a link to a Qualtrics survey to complete all measures. The entire 
survey took approximately 30 minutes and had to be completed in a single sitting. Participants 
earned subject-pool research credits for their participation. Responses were reviewed in order of 
appearance and evaluated based on the below inclusionary/exclusionary criteria.  
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 Inclusion/Exclusion criteria. Any woman who self-reported clinical or near-clinical 
premenstrual symptoms and who was otherwise healthy was eligible to advance to Step 2, the 
main part of the study.  
Because the DSM criteria are arguably the most well-established by both research and 
consensus, the presence and severity of premenstrual symptoms were determined using the 
DSM-5 PMDD Checklist of Symptoms, where “clinical” = 5 or more symptoms endorsed (at 
least one of which had to be a mood symptom) with functional impairment rated as moderate or 
worse in at least one domain (all of which is consistent with a DSM-5 diagnosis of PMDD; APA, 
2013). “Near-clinical” = 4 symptoms endorsed with at least moderate impairment in at least one 
functional domain. Scores on the DSM-5 PMDD VAS and 10-item PAF were also considered. 
However, as we have seen, retrospective reports are problematic, and were therefore interpreted 
gently. A participant who endorsed all 11 DSM-5 criteria for PMDD, for example, was not 
assumed to experience PMDD symptoms at literally twice the level of severity compared to 
another participant who endorsed only 5 of the 11 DSM-5 criteria for PMDD. Both results 
indicated only that distress was present and that the participants were appropriate for the present 
study. 
To ensure that our participants were generally healthy with (as best we could deduce) 
typical hormonal fluctuations, we examined responses on the Health & Eligible questionnaire 
and considered excluding participants if there was substantial evidence to suggest that their 
biological fluctuations were atypical and/or that their symptoms were caused primarily by 
something other than menstrual-cycle-related fluctuations. Thus, we excluded anyone who 
currently used hormonal contraceptives or “birth control”; anyone who had been pregnant or 
breastfeeding within the last year; anyone who met criteria for substance dependence; anyone 
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who used substances known to impact systemic hormones; or anyone with comorbid severe 
depression or anxiety. 
There were no outright reasons for a participant to be excluded unless she did not report 
premenstrual distress. Knowing her biological characteristics allowed us to maintain an “eyes-
wide-open” approach to understanding participants’ experience that honored the many potential 
causes of fluctuation and allowed for the potential discovery of novel patterns in women who, for 
the factors mentioned above, would typically be excluded from studies of PMS/PMDD. 
Additionally, premenstrual symptoms are thought to be caused by the biological changes 
(especially hormones) of a typical menstrual cycle and, if we found evidence of cycle-related 
changes in experiences for a participant whose cycle/biology was atypical (e.g., someone with a 
shift-work schedule), that could be of great interest to science. 
Screening Step Results 
Select findings from the screening step are reported here and questionnaire results are 
shown also in Table 4. On the Health & Eligibility questionnaire, 72.6% of all screening 
participants reported having a regular menstrual period, and 39.2% of participants reported they 
currently take a hormonal birth control medication. On the Premenstrual Assessment Form, the 
mean score was in the Average range at 34.21 (SD = 11.07). On the DSM-5 PMDD Visual 
Analogue Scales, the mean score for mood symptoms was in the mild to moderate range for both 
mood (M = 49.86, SD = 25.18) and total symptoms (M = 50.07, SD = 20.94). On the DSM-5 
PMDD Checklist of Symptoms, participants endorsed, on average 2.56 mood symptoms (SD = 
1.35) and 6.91 total symptoms (SD = 2.88), indicating that, on average, participants (by self-
report alone) endorsed clinically significant symptoms of PMDD. Finally, participants endorsed, 
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on average, slightly abnormal levels of anxiety (M = 13.70, SD = 10.56) and normal levels of 
depression (M = 8.74, SD = 9.97).  
Step 2: Descriptive Experience Sampling & Cycle Tracking 
 The purpose of Step 2 was to use descriptive experience sampling (DES) to explore the 
naturally occurring pristine inner experience of women who self-reported significant 
premenstrual symptoms and, eventually, to determine whether pristine inner experience differed 
across the menstrual cycle.  
Participants 
 All women deemed eligible in the Screening step were invited by phone or email to 
participate in the Step 2. Of the 339 total screening participants, 232 were evaluated for 
eligibility (the remaining 107 were never considered due to time constraints). Of the 232 
participants evaluated for eligibility, 82 were deemed eligible and invited to participate in Step 2; 
10 agreed to participate and attended, at least, the Consent and Instruction Meeting. One 
participant dropped out after the Consent meeting citing scheduling difficulties. The remaining 9 
participants each completed at least one day of DES sampling. 
Five women ultimately completed the entire study (Mage = 21.2, SD = 5.54, range = 18-31) 
and will hereafter to be referred to as the “DES Participants.” Of those five, 2 identified as 
Hispanic or Latinx, 1 as White or Caucasian, 1 as Asian and/or Pacific Islander, and 1 as 
“Other.” All were currently enrolled in college courses; one also worked full-time, two worked 
part-time, and two were unemployed outside of their schooling.  
See Table 4 for a summary of Screening results for all screening participants and the 5 
DES participants. A review of Table 4 shows that the Screening step was apparently effective: 
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The DES participants reported higher numbers and severity of premenstrual symptoms across all 







Screening Questionnaire Mean (SD) Results by Participant Group 
 
Screening Participants  DES Participants  
N 339 5 
Visual Analogue Scales –  
Mood Symptomsb 
49.86 (25.18) 70.05 (20.20)  
Visual Analogue Scales –  
Total Symptomsb 
50.07 (20.94) 66.13 (18.74) 
Premenstrual Assessment Forma  34.21 (11.08)  40.0 (11.22)  
DSM-5 PMDD  
Mood Symptomsc 
2.55 (1.35) 3.0 (1.0) 
DSM-5 PMDD  
Total Symptomsd 
6.91 (2.88) 8.4 (2.51) 
Hospital Anxiety and Depression Scale – 
Anxietye 
13.70 (10.56) 8.8 (6.98) 
Hospital Anxiety and Depression Scale – 
Depressione 
8.74 (9.97) 4.8 (6.38) 
Nevada Inner Experience Questionnairef – 
Inner Speaking 
59.75 (26.73) 62.5 (22.93) 
Nevada Inner Experience Questionnairef – 
Inner Seeing 
51.95 (26.44) 57.5 (16.92) 
Nevada Inner Experience Questionnairef – 
Feelings  
68.30 (22.25) 75.9 (13.81) 
Nevada Inner Experience Questionnairef – 
Sensory Awareness 
50.64 (23.38) 66.6 (13.50) 
Nevada Inner Experience Questionnairef – 
Unsymbolized Thinking 
38.20 (26.10) 37.0 (31.72) 
a In a non-clinical sample of women, the average score was 30 with a standard deviation of 10. 
b Scores range from 0 to 100 where 38-44 = “Mild,” 52-55 = “Moderate,” and 66-73 = “Severe” (Steiner et al., 2005)  
c Recall that the DSM-5 diagnosis of PMDD requires at least 1 of the 4 possible mood symptoms be present.   
d Recall that the DSM-5 diagnosis of PMDD requires at least 5 of the 11 possible symptoms be present.  
e Scores range from 0 to 21 where 0-7 = “Normal,” 8-10 = “Borderline,” and 11-21 = “Abnormal” (Zigmond & 
Snaith, 1983) 
f Recall that responses on the Nevada Inner Experience Questionnaire refer to how much of the time a participant 





 DES Sampling. 
Beeper. Participants were issued the standard 4.15” x .85” x 2.40” beeper and single 
earphone used in DES studies (Hurlburt & Heavey, 2006a; see also Figure 4). The beeper 
delivers a 700 Hz tone (beep) at uniformly distributed random intervals (mean = 30 minutes) 
through an earphone. The beep cues participants to attend to their current ongoing experience.  
Notebook. Participants will be issued a 3” x 5” spiral-bound notebook in which to jot 
down notes regarding each experience.  
Cycle Tracking. 
KNOWHEN Saliva Ovulation Test Kit. Participants were each issued a commercially 
available, FDA-approved KNOWHEN ® Advanced Ovulation microscope test kit. Each kit 
contained a lipstick-shaped, hand-held mini microscope shown below in Figure 5. The kit could 




The KNOWHEN Advanced Ovulation Test by Hilin Life Products, Inc. 
 
Note. Re-printed and retrieved from https://www.knowhen.com/en/ovulation-test/knowhen-ovulation-test. 
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As previously mentioned, KNOWHEN ® is designed to detect the five most fertile days 
of a woman’s cycle (i.e., ovulation and surrounding days) based on a salivary ferning pattern. 
Users examine and compare the crystallization pattern on the microscope to determine the 
likelihood of ovulation based on example patterns provided in the test kit (See Figure 6 below). 
The KNOWHEN system is marketed as fast (“results in minutes”), easier to use than “messy 
urine strips,” and affordable (as it can be reused daily for years and requires no refills or 














Consent and Instruction Meeting. Those who agreed to participate in Step 2 of the 
study met with this author at the Inner Experience Sampling Lab located on UNLV’s campus for 
a consent and instruction meeting. During this meeting, participants were informed of the 
purpose of the study, the risks and benefits of participation, and the limits of confidentiality. 
They were informed that DES is a fundamentally collaborative procedure in which they, as the 
participant, would be considered a “co-investigator” (Hurlburt & Heavey, 2006a) who would 
always hold “51% of the vote” and be free to suggest modifications or to discontinue the 
procedure at any time. Scheduling sampling interviews and sharing cycle tracking data required 
participants to maintain daily contact with this author and therefore, to ensure confidentiality, 
participants also selected at this meeting a pseudonym to be attached to their study data (e.g., cell 
phone numbers, sampling descriptions, KNOWHEN results, etc.).  
After obtaining informed consent, this author explained the DES sampling and cycle 
tracking procedures. With respect to cycle tracking, each participant was provided with her own 
KNOWHEN ®ovulation test kit and an instructional handout for how to use the device and 
communicate results with the present author. With respect to DES, this meeting included 
reiterating the purpose of DES, clarifying what is meant by DES terms such as “inner 
experience” and “the moment of the beep,” and demonstrating how to operate the beeper. In 
DES, consent is treated as a living, breathing process and, therefore, was reiterated anew at each 
interaction.  
Finally, the first DES expositional interview was scheduled according to all parties’ 
availability. Participants were instructed to wear the beeper within 24 hours of the expositional 
interview for approximately three hours (or long enough to collect six beeps) during a time of 
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their choosing. Participants were asked to provide consent for expositional interviews to be 
videotaped, and all did so without reservation.   
Cycle Tracking. Recall that, if ovulation (the key event of the menstrual cycle) can be 
detected with some degree of confidence, then the surrounding cycle phases can be relatively 
easily deduced.  Recall also that we chose to use an ovulation microscope as the means to detect 
ovulation. Participants were instructed to use their KNOWHEN ® ovulation microscope test kit 
daily until the cessation of their DES sampling. However, when participants struggled to 
establish this daily habit (as was the case with Allison, for example), they were strongly 
encouraged to aim for using the KNOWHEN ® kit at least on the days surrounding DES 
sampling days (i.e., the day before sampling, the day of sampling, and the day after sampling). 
That improvised method, though it produced a less complete sense of the overall pattern of a 
participant’s results, still allowed for determinations to made as to whether ovulation was present 
around the time of sampling. This author explained the procedure recommended by the makers 
of KNOWHEN ®: Participants were asked to apply a thick drop of saliva to the glass surface of 
the microscope each morning before eating drinking, smoking, or brushing their teeth. When the 
saliva had dried completely (approximately 5-15 minutes), they were instructed to take a photo 
of the resulting salivary pattern and to text that photo to this author who would ‘read’ the result 
for the presence of the ovulation ferning pattern and securely store a note of the result. After 
sending the photo, participants were to wipe the glass surface of the microscope, return it to the 
holding tube, and repeat the same procedure the next morning. 
Participants were asked to send me ovulation-test photos daily. I typically accumulated 
those photos in batches of 10 or more days before I interpreted the photos, thus keeping me 
largely blind to the participant’s current cycle phase. I was typically only aware of a participant’s 
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cycle phase at the end of her participation if we determined it was necessary to strategically 
schedule in phases for which we desired more data. Russell Hurlburt (RTH), however, was 
always blind to ovulation test results and participant’s cycle phase.  
DES Sampling. Sampling followed the typical DES procedure described before and in 
Hurlburt (2011; Hurlburt & Heavey, 2006). In brief, participants wore a random-interval beeper 
for approximately three to four hours while going about everyday activities. When the beeper 
sounded, they were instructed to attend to and immediately jot down notes about whatever 
experience was ongoing at the last undisturbed moment before the beep. Then, within 24 hours, 
they met with a team of DES investigators for an “expositional interview” intended to describe 
with fidelity their experience at each beeped moment. Most participants completed all interviews 
in-person though, due to limitations related to the coronavirus pandemic, two participants 
completed at least some of their interviews by videoconference.  
The goal was for this natural-environment-sampling-followed-by-expositional-interview 
procedure to be repeated approximately 20 times (roughly eight times per menstrual cycle for 
two to three menstrual cycles). However, a participant was considered to have successfully 
completed the study if she obtained samples on at least 6 days for at least 2 menstrual cycles 
(i.e., at least 12 sampling days total). As is typical of DES, participants were asked to collect 
approximately six experience samples on each sampling day, therefore resulting in 
approximately 19 days (excluding day 1 samples as training, as is DES custom) × 6 samples per 
day = 114 total samples per participant, or 5 participants × 114 samples per participant = 570 
total samples across all participants.  
Because the number of sampling days varied for participants (M = 19.6, SD = 2.3, range 
= 16-22) and because participants sometimes only collected five samples on a given sampling 
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day or an interview only had time to discuss five samples, we actually obtained an average of 
107.8 samples per participant for the five participants resulting in a grand total of 539 samples 
across all participants.  
DES Analysis and Characterization. The analysis of each participant’s sampling data 
occurred in two parts. Part One was typical of DES: We reviewed and characterized all samples 
blind to the associated menstrual cycle phase, the object being to create an idiographic 
characterization of the individual participant. Part Two was specific to the present study and 
involved separating sampling days by menstrual cycle phase and comparing experiential 
characteristics and frequencies across phases.    
Part One: The individual (blind to menstrual cycle phase). Recall that the first part of 
the analysis was typical of DES studies in that the goal was to review and characterize all 
samples together blind to and regardless of associated menstrual cycle phase. Upon completion 
of a participant’s sampling, the present author and RTH met to review each sample of her 
experience. The purpose of this meeting was to re-encounter each sampled experience for five 
overlapping reasons: (a) the important characteristics of any particular sampled experience might 
not be evident when that experience is initially encountered—thematic characteristics might 
emerge from later samples that must then be reapplied back to the earlier samples. That is, what 
might have seemed to be an insignificant detail at first encounter might become a salient aspect 
when viewed from the perspective of subsequent samples; (b) it serves to reawaken recollections 
of earlier samples. Our study sampled women across three or more months, and we needed some 
mechanism to overcome any recency effect; (c) we need a means of keeping the sampled 
experiences easily available. Our study accumulated approximately 100 experience samples for 
each participant, which we needed to keep “fresh in mind”; (d) we needed a convenient, flexible 
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ways to be able to access each sample from whatever variety of perspectives that might occur; 
and (e) we wanted our final idiographic characterization of a participant to be shaped by all of 
her experiences. To serve all those goals, during this sample-review meeting we collaboratively 
wrote a brief “caption” for each sampled experience. These captions summarize in a few words 
the phenomena and other characteristics that we understood to have been present at the moment 
of the beep or that we wondered about (and therefore intended to keep alive as we encountered 
and re-encountered each sample. For example, a sample caption may be as simple as “IS” (short 
for “inner speaking”) or may require more detail, such as this caption of Lane’s: “IS, SA (short 
for sensory awareness) sound, separate apprehension short of cognitive but more specific than 
just hearing, multiple.” These captions serve as signposts that point back to and help re-awaken 
in us the experiences themselves. When needed for clarification or to resolve disagreements in 
understanding, investigators returned to the original videotape of the interview. When 
disagreements persisted, they were reflected in the final characterization. This meeting very often 
awakened investigators to features of a participant’s inner experience that had not been clear or 
apparent when encountered at each sample. Sometimes, when taken together and considered 
side-by-side with other similar or dissimilar experiences, nuances and “edges” of experiential 
characteristics emerged or were clarified. 
As soon as possible after (usually within 24 hours of) the review of all samples, RTH and 
I independently wrote a brief characterization of the participant’s inner experience and circulated 
those characterizations to each other to identify any major discrepancies. The goal was to ensure 
that each of our general impressions were commensurate, and that no phenomenon would be 
overlooked or mischaracterized.  
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 Guided by those brief characterizations, I created an Excel file containing, as columns, all 
relevant idiographic phenomena or other characteristics that were identified in the sample review 
and, as rows, each sampled experience. RTH and I then independently coded each experience 
sample for the occurrence of each of the idiographic phenomena/characteristics. We used the 
typical DES coding scheme where “1” = confidently present, “0.5” = possibly but not confidently 
present, and “0” = not at all present. The coding process was ever evolving; if it became clear 
that a certain category could not meaningfully capture the experiential phenomena, that category 
could be reconceptualized or discarded; conversely, if another, previously overlooked category 
presented itself as being useful, it could be added.  
 After we had independently coded each sampled experience for a given participant, we 
considered any disagreements between coders, a process DES calls “rectification.” Rectification 
is designed to correct coding mistakes, if any, but as each coder defended the thinking that led to 
a coding, the particular phenomenon might be clarified, adjusted, and/or solidified to (as best we 
could jointly determine) reflect the participant’s experience. Consensus was not necessarily 
valued; lingering disagreements were noted and reflected in the final characterization in so far as 
they helped describe the phenomena.  
Part Two: Comparing experience across menstrual cycle phases. After all samples were 
reviewed and characterized blind to cycle phase, we turned our attention to cycle-phase-related 
differences.  
Recall that, throughout a participant’s sampling, RTH was fully blind to that the 
participant’s cycle-phase information. I was usually fully (sometimes only partially) blind to the 
cycle phase associated with each of her sampling days; recall that I typically accumulated daily 
ovulation-test results in batches of 10 or so days before I interpreted them. Therefore, in general, 
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sampling days were selected primarily based on scheduling convenience alone, not by 
handpicking certain cycle phases (as we had originally proposed). Because most participants 
elected to sample weekly until they completed the study, and because cycle phases (except for 
ovulation) last approximately one or two weeks each, this scheduling strategy typically 
effectively captured samples from within each cycle phase. On one or two occasions, a 
“positive” ovulation test prompted a participant to suggest an immediate DES sampling (so as to 
capture the ovulation window which lasts only 1-2 days) and, on those occasions, I was not blind 
to cycle phase, though RTH still was.  
Near the end of a participant’s sampling participation (e.g., on the 17th or 18th day of 
sampling), I reviewed the cycle phases in which we had actually sampled with that participant to 
determine whether additional sampling days were needed in any particular phase or phases. I 
made these cycle phase determinations based on the best available evidence, using the ovulation 
ferning results (to mark the time of ovulation), the cycle day, and the cycle length. Sampling 
days were classified into one of the following three phases: ovulation; late luteal/premenstrual; 
or what we called the “traditionally non-symptomatic” phase. We were primarily interested in 
ovulation and the late luteal/premenstrual phase as they are associated with dramatic changes in 
hormone levels, whereas the periods included in the traditionally non-symptomatic phase are 








Menstrual Cycle Phase Classifications  
Phase Classification Part(s) of Typical Menstrual Cycle Biological (Hormonal) Associations 
“Traditionally Non-
Symptomatic”  
Follicular (beginning of cycle to 
ovulation) and Early Luteal (immediately 
post-ovulation to late luteal) phases; 
theoretically days 1-13 or 14; and 15 or 
16-21 
Estrogen and progesterone 
remain relatively stable; 
fluctuations, if any, are minor 
and gradual 
“Ovulation” Theoretical midpoint of cycle; 
theoretically 1-2 days surrounding day 14 
Rapid spike in estrogen 
“Late 
Luteal/Premenstrual”  
Final 7-10 days of cycle, generally 
considered days 21+ 
Withdrawal of progesterone 
 
 
For two participants (Candy and Cat), that procedure caused us to request the participant 
to monitor her ferning and schedule sampling within particular phases that needed additional 
sampling. In those cases, I was not blind to cycle phase, though RTH still was. However, for two 
of the other participants (Allison and Lee), we had obtained an adequate number of experiences 
within each cycle phase scheduling by convenience alone and therefore need no additional 
strategic sampling. For Lane, we would have liked to continue sampling—especially around 
ovulation—but were unable to do so because she requested to terminate her participation due to, 
she said, scheduling difficulties (she was working full-time and going to school). Thus, across all 
participants, I was blind to the participant’s cycle phase (as a rough estimate) 90% or so of the 
time.  
After sampling days were classified within one of the three cycle phases, we explored 
menstrual-cycle-related differences in inner experience.  This was intended to be a consideration 
of phenomenological characteristics, but one quantitative analysis presented itself, unplanned, in 
the course of our consideration of the phenomena of our first participant, Candy, across cycle 
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phases. As a way of keeping track of potential differences in experience across phases, and 
because she had collected more than 100 experience samples, we arranged the sample captions in 
a table that “binned” all sample captions by cycle phase. As mentioned before, the sample 
captions attempt to summarize in as few words as possible the salient phenomena and any other 
relevant characteristic present in the experience. Recall also that captions are signposts pointing 
back to the experiences themselves and thus, the table displaying these captions binned by cycle 
phase was a feasible way for us to recollect and consider all experiences and the ways they 
potentially differed in different phases.   
When we observed Candy’s table of sample captions “binned” by cycle phase, we 
noticed that the captions from the ovulation phase appeared to be much longer than the captions 
in the other cycle phases. To test that observation, we conducted an exploratory single-factor 
ANOVA comparing sample caption lengths across cycle phases. This post hoc procedure 
violates the ANOVA assumptions, which we justified by using it in an exploratory way. 
Therefore, when we say that Candy’s result was “significant,” we mean that had we not violated 
the assumptions, the resulting ANOVA test statistic could be said to be larger than would be 
expected by chance. We discovered that Candy’s caption lengths were indeed significantly 
different across phases by this definition. There was apparently something that varied across 
menstrual phases that was captured by the differences in caption length. As a second step for 
Candy, we asked her to participate in two more days of DES sampling—one during ovulation 
(where caption lengths had been long) and the other in the late luteal/premenstrual phase (where 
caption lengths had been short). We then could conduct a t test comparing caption lengths in 
those two days. That t test was significant (this time without the post-hoc violations of the 
ANOVA assumptions). This suggested that the ANOVA of sample captions might be a helpful 
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tool, so we determined to use this quantitative method as a standard analysis for all later 
participants (therefore violating fewer assumptions for the subsequent participants).  
Finally, to assess for potential differences in the frequencies of experiential phenomena 
across cycle phases, we conducted exploratory chi-squared analyses to test whether a 
phenomenon’s frequency differed across cycle phases. Given that these analyses were 
exploratory, we did not adjust for multiple tests; we use the term “significant” to imply only that 
the differences were relatively large.  
Figure 7 schematizes the overall Step 2 procedure. Notice that, though it was not feasible 
to remain fully blind to cycle phase and/or experience at all times, principled efforts were made 
to be blind (to the extent possible) to biasing factors throughout. There, the top ellipse illustrates 
that we created a sampling strategy that emphasized the desirability of particularly frequent 
sampling during the ovulation and the late luteal phases. This strategy was created before any 
sampling had begun and was therefore blind to any particular participant’s characteristics.  Then, 
for each of our five individual participants, we decided which days to sample based on 
considerations blind to the participant’s own experiential characteristics—the days themselves 
occurring mostly weekly. Then, within each sampling day, the time of each sample was selected 
randomly (and therefore blind to participant characteristics). Then, at the end of a participant’s 
participation, our sample review (and caption creation) was conducted blind to cycle phase, as 
was the preparation of the idiographic characterization of that participant. Then we binned 
samples by phase, which took into consideration the ovulation-test and day within cycle but was 
kept blind to the experiences themselves. Then we considered differences across phases, a 
procedure that unblinded the experiences themselves and the phase binning, both of which were 
constrained by the previous steps. Then, finally, we considered similarities or differences across 
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participants, constrained by all the previous results. Those kinds of efforts are designed to 


































Chapter 4: Results by Participant: Overview and Summary 
 The next five chapters will be devoted to characterizing each of the five DES 
participants. While the overall aim and general analyses were the same, there are important 
differences between participants’ chapters. This is in keeping with the truly idiographic nature of 
DES: Approaches and analyses were regularly adapted when those adaptations seemed better-
able to capture an individual’s experience. Thus, to prepare the reader, what follows is a preview 
of the chapters to come. Efforts have been taken to ensure a participant’s anonymity; all names 
are pseudonyms. 
 Chapter 5 presents Candy, a Hispanic woman who was between the ages of 18 and 25 at 
the time of her participation (we specify only an age range to protect her anonymity). Candy 
ultimately completed 19 days of DES sampling, collecting a total of 112 beeped experiences. 
Across the more than 120 days of her involvement, the ferning test detected ovulation on only 
one occasion, which may have been an artifact of the test (i.e., frequent “false negatives”) or an 
indication that Candy was not regularly ovulating. Regardless, we were able to make a fairly 
confident determination (including the positive ferning test result) that she was ovulating on two 
of her sampling days. In general, Candy’s experience was fairly straightforward with typical (by 
DES standards) phenomena—most often inner speech and sensory awareness. With respect to 
menstrual cycle phase, Candy’s experiences differed appreciably: especially by comparison to 
the late luteal/premenstrual phase, candy’s experiences during ovulation were more frequently 
unclear and complex with inchoate, not-fully-figural phenomenon.  
 Chapter 6 presents Lane, a Caucasian woman between the ages of 25 and 35 at the time 
of her participation. Lane completed 16 days of DES sampling, collecting a total of 88 beeped 
experiences. Lane’s participation was unusual in that after 12 days (66 sampled experiences) of 
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sampling, she requested a pause in sampling.  During that pause, Lane was diagnosed with 
ADHD and Bipolar Disorder and started psychotropic medications. Those medications (she and 
we suspected) caused her to stop having menstrual periods. Even though that would make our 
usual determination of cycle phase impossible, we continued sampling with her for four more 
sampling days (22 experience samples). As a result, we divided our analysis of Lane into two 
parts. The first part is our usual analysis—the characterization of her 66 non-medication 
experiences in general and then with respect to cycle-phase-related differences. We found that 
her experiences were notably clearer and simpler around the time of ovulation (an observation 
that was supported by the ANOVA of caption lengths) as compared to non-ovulation phases. The 
second part of Lane’s characterization focuses on the potential impact of medication on inner 
experience: We explored whether the 22 with-medication samples differ from her 66 without-
medication experiences. We found that Lane’s experiences with-medication were even messier 
than her non-ovulation-phase experiences had been in the first analysis; her with-medication 
samples were often busy, unclear, and with unusually (by DES standards) specific phenomena. 
Chapter 7 presents Allison, a Hispanic woman who was between the ages of 18 and 25 at 
the time of her participation. Allison completed 19 days of DES sampling, collecting a total of 96 
beeped experiences. Allison’s sampling days were difficult to classify within cycle phases as it 
seemed the ovulation (ferning) test was ineffective for her, frequently producing positive results 
that were either “false positives” or indicative of atypical hormone activity. As a result, some of 
the determinations of cycle phase for particular sampling days were made crudely (e.g., based 
only on the day within the cycle) and were at higher risk of inaccuracy. Even with those crude 
determinations, we found subtle differences in Allison’s experience across cycle phases. 
Specifically, Allison’s sensory awarenesses seemed different during ovulation as compared to 
103 
 
the late luteal/premenstrual phase; her ovulation sensory experiences more often involved her 
face and seemed to “grab” and “move” her in ways they did not during other cycle phases.   
 Chapter 8 presents Lee, a multi-ethnic woman who was between the ages of 18 and 25 at 
the time of her participation. Lee completed 21 days of DES sampling, collecting a total of 111 
beeped experiences. In general, Lee’s experience was rich, detailed, and sometimes creative. She 
experienced each of the five frequent phenomena (5FP; Kühn et al., 2014; inner speaking, inner 
seeing, feelings, sensory awareness, and unsymbolized thinking) in approximately 20-25% of her 
samples. Because Lee was inconsistent in providing ovulation test (ferning) results, we 
sometimes had to crudely determine which cycle phase a sampling day belonged in based only 
on the cycle day. Like Allison, this increased the possibility of inaccuracy. However (also like 
Allison), even with those sometimes-crude classifications, we found differences in experience 
across cycle phases. Specifically, Lee more frequently had experiences that were unusual by 
DES standards (e.g., experiencing emotional feelings in color or innerly seeing words) during the 
late luteal/premenstrual phase, whereas such unusual experiences never occurred during 
ovulation.  
 Finally, Chapter 9 presents Cat, an Asian woman who was between the ages of 18 and 25 
at the time of her participation. Cat completed 21 days of DES sampling, collecting a total of 126 
beeped experiences. Cat provided consistent ovulation test results and the test appeared to be 
highly effective for her, thus allowing for more confident classifications of her cycle phases. In 
general, Cat’s experience was dominated by sensory awareness (occurring in more than half of 
all samples) and inner speech (occurring in roughly one-third of all samples). With respect to 
menstrual cycle phases, we observed that Cat’s inner experience was somewhat more complex 
around ovulation. Whereas her experience was usually straightforward with one or maybe two 
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focused and clear phenomena, her ovulation-phase experiences were more often “busy” and 




Chapter 5: Candy 
Candy is a Hispanic female. At the time of sampling, she was between the ages of 18 and 
25 years old (for anonymity, we provide only an age range). She was a full-time undergraduate 
university student and also worked part-time.  
Step 1: Screening  
 Candy reported she had regular menstrual periods. She denied any medical conditions, 
behaviors (e.g., shift work), or medications (including birth control) that would alter her 
hormone function. Her screening results indicated slightly atypical levels of anxiety, but she 
denied any current or previous diagnosis of an anxiety disorder.  
 Candy’s responses indicated she experienced clinically significant symptoms of 
Premenstrual Dysphoric Disorder (PMDD). She endorsed all 11 DSM-5 symptoms of PMDD 
and noted that those symptoms profoundly impacted her schooling, social activities, 
relationships, and activities of daily living. On the Premenstrual Assessment Form (PAF), Candy 
earned a score of 53, which placed her score higher than 98% of those in the normative, non-
clinical sample. On the Visual Analogue Scales of PMDD symptoms, she reported that her mood 
symptoms were, on average, 90% worse during the premenstrual phase as opposed to the rest of 
her cycle. She reported all PMDD symptoms (mood and behavioral) were, on average, 73% 
worse during the premenstrual phase as opposed to the rest of her cycle.  
Step 2: DES Sampling & Cycle Tracking 
Candy completed 19 days of natural-environment Descriptive Experience Sampling 
(DES), amassing 112 total beeped experiences (this count excludes day 1 which was discarded as 
training, as is typical of DES). She followed the typical DES sampling-interview procedure that 
is described fully in Chapter 3 (Method), Step 2.   
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Candy participated in the study across a total of four menstrual cycles. With few 
exceptions (approximately 16 days missed over the course of more than 120 days of active 
sampling), Candy shared daily pictures of her ovulation test kit results. However, for Candy, the 
test successfully detected ovulation (ferning) on only one occasion. We cannot say whether this 
was related to the test itself (e.g., the test failed to detect ovulation when it was, in fact, present; a 
“false negative”) or to Candy’s hormone activity (e.g., perhaps she was not regularly ovulating). 
Therefore, to determine which sampling days occurred during ovulation, we first considered the 
midpoint of her cycles. Over the time she participated, her average cycle length was 29 days, 
therefore estimating ovulation as occurring approximately between cycle days 13 and 17. 
Consistent with that range, the lone occasion on which her test indicated ovulation was cycle day 
17. Table 6 displays in the top panel the breakdown of Candy’s sampling days by cycle phase. 
The bottom panel displays the frequencies of her salient experiential phenomena within each 





Characteristics of Candy’s inner experience overall and by cycle phase 
 
a  Note that % need not up add to 100 because a single sample can contain multiple phenomena. 
* “significant” (recall that this analysis did not adjust for multiple tests) at p < .05 
 





Premenstrual Total X2(2) 
Days of Menstrual Cycle 1-12 and 18-20 13-17 21+   
Number of Sampling Days 6 6 7 19  
Number of Samples 36 36 40 112  
Frequencies (%)a of Experiential Phenomena 
Inner speaking (IS) 29.2 19.4 32.5 27.2          1.73 
Inner seeing 2.8 8.3 12.5 8.0          2.43 
Unsymbolized thinking 0.0 1.4 2.5 1.3          0.90 
Feeling 6.9 12.5 10.0 9.8          0.63 
Sensory awareness (SA) 13.9 23.6 20.0 19.2          1.12 
IS while reading 9.7 11.1 0.0 6.7          4.52 
IS while texting/typing 2.8 8.3 2.5 4.5          1.87 
Word-by-word 1.4 20.8 0.0 7.1        15.05* 
Bodily feelings 6.9 9.7 12.5 9.8        0.66 
Visual SA (all) 5.6 15.3 12.5 11.2        1.83 
Visual SA bright/shiny 0.0 8.3 7.5 5.4        3.03 
Bodily SA 5.6 5.6 7.5 6.3        0.17 
Nothing 13.9 19.4 17.5 17.0        0.41 
Almost or barely containing 
       phenomenon 
11.1 26.4 7.5 14.7        5.94 
Just doing, physical action 6.9 8.3 0.0 4.9        3.29 
Seeing 12.5 19.4 20.0 17.4        0.89 
Hearing 11.1 9.7 2.5 7.6        2.35 
Words present without  
       semantic meaning 




 We followed the usual analysis described in Chapter 3 (Method), Step 2: We first 
reviewed and “captioned” all samples together (blind to their associated cycle phase) and then 
separated sampling days by cycle phase and phenomenologically and quantitatively examined 
differences in experience across phases.  
The Individual (blind to menstrual cycle phase). Across all her samples, Candy’s 
experience was relatively simple, usually one or perhaps two ongoing phenomena. The 
phenomena themselves were typical by DES standards and included frequent inner speech and 
sensory awareness. However, we noticed that, while the sample captioning process was usually a 
simple task (we could easily write as a caption, for example, that Candy was engaged in “inner 
speech” or “sensory awareness, visual, brightness”), it was sometimes not as simple.   
With Respect to Menstrual Cycle Phase. After “binning” Candy’s sample captions by 
cycle phase, we phenomenologically observed evidence of what we had experienced during the 
sample captioning process: Captions appeared to be longer in the ovulation “bin” than in the 
other bins, particularly more than in the late luteal/premenstrual bin. That is, we apparently had 
needed, during the sample review meeting, to use more words to characterize the ovulation-
phase experiences than the late luteal/premenstrual-phase experiences. To test that notion, we 
compared [using exploratory analysis of variance (ANOVA)] the caption character count across 
the three cycle phases, finding that they were significantly different, F(2, 99) = 7.36, p = 0.001. 
Inspection, justified by considering these as exploratory, showed that the ovulation caption mean 
(35.38 characters) was indeed the largest and the late luteal/premenstrual caption mean was the 
smallest (16.19 characters); the traditionally non-symptomatic mean was intermediate (26.64 
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characters). We speculated that this reflected how Candy’s experiences during ovulation were 
somehow more complex/less straightforward than the others.  
We then deviated slightly from the usual analysis in that we designed a brief experiment 
to test our hypothesis that candy’s ovulation-phase experiences were more complex/unclear than 
her late luteal/premenstrual-phase experiences. We asked Candy to wear the beeper twice more, 
once during ovulation and once in the late luteal/premenstrual phase (these became Candy’s 
sampling days 19 and 20). For these final two sampling days, the present author was aware of 
cycle phase, but RTH continued to be fully blind. Upon completion, we reviewed and captioned 
those day 19 and 20 samples in the same way we had for the earlier review and captioning with 
the goal of understanding and identifying the emergent/salient characteristics of Candy’s 
experiences at each sample. We were sensitive as best we could be to the pressures our 
hypothesis put on this process (e.g., that we might be tempted to use more words to describe the 
ovulation beeps to fit our observation about the complexity/lack of clarity). In the end, our earlier 
hypothesis was supported: Candy’s experiences on sampling day 19 (ovulation) were more 
complex and more difficult to classify (and required longer captions) than were her experiences 
on sampling day 20 (late luteal/premenstrual).  
Then, and finally, we conducted the usual exploratory chi-squared tests to examine 
whether the frequency of individual phenomena varied across cycle phases. Because this study 
was exploratory, we did not correct for the multiple chi-squared tests, and what we will call 
“significant” implies only that the frequency differences were relatively large. For Candy, there 
was one significant finding: “Word-by-word” experiences (in which Candy was aware of only a 
single word even though the word belonged within a longer stream of words such as during inner 
speech) were far more frequent during ovulation (20.8% of samples) than they were across other 
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cycle phases (1.4% of traditionally non-symptomatic and 0.0% of late luteal/premenstrual 
samples), X2 (2) = 15.05, p = .001. One other finding was suggestive: Candy had more 
experiences coded as “almost or barely containing some phenomena” (i.e., close to nothing in 
experience) during ovulation (26.4% of samples) than the traditionally non-symptomatic (11.1% 
of samples) and late luteal/premenstrual (7.5% of samples) phases, X2(2) = 5.94, p = 0.051. 
Thus, on the basis of 20 days of natural-environment sampling and careful description of 
112 individual moments of private inner experience, it appeared that Candy’s experience did 
fluctuate with her menstrual cycle. Specifically, we observed that Candy’s experiences during 
ovulation were more complex, unclear, and difficult to classify neatly than were her experiences 
during the late luteal/premenstrual phase. this ovulation complexity did not appear to be an 
artifact of the method or a failure of language but rather reflected the experiences themselves. 
That is, Candy’s actual lived experiences during ovulation were more complex—sometimes 
because phenomena were sort-of-but-not-fully-present and sometimes because a phenomenon 
was similar to a common phenomenon but somehow “less” present/full/rich. In contrast, Candy’s 
experiences during the late luteal/premenstrual phase were much more straightforward with 
clearly and fully present common phenomena. In brief, candy’s late luteal/premenstrual phase 
experiences generally had a clear “figure” apprehended against a less clear “ground” (borrowing 
the terms from Gestalt Psychology), whereas the figure of her ovulation phase experiences was 
not as clearly distinct from the ground.  
The concept of “figure-ground” was introduced by Gestalt psychologists and is typically 
applied to visual perception. The idea, though revolutionary at the time, is actually quite simple: 
To make sense of our complex and often chaotic world, people combine separate elements into a 
unified whole with a central figure (focus) distinguished from the ground (background). The 
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figure emerges clearly and distinctly: It tends to appear larger, closer, isolated from other 
elements, and with clear details, edges, and contrast. The ground, in contrast, is indistinct, 
blurrier, and has few details. As we extend that concept here with respect to inner experience, we 
note that the experiential figure tends to capture us, grabs our interest and involvement, and has 
apprehended force or power, whereas the ground disappears or is perceived mostly in how it 
holds or surrounds the figure.  
With respect to Candy, during the late luteal/premenstrual phase, her experiences had, in 
general, a clear central “figure”: a sample was, without equivocation, the experience of innerly 
speaking while reading; another sample was, without equivocation, a sensory awareness of 
brightness; another sample was, without equivocation, the experience of innerly seeing (seeing a 
detailed image). These phenomena were, without her having any doubt or difficulty, present to 
her as ongoing at the moment of the beep. For example, sample 12.2: 
12.2: [Candy is staring at her rose gold glitter iPhone case.] She is drawn to the 
glitteriness of the case. This is a sensory awareness of the glitteriness [not the color] of 
the case with little or no experience of the fact that it is a phone case or its 
purpose/functionality.  
That sample was an example of what DES calls “sensory awareness,” the experience of attending 
to a particular sensory aspect of an object (internal or external) without particular regard for 
instrumentality (Hurlburt, Heavey, & Bensaheb, 2009). Candy’s experience was fully, singularly, 
and unequivocally aimed at the glitteriness of her phone case. The glittery visual sensation was 
unabashedly the figure of her experience; it emerged clearly and completely; the phone, its 
potential function, and the rest of the universe had disappeared from her experience. As another 
example, consider sample 15.6: 
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15.6: [Candy is watching a video of Kylie Jenner applying makeup.] She is drawn to the 
motion of Kylie’s hand [as it applies the eyeshadow], a sensory awareness of the stroke-y 
motion [ambivalent to the fact that the motion is to apply eye shadow]. At the same time, 
Candy feels calm/relaxed in her body all over, head-to-toe. [The calm is apparently 
created by watching Kylie’s motion/strokes.] 
As in sample 12.2, at sample 15.6, a sensory awareness (in this case, of stroke-y motion) clearly 
and fully emerged as the figure of Candy’s experience. She was aimed squarely at the motion 
made by Kylie’s hand, an awareness of a specific visual sensory/motion quality. Her experience 
was not aimed at eye shadow application (instrumentality) but rather, at the gentle, back-and-
forth stroke-y motion of Kylie’s hand (as she, in fact, applied eye shadow). That is, the stroke-y 
motion was the figure and the rest of the eye-shadow process had disappeared into the ground. 
At the same time, Candy felt calm, a bodily experience of emotion. Like the sensory awareness 
of the stroke-y motion, this calm feeling was a clearly present figure. She apprehended the 
feeling distinctly as calm/relaxed (not, for example, happy/sad/bored/etc.) and she apprehended 
it, without question, in her body (as opposed to mentally), all over from head-to-toe.  
Those samples (12.2 and 15.6) were both in Candy’s late luteal/premenstrual phase. by 
contrast, during ovulation, Candy’s experiences did not generally include such distinct, clear, and 
dominant figures. Indeed, 26.4% (9.5 of 36) of Candy’s ovulation samples were coded as 
“almost or barely” containing some phenomenon (in comparison to only 3 of 40, or 7.5%, of 
Candy’s late luteal/premenstrual samples and 2.5 of 36 or 6.9% of all traditionally non-
symptomatic samples). See, for example, from the ovulation phase: 
9.4: [Candy is watching a video she had just taken of her and her brother.] Mostly 
(approximately 90% of the total experience), she sees her brother’s face. This is an idle 
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seeing; she sees his face as it appeared on the video and is not drawn to or focused on 
anything in particular. In fact, in the video, her brother’s entire body is shown, and he 
was dancing, but she isn’t paying attention to (or even seeing) any of that at the moment. 
She simply sees, without much engagement, his face. At the same time but less salient 
(10% of the total experience), she hears idly or barely her brother singing in the video, “a 
tus amigas video.”  
Thus, at that sample, Candy’s attention had a directed quality (she saw her brother’s face 
but not the rest of his body) but did not have the clarity, force, power, or interest that 
characterized the figures of the late luteal/premenstrual phase. She was watching a video, seeing 
with little engagement her brother’s face (in reality, a small aspect of the video) and hearing with 
hardly any engagement what he was singing. She saw his face but didn’t really care about it—it 
had no force for her. Contrast that with the glitteriness of the phone case in 12.2, where, despite 
its real insignificance, the glitteriness powerfully dominated her experience.  Experiences of this 
sort-of-watching-the-video-of-me-and-my-brother kind were relatively common for Candy, and 
we came to understand them best as “idle” seeings and hearings.  They were coded as “almost or 
barely” containing some phenomena (in this case, barely seeing and barely hearing). Here is 
another example from the ovulation phase: 
10.4: [Candy is about to check the weather via the Weather app on her phone. However, 
she is side-tracked in the process when the Calendar icon catches her attention.] At the 
moment of the beep, she is seeing the Calendar icon (which happens to be white with 
black letters “18” for the date). Her experience is of seeing the icon as it is. She is not 
drawn to any particular sensory aspect nor is she having any accompanying cognitive or 
evaluative experience.  
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At that sample, Candy was (as in the video-watching sample 9.4) seeing idly, with little or no 
engagement. Her eyes were aimed at the Calendar icon and the icon registered, but with little 
force, power, or figural clarity, in her experience. The experience seemed almost accidental, 
happenstance, with no real directed attention or interest. 
These “almost or barely” examples help illustrate the way Candy’s ovulation-phase 
experiences lacked a fully present central figure. To further illustrate, consider sample 9.6: 
9.6: [Candy is preparing to send a video to a friend. She is holding her phone about arms-
length in front of her while making hand gestures to the phone camera with her other 
hand (as if the phone were a mirror). At the moment of the beep, Candy’s arm is 
outstretched beside her head and she is twisting and twirling her hand.] In her experience, 
she sees (in the camera) her hand gesture. That is, she is watching her hand twist and 
twirl. The camera shows her entire arm and hand (and maybe also her face), but she is 
paying attention mostly or only to the hand. There is no accompanying 
evaluation/analytic experience, no thought about the hand or her friend or anything else. 
Thus, at that sample, Candy was watching in her phone camera as she twisted and twirled 
her hand, but her experience was not of doing the twirling, nor was she in any way thinking or 
cognizing about how she looked or what she was doing. Her experience was of seeing her hand, 
which was, phenomenologically speaking, a perception (seeing), yet it would not be accurate to 
classify her experience as only perception. She was slightly more experientially involved. Her 
seeing was not idle in the way we described for samples 9.4 and 10.4; she was watching her hand 
with some apparent interest. But while this hand-twirling experience was more than idly seeing, 
it did not reach the powerful, gripping sensory awareness of, for example, the stroke-y hand 
motion in sample 15.6 or the glitteriness of the phone case in sample 12.2. Like sample 15.6, 
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Candy was watching motion but, unlike 15.6, she was not fully, clearly, unequivocally noticing 
any particular quality of the motion. Her interest was not, for example, grabbed by the twirling 
motion or the daintiness of her hand or its color or any other sensory quality. The twirling-hand 
sample 9.6 was, like others of her ovulation-phase experiences, difficult to neatly classify. The 
experience seemed to be inching toward sensory awareness but yet, no sensory quality emerged 
as the distinct central figure. Sample 6.5 during ovulation was another example of the failure of a 
figure to emerge clearly:  
6.5: [Candy is erasing her whiteboard.] She is mostly (approximately 70% of the total 
experience) trying to get everything completely erased. Simultaneously (approximately 
30% of the total experience), she is visually and motorically noting the pleasantness of 
the erasing [That is, it’s cool/nice/satisfying both to be performing the action of erasing 
and to see all of the writing wash away.] 
Here again Candy’s experience seemed to be “in the ballpark” of but just shy of sensory 
awareness. She experienced more than merely the act of erasing—there was something bodily 
and visually pleasant about it—but the figure of that pleasantness did not emerge clearly or 
dominantly. She was not, for example, drawn to the contrast of the white board and the color of 
the marker or of the shape created by her erasing or the circular motions of her hand or any other 
sensory quality. Again, it seemed the experience was in the direction of sensory awareness, but 
the figure did not fully emerge. Moreover, other samples (such as the glittery phone case) 
demonstrated unequivocally that Candy could apprehend and describe sensory awareness when it 
emerged as a central figure in her experience. Thus, her almost-but-not-quite sensory awareness 
experiences, such as of her twirling hand or erasing the white board, were apparently not the 
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result of lack of skill or descriptive ability, but rather, we think, were the result of differences in 
the experiences themselves.  
These examples have centered primarily on sensory awareness, but the difference 
between Candy’s ovulation and late luteal/premenstrual phase experiences extended to other 
phenomena as well. For example, let us consider examples of inner speech. Sample 4.1 was an 
example of inner speech during the late luteal/premenstrual phase and, consistent with what we 
observed of that phase, was clear and straightforward: 
4.1: Candy hears the bell on her dog’s collar [meaning the dog was approaching her, 
following her, probably wanting something from her]. She innerly says in her own voice 
in a slightly annoyed/exasperated tone, “How annoying.” [Her annoyance is aimed 
mostly at the bell sound.] 
That sample was a straightforward, unambiguous, garden-variety example of inner speech. “How 
annoying” was unequivocally the figure of her experience apprehended clearly in a voice with 
specific tone and specific words in a way that without question fit the DES nomothetic category 
“inner speaking.” See also sample 2.2 of inner speech while reading (a fairly common experience 
for Candy occurring in 7.6% of all samples): 
2.2: [Candy is watching an Instagram story] and reading the text on the story, “Autism 
Awareness Month,” which she simultaneously sees on the screen and innerly says in her 
own voice but in a monotone/flat tone. She is comprehending the meaning as she reads; 
that is, she understands what “Autism Awareness Month” means/alludes to/etc. 
Like the “How annoying” sample before, this was a straightforward example of inner speech. 
Candy said in her own voice “Autism Awareness Month” as she read it. Again, the figure was 
117 
 
clearly present, apprehended in her own voice, with specific words, in a specific tone, and with 
meaning.  
In contrast, sample 10.1, during ovulation, was a subtly—but importantly—more 
complex example of inner speech: 
10.1: [Candy is reading a comment on a YouTube video.] She is reading with some 
comprehension—getting, at least, the ‘gist’ of the comment—and innerly speaking the 
words in her own voice as she reads them. At the moment of the beep, her experience is 
of innerly speaking “innovative.” This is a single word experience; that is, her experience 
is of “innovative,” not, at that moment, of any other words, including those in the larger 
sentence to which “innovative” belongs. [We believe that Candy understood the 
distinction between apprehending word-by-word as opposed to apprehending the arc of 
the sentence and was, herself, surprised at the word-by-word characteristic. We probed 
about this repeatedly with skill and adequate bracketing (see also samples 9.5, 10.2, 
10.6).] 
Thus, as with the late luteal/premenstrual “How annoying” and “Autism Awareness Month” 
samples, Candy innerly spoke while reading; however, unlike those samples, her experience was 
of only a single word (what we ultimately categorized as “word-by-word” experiences) and 
limited meaning. Even though “innovative” belonged to a larger sentence, none of the 
surrounding words were present in Candy’s experience. It was as if her experience didn’t care to 
gather up the surrounding words to make a meaningful whole (figure). She confidently and with 
adequate skill and consistency asserted that only the word “innovative” was present. Moreover, 
whereas in the “Autism Awareness Month” sample, she had comprehended the meaning of the 
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phrase, in the “innovative” sample, she was only somewhat comprehending, grasping the “gist” 
of the reading.  
The single-wordedness of Candy’s “innovative” ovulation sample 10.1 is relatively 
remarkable by DES standards: Typically, when the beep “catches” people engaged in inner 
speech, they confidently assert that an entire sentence or phrase is present. Those (sometimes 
many) words are “held in experience,” so to speak, even when, in some cases, as many words 
could not simultaneously exist at a single microsecond in time. Sample 9.3, also during 
ovulation, was perhaps an even more remarkable example:  
9.3: [Candy has some free time and is going through her text messages responding to 
people she has not texted back. A friend asked, “How are you?”] and now, at the moment 
of the beep, Candy is typing “I’m good.” She innerly says the words in her own voice as 
she types them: “I’m goo—“. [The beep interrupts her such that she only innerly says 
“I’m goo—” even though, had she not been interrupted, she would have continued on to 
say “I’m good.”] [Her experience is of saying the words at a normal rate of speech, even 
though in actuality they would have to be said slower to match her texting rate.] 
This sample was thus of the same word-by-word ilk as “innovative” sample 10.1 except that, in 
this sample, the discreteness of the word was even more extreme. Her experience was of even 
less than a single word; it was a single sound. Candy split the word “good,” only experiencing at 
the moment of the beep “goo” even though she was clearly intending to type and say “good.” It 
would be much more typical for a DES participant to report innerly saying the entire phrase “I’m 
good” even if he or she had not yet completed typing “good”; such disconnect-between-inner-
words-and-typed-words experiences are common, in fact. We conceptualized these word-by-
word experiences as yet another manifestation of the complex, non-fully-figural quality of 
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Candy’s ovulation-phase experiences. That is, during ovulation, words (the figure) did not 
always fully emerge as a unified whole of a phrase like they did in late luteal/premenstrual 
samples. The chi squared analyses supported that conceptualization: In fact, whereas this 
remarkable single-worded experience was frequent for Candy during ovulation (7.5 of 36 
samples, or 20.8% of samples), there were no examples of single-worded experience during the 
late luteal/premenstrual phase (and only one possible example during the traditionally non-
symptomatic phase), X2 (2) = 15.05, p = .001. 
Summary 
At the time of her participation, Candy was a Hispanic, undergraduate university student 
between the ages of 18 and 25. Her screening responses indicated she experienced clinically 
significant symptoms of premenstrual distress. She agreed to participate in DES sampling and 
ultimately did so 19 times across a total of four menstrual cycles, collecting a total of 112 beeped 
experiences. Her menstrual cycles were regular during the course of her participation with an 
average length of 29 days; however, it is possible Candy was not regularly ovulating given that 
the saliva ovulation test only definitively detected ovulation on one occasion (other explanations 
are also possible, for example, that the test was insensitive or that she used it improperly). On the 
basis of those 112 moments of experience, it seemed that Candy’s experience differed across 
menstrual cycle phases. Specifically, her experiences during ovulation were more often unclear, 
complex and almost or barely containing some phenomenon that had not, as we analogized, fully 
emerged as a figure against the ground. In contrast, her experiences especially during the late 
luteal/premenstrual phase were clear, unambiguous, and straight-forward. The complexity of 




Chapter 6: Lane 
Lane is a Caucasian female. At the time of sampling, she was between 25 and 35 years 
old. She was employed full time while attending school part-time for an undergraduate degree in 
the social sciences.  
Lane’s chapter differs from the others in that it will proceed in two parts. The first part is 
the usual analysis, an exploration of menstrual-cycle-related differences in inner experience. The 
second part will focus on the potential impact of medications on experience because, after 
completing 12 days of DES sampling, Lane chose to suspend her participation so that, she said, 
she could focus on schoolwork. When she returned approximately three months later, she 
informed us that she had undergone a psychiatric evaluation and was diagnosed with Attention-
deficit/Hyperactivity Disorder (ADHD) and Bipolar II Disorder and prescribed Adderall (for 
attentional symptoms) and Lamotrigine (for mood stabilization). Lane stopped menstruating after 
she began taking these medications, as is a common side effect of antipsychotic medications like 
Lamotrigine (Seeman, 2011). We continued sampling with Lane for four more sampling days 
(days 13-16) even though she was no longer regularly menstruating; As a result, we could not 
make the same inferences about her menstrual cycle phase (and, by deduction, hormone levels) 
on those days as we usually did for this study. We could, however, compare those four with-
medication days to Lane’s first 12 without-medication days to explore whether the introduction 
of psychotropic medications had any impact on her inner experience. This was an unexpected 
avenue by which to approach the study’s broader interest, which is how biology relates to inner 
experience.  
Step 1: Screening  
Lane’s screening results indicated she was appropriate for the study. She reported she had 
regular menstrual periods. She denied any medical conditions, behaviors (e.g., shift work), or 
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medications (including birth control) that would alter her hormone function. She endorsed a prior 
episode of depression (approximately three years prior) for which she was treated with 
antidepressant medication. Lane’s responses indicated she experienced clinically significant 
symptoms of Premenstrual Dysphoric Disorder (PMDD). She endorsed all 11 DSM-5 symptoms 
of PMDD and noted that those symptoms profoundly impacted her functioning at work and 
school. On the Premenstrual Assessment Form (PAF), Lane earned a score of 47, which 
translates to a z score of 1.7 and therefore placed her score higher than approximately 95% of 
those in the normative, non-clinical sample. On the Visual Analogue Scales of PMDD 
symptoms, she reported that her mood symptoms were, on average, 72.25% worse during the 
premenstrual phase as opposed to the rest of her cycle. She reported all PMDD symptoms (mood 
and behavioral) were, on average, 85% worse during the premenstrual phase as opposed to the 
rest of her cycle.  
After meeting Lane, we learned of several factors that may have complicated her health 
and hormone function. Specifically, Lane described a prominent history of distressing menstrual-
related symptoms for which, she said, she had unsuccessfully sought treatment for more than ten 
years. She reported that, within the last year, she underwent elective tubal ligation surgery for 
endometriosis. Endometriosis is a disease characterized by the growth of endometrium-like 
tissue outside the uterus, most typically in pelvic organs, including the ovaries. The most 
commonly cited consequences of endometriosis are pain and infertility, though many other 
quality-of-life aspects are affected (Agarwal et al., 2019). Endometriosis is associated with 
elevated levels of estrogen (Kitawaki et al., 2002) and may impair spontaneous ovulation, though 
research on the impact of endometriosis on ovulation is mixed (Benaglia et al., 2009; Maggiore 
et al., 2015). Tubal ligation, in contrast, generally has little effect on ovarian hormone function 
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and is not known to disrupt ovulation (Fagundes et al., 2005; Tiras et al., 2001). Lane’s fairly 
confident impression was that she was still ovulating post-surgery. 
If Lane’s health complications had, in fact, disrupted her ovarian hormone function, then 
she was not the ideal candidate for our study. In another manner of speaking, however, the 
severity of Lane’s premenstrual symptoms made her the ideal candidate for our study. 
Ultimately, we chose to engage Lane in sampling and interpreted her results (wherever possible) 
separated by cycle phase. We also, however, acknowledge the possibility that, when we 
separated Lane’s experiences by cycle phases, those cycle phases were not characterized by the 
same levels of and changes in hormones as would be expected for a woman with typical 
hormone function.  
Recall that the status of Lane’s biology became further complicated when, after her first 
12 days of DES sampling, she began taking psychotropic medications for ADHD and Bipolar 
Disorder. We, of course, did not and could not have anticipated that at the time of Screening.  
Step 2: DES Sampling & Cycle Tracking (the usual analysis, without-medication) 
Lane completed 16 days of DES sampling; however, because psychotropic medications 
caused her to stop regularly menstruating after sampling day 12, only the first 12 sampling days 
could be classified according to menstrual cycle phase and analyzed in the usual way. During 
those first 11 days of natural-environment DES sampling, Lane collected a total of 66 beeped 
experiences. (this count excludes day 1 which was discarded as training, as is typical of DES). 
[This first analysis (Step 2) will consider only those 11 days with the usual menstrual-cycle-
related analysis but recall there will be a second analysis (Step 2b) that compares Lane’s 
experience with- and without-medication.]  
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With only one exception during those 11 sampling days, Lane shared daily pictures of her 
ovulation test kit results. Across the three menstrual cycles, her average cycle length was 25 
days, therefore estimating ovulation around days 10-14. Consistent with that estimation, the two 
sampling days we identified by ferning as occurring in the ovulation phase were on cycle days 12 
and 15. Thus, the ovulation test kit appeared to be effective for Lane.  
Analysis 
The Individual (blind to menstrual cycle phase). As usual, we completed all 16 days of 
DES sampling before reviewing or analyzing any samples. Then, we reviewed and captioned all 
16 days of samples before conducting two separate analyses. This was the usual analysis: a 
consideration of cycle-related differences in experience during Lane’s first 11 days of sampling 
(without-medication).  The top panel of Table 7 displays the breakdown of Lane’s sampling days 
by cycle phase for those 11 sampling days. The bottom panel displays the frequencies of Lane’s 








Characteristics of Lane’s inner experience overall and by cycle phase (the usual analysis, 
without-medication) 
 
a  Note that % need not up add to 100 because a single sample can contain multiple phenomena. 
* “significant” (recall that this analysis did not adjust for multiple tests) at p < .05 





Premenstrual Total X2(2) 
Days of Menstrual Cycle 1-12 and 16-20 12-15 21+   
Number of Sampling Days 7 2 2 11  
Number of Samples 42 12 12 66  
Frequencies (%)a of Experiential Phenomena  
Inner speaking 35.7 25.0 66.7 39.4    5.02 
Inner seeing 6.0 33.3 8.3 11.4    7.08* 
Unsymbolized thinking 42.9 41.7 16.7 37.9    2.81 
Feeling 14.3 25.0 12.5 15.9    0.93 
Sensory awareness 38.1 33.3 62.5 41.7    2.71 
Multiplicity 22.6 4.2 45.8 23.5    5.85 
“Organismic apprehension”  41.7 25.0 50.0 40.2    1.67 
Bodily feelings 4.8 8.3 12.5 6.8    0.93 
Bodily + mental feelings 4.8 8.3 0.0 4.5    0.97 
Multiple simultaneous sensory    
    awarenesses  
23.8 8.3 16.7 19.7    1.50 
Bodily sensory awareness 28.6 25.0 37.5 29.5    0.50 
Feeling/sense in specific  
    body region 
4.8 16.7 8.3 7.6    1.90 
Tactile sensory awareness 11.9 16.7 16.7 13.6    0.29 
Auditory sensory awareness 0.0 0.0 16.7 1.5    9.28* 
Seeing 4.8 25.0 25.0 12.1    5.87 
Hearing 7.1 0.0 8.3 6.1    0.97 
125 
 
With Respect to Menstrual Cycle Phase (the usual analysis, without medication). 
Once separated by cycle phase, Lane’s experiences appeared clearer and simpler during 
ovulation as compared to other cycle phases, especially the late luteal/premenstrual phase. The 
ANOVA of caption lengths confirmed this observation, showing that the caption length differed 
“significantly” across cycle phases, F(2, 63) = 4.20, p  = 0.019. Inspection (justified by 
considering these analyses exploratory) showed that ovulation captions were shortest (M = 
23.58) and that traditionally non-Symptomatic (M = 61.79) and late luteal/Premenstrual (M = 
57.33) captions were similar in length and longer than during ovulation. We speculated that this 
reflected how Lane’s ovulation-phase experiences were clearer, simpler, and more 
straightforward than experiences during other phases, thus requiring fewer words to summarize.  
 We then conducted the usual chi squared analyses to test whether the frequencies of 
experiential phenomena differed across cycle phases. There were two “significant” (this was 
exploratory, and so did not adjust for multiple tests) findings: 
 Inner seeing differed across cycle phases. By inspection, inner seeings were more 
frequent during ovulation (33.3% of samples) than they were in the other phases 
(6.0% of traditionally non-symptomatic samples and 8.3% of late luteal/premenstrual 
samples), (X2 (2) = 7.08, p = 0.029).  
 Auditory sensory awareness differed across cycle phases. By inspection, auditory 
sensory awareness never occurred during ovulation or the traditionally non-
symptomatic phase, whereas it occurred in 16.7% of all late luteal/premenstrual 
samples, (X2 (2) = 9.28, p = 0.010). However, note that, given the small number of 
late luteal/premenstrual samples, 16.7% only corresponds to 2 total experiences. 
Two other findings were suggestive:  
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 Multiplicity seemed to differ across cycle phases (X2 (2) = 5.85, p = 0.054).  By 
inspection, multiplicity was less frequent during ovulation (4.2% of samples) than it 
was in the other two cycle phases (22.6% of traditionally non-symptomatic samples 
and 45.8% of late luteal/premenstrual samples). 
 Seeing seemed to differ across cycle phases (X2 (2) = 5.87, p = 0.053).  By inspection, 
seeing was more frequent during ovulation and the late luteal/premenstrual phase 
(25.0% of samples in each of those phases) than it was during the traditionally non-
symptomatic phase (4.8% of samples).  
 To illustrate this clarity-during-ovulation observation, let us first consider examples of 
unclear, highly complex experiences in non-ovulation phases, such as this one from the late 
luteal/premenstrual phase:  
10.6: [Just before the beep, Lane was reading a Reddit thread that began with the 
question, “What was the black market of your high school?” Other users’ answers had 
been, to her ear, “innocent” things like “PB&J sandwiches,” which surprised her because, 
at her school, Xanax was the black-market item.] At the moment of the beep, she 
somehow experiences being in her high school courtyard, a sort of collage of 
rememberings/re-experiencings. She experiences simultaneously many different aspects 
of the courtyard and her experiences there (e.g., seeing the courtyard, focusing on a 
particular memorable shaded region, recalling a girl who used to sell Xanax). The re-
experiencings are rich in that they include senses of where things were, what they looked 
like, who was there, how it felt, all of which is present to her simultaneously, but none of 
which is fully articulated for any of the simultaneously present aspects. Her experience at 
this moment is entirely captured by this re-experiencing-collage of the courtyard. [She 
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cannot even recall where she was or what she was doing in reality at the time the beep 
occurred.] 
Notice that, at the moment of that beep, Lane’s experience was rich and complex but not well-
articulated. For example, it had visual details (the shaded region of the courtyard for instance), 
yet she did not have the experience of imaginarily seeing anything. She somehow, without 
actually innerly seeing, imagined the shaded courtyard. Another part of the complexity of this 
high-school-courtyard sample was its multiplicity. “Multiplicity” refers to experiences in which 
there are several simultaneous but different (and often disjointed) aspects ongoing at a single 
moment—what Lane herself called a “collage.” That is, Lane directly apprehended (though how 
was not entirely clear) what the courtyard looked like, how it felt to be there, who was typically 
there, and even specific memories such as a classmate selling Xanax. Each of those aspects was 
simultaneously present to her and yet none was apparently the central focus or “figure” of her 
experience.  
Sample 7.5 during the traditionally non-symptomatic phase was another of Lane’s 
“messy” experiences: 
7.5: [Lane is lying down.] Mostly (60% of the total experience), she feels pains in her 
hip, leg, and knee. [It’s the same pain, probably, by origin] but is differentiated in her 
experience such that there seem to be separate sensations in each location and each 
sensation is appreciably (even if only minorly) different from the others [She cannot say 
exactly how they differ at the moment of the beep. In each location there is a lightly 
pulsating sensation, but perhaps the knee feels a little sharper at the moment whereas the 
hip is duller and perhaps these differences are changing moment to moment]. At the same 
time (40% of the experience), she wonders in a cognitive way without words or pictures 
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whether yoga has been helping with the pain. As part of that experience, she remembers 
how it felt to be in her yoga class earlier that day. This is a mostly physical 
recollection/re-impression or sense of being-there-in-yoga-class but is not specific. That 
is, it is not that she re-experiences any specific feeling, interaction, or body sensation that 
happened during the class. Rather, she remembers how it was where the it is more-or-less 
inchoate/unarticulated in her experience. Thus, this is one yoga experience with a 
cognitive aspect aimed at yoga generally and a more (as best we could say) physical 
aspect aimed at how it was to be in a specific yoga class earlier.  
Like the high-school-courtyard sample before, the complexity in this sample arose from two 
features: (1) the unarticulated/undifferentiatedness of the being-there sense which, though 
difficult to describe, was without question present to Lane at the moment, and (2) the multiple 
ongoing phenomena (three simultaneous but separate physical sensations of pain + a thought 
process + a being-there sense/remembering). Consider also sample 4.2 during the traditionally 
non-symptomatic phase: 
4.2: [Lane is typing “Jan” into her weekly to-do list for Saturday.] She is somehow 
cognitively anticipating that Jan and Jan’s boyfriend are coming over to her house on 
Saturday to swim and, simultaneously, somehow cognitively recalling the last time Jan 
had come over to swim and had FaceTimed this boy (whom Jan had just met but who is 
now Jan’s boyfriend) for several hours. This is one experience with two aspects – one 
imaginary anticipatory awareness/thought of Jan and her boyfriend coming over and one 
recollective imaginary awareness/thought of the last time she was with Jan and (by 
unintended FaceTime) Jan’s boyfriend. [There was perhaps something comparative about 
these two aspects—comparing the last time to this upcoming time, but if or how 
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comparison was present was not clear]. This experience is not visual; that is, she does not 
see them at the pool either in the past or future. Nor, is it very specific: Lane knows they 
will be in her backyard on Saturday—that part is specified—but, beyond that, the 
thought/awareness is unspecific.  
That sample was, again, a complex, highly undifferentiated experience. Lane definitely had some 
“awareness” of her last visit with Jan and, simultaneously, her upcoming visit with Jan, but how, 
exactly, those awarenesses presented themselves was not clear. It would not be faithful to say 
that Lane was innerly seeing her past or upcoming visits with Jan because—even though there 
were details that seemed visual (e.g., remembering that they had been previously and would be 
this time in her backyard)—she did not experience herself as seeing at the moment. It would not 
be faithful to say Lane was thinking (like an unsymbolized thought process) of Jan because her 
experience was not distinct and explicitly cognitive in the way unsymbolized thought processes 
typically are. And it would not be faithful to say that Lane had some feeling about her past and 
upcoming visits with Jan because there was apparently no emotion ongoing.  
Thus, as those examples illustrate, Lane’s non-ovulation samples were often highly 
complex, usually multiple, and often not well-articulated/differentiated. in contrast, let us now 
consider some of lane’s ovulation samples, which were more often clear and relatively simple 
with a central “figural” phenomenon (such as sample 5.5): 
5.5: [The wind has been blowing Lane’s office door open and closed, triggering the door 
alarm to beep.] At the moment of the beep, she hears the door beep, sees on the security 
video that the front door is flapping with no one entering or leaving, and innerly says in 
her own voice with a slightly annoyed tone, “I wish the door would stop beeping.” The 
inner speaking is experienced as equally spoken and heard.  
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 Ovulation samples 5.3 and 6.2 were also clear and straightforward despite containing 
multiple phenomena: 
5.3: [Sometime before the beep, Lane let a man into her office so that he could drop off 
boxes. Now, she is preparing her lunch,] and (90% of the total experience) is wondering 
in a cognitive way without words or pictures something like, Will he [the man with the 
boxes] be done by the time I’m done prepping my lunch? Will he say goodbye or just 
leave on his own? At the same time but much less prominent (10% of the experience), 
she’s looking at the grapes she’s washing, trying to spot moldy ones so she can remove 
them from the bunch. She is not particularly drawn to any visual or tactile aspects of the 
grapes. 
6.2: [Lane gathers her DES beeper, notepad, and pen and starts to walk toward the 
bathroom.] At the moment of the beep, she innerly says to no one in particular, 
“Unfortunately, I have to carry this thing [referring to the awkwardness of having no 
pockets and therefore having to carry the beeper with her to the bathroom].” This is in her 
voice in a matter-of-fact tone, and her experience is of speaking, of producing the words. 
At the same time and equally present, she feels a pins-and-needles sensation [her leg is 
asleep] in her lower left leg from the top of her foot to her knee. This is an entirely 
sensory experience; she is not analyzing or otherwise thinking about the sensation, just 
feeling it.  
Lane’s experience at these three beeps was clear, well-articulated, and relatively simple. 
Note that Lane’s clarity during ovulation was apparently not due only to a lack of multiplicity as, 
even during ovulation, she had experiences with multiple simultaneous phenomena (such as in 
the wondering-about-the-delivery-man sample 5.3 and beeper-carrying sample 6.2). However, 
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the multiplicity at those moments was noticeably less complex than that of the non-ovulation-
phase experiences described earlier. For example, at the delivery-man sample 5.3, the two 
simultaneous phenomena (an unsymbolized thought process about the delivery man as well as 
looking with intention at the grapes) were each well-articulated and neatly constrained: The 
aspect about the delivery man was without question and exclusively an unsymbolized thought 
process, and the aspect about the grapes was without question and exclusively a visual 
perception. This was in stark contrast to, for example, the non-ovulation high-school-courtyard 
sample 10.6, during which Lane was somehow experiencing many aspects of the courtyard yet 
none of those aspects was well-articulated.  
Moreover, at the ovulation delivery-man sample, there was a clear focus: Lane was far 
more interested in the delivery man than the grapes (90% compared to 10%). The delivery man 
was clearly the figure whereas the grapes were the background. In contrast, during some non-
ovulation samples, there did not seem to be a single aspect that was the most salient, central 
figure. For example, at the late luteal/premenstrual 10.6 high-school-courtyard beep, no single 
aspect of the courtyard was most important. Similarly, at the Traditionally Non-Symptomatic 
three-simultaneous-pains sample, Lane was only slightly more interested in the physical pain 
sensations than the being-there sense about the yoga class (60% compared to 40%)1. Moreover, 
the “60%” of her experience aimed at the physical sensations was, itself, divided among three 
separate but simultaneous sensations each in a different bodily location.  
Thus, there seemed to be, during ovulation, a striking clarity and simplicity in Lane’s 
experiences as compared to other phases of her cycle which were characterized more frequently 
 
1 Note that the percentages themselves are arbitrary; by “60% and 40%,” we understand Lane to mean something 
like, “I’m just a little more into the pain than the yoga class” whereas “90% and 10%” convey something like, “I’m 
way more into the delivery man than the grapes.” 
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by multiple phenomena including phenomena that were inchoate, unarticulated, or otherwise 
difficult to describe. And, indeed, there were fewer samples coded as “multiple” during 
Ovulation as compared to the other phases, a finding that was suggestive (p = 0.054). 
To illustrate the clarity and simplicity of lane’s ovulation-phase experiences further, let 
us narrow in on Lane’s visual experiences. Typically, when DES participants have a visual 
experience, they experience themselves as seeing and can describe, often in great detail, what 
they see. DES calls this phenomenon “inner seeing” (elsewhere called “having a mental image,” 
“visualizing,” etc.). In total, 7.5 (11.4% of all 66 without-medication samples) of Lane’s 
experiences were coded as “inner seeing.” Inner seeings were more frequent during ovulation: 4 
of the 12 ovulation samples (33.3%) were inner seeings compared to 3.5 of the 54 non-ovulation 
samples (6.5%). During non-ovulation phases, Lane’s experience was sometimes (4 samples in 
total, or 7.4% of non-Ovulation samples) seemingly but not explicitly visual (i.e., in the direction 
of an inner seeing), which is not the same phenomenon as what DES calls “inner seeing.” Lane 
had no such in-the-direction-of-seeing experiences during ovulation; when Lane’s experience 
was visual during ovulation, it was an unequivocal inner seeing.  
For example, at sample 3.1, during the non-ovulation late luteal/premenstrual phase, Lane 
had a nearly but not explicitly visual experience: 
3.1: [Lane is looking at herself in the mirror.] At the moment of the beep, she is looking 
at her eyebrows, noticing that they are uneven, that one is higher than the other. More 
than simply noticing, she somehow imagines a line extending from the top of each 
eyebrow (that is, as if there were a line continuing from the top of each eyebrow 
horizontally across her forehead). She recognizes the position of the imagined lines and 
that they do not overlap perfectly. Lane’s experience was of lines, even though the lines 
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were not seen in any form, inner or outer. [Lane often used visual language like 
“picturing” during this description but was believably consistent that there was nothing 
explicitly visual about this experience.] Simultaneously in experience, Lane feels an itch 
just inside her ear (a sensory awareness). 
Lane’s experience was of imaginary lines extended across her forehead from each of her 
eyebrows; however, she did not see those lines at the moment. For Lane, there seems to exist a 
continuum of visual experiences with one end being explicitly visual (i.e., seen) and the other not 
(i.e., known to be visual but not seen); this experience belonged on the latter end.   
Consider also sample 11.3 during the non-ovulation traditionally non-symptomatic phase. 
At this beep, Lane’s experience was of innerly seeing; however, the details of the inner seeing 
were not elaborated. This experience therefore belonged somewhere in the middle of the 
continuum from not at all explicitly visual to explicitly visual.   
11.3: [Lane is talking to her boyfriend who has just asked about the possibility of 
throwing a party at their house. Lane has surmised that the party will include visitors 
from out-of-town who will likely stay with them, which means she would have to give up 
the guest bedroom and bathroom for a couple nights. There is a pause in the conversation 
– it’s Lane’s turn to speak, but she hasn’t yet.] In her experience, Lane innerly sees 
(though not clearly, more like hintily) the guest bedroom (which she uses as a 
closet/dressing room) and guest bathroom (where she gets ready in the morning). 
Unclearly and with very few explicit visual details, she (innerly) sees the doors to these 
rooms from the perspective of standing in the hallway facing them (the doors are 
adjacent). It is not merely a knowing or awareness of the rooms—it is (slightly) visual. 
Even though she does not explicitly see these details, also present to her are the facts that 
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the guest bedroom contains all of her clothes, that her toiletries are in the bathroom, that 
she gets ready there in the morning so she can be out of the way of her boyfriend who is 
still sleeping, etc. These known details are in the direction of a cognitive experience but 
less explicit, more sensed/felt than explicitly thought. Simultaneously present to Lane is a 
cognitive/affective (maybe slightly more cognitive) sense or idea that she likes having 
those rooms to herself and that it would be sad to give them up. There is no explicit 
feeling ongoing (i.e., she does not feel sad about giving up the rooms), but there is an 
experienced affective tinge to the thought, similar to what we have, in the past, called a 
“thought/feeling.”  
Neither of these samples (eyebrows or guest rooms) is a typical (by DES standards) inner seeing. 
Sample 3.1 (about her eyebrows) seemed visual but was not experienced as visual (i.e., Lane did 
not experience herself as seeing); and sample 11.3 (about the guest rooms), though she did 
experience herself as seeing, had very few seen details. Instead, the details were “known” in 
some cognitive way short of a thought process. These samples exemplify the complexity that 
characterized Lane’s non-ovulation-phase experiences generally. 
In contrast, during ovulation, one-third of Lane’s experiences were inner seeings and 
those inner seeings contained explicitly visual details and elaboration as is typical of a full-blown 
inner seeing. For example: 
5.4: [Lane is listening to music but is not at all attending to the music at the moment. In 
her words, she is “totally daydreaming”: She imagines a place that she believes she “goes 
to often” when daydreaming—it’s a green, shaded courtyard with cement ground 
surrounded by vine-covered buildings.] At the moment of the beep, Lane innerly sees 
herself walking into one of the buildings. There are two simultaneous perspectives: She 
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(innerly) sees herself from behind (third-person perspective as if following herself into 
the building) and experiences herself as in the inner seeing (first-person perspective) She 
has an anticipatory sense that she is going into the building to see another person [but she 
doesn’t see anyone, nor does she know who it is that she will see.] [Though she knows 
she is walking into a building, the inner seeing is not in motion. Rather, she thinks it is 
more like a series of still pictures, first of the courtyard without her in it and now of her 
walking into a building]. She sees this clearly and in color. 
Notice the dramatic differences between this ovulation visual experience and the non-ovulation 
hintily or nearly visual experiences described before. At this sample, Lane definitely experienced 
herself as seeing (unlike at sample 3.1 about the eyebrows) and, moreover, she saw clearly and in 
detail an entire scene (unlike at sample 11.3 about the guest rooms). Also notice the dramatic 
difference between this clear and detailed image of a courtyard and the much more nebulous, 
complex high school courtyard experience at sample 10.6; the contrast exemplifies what we 
observed about clarity around ovulation. Consider also sample 6.4 during ovulation: 
6.4: At the moment of the beep, Lane feels her legs (lower thighs above her knee) 
sticking to the chair [she’s wearing a dress]. There is nothing evaluative about this—she 
simply feels her skin being stretched by the sticky leather, a sensory awareness. At the 
same time and equally present, she thinks that she should get medicine because her hip 
hurts. This is a cognitive experience without words, pictures, or other symbols. That is, 
her experience is a thought about hip pain, not a sensation of hip pain. [Note that, around 
this time in her last cycle, Lane also had hip pain. She believes both pain events to be the 
result of inflammation triggered by ovulation.] Also, at the same time and equally 
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present, Lane innerly sees the spot in her bathroom where the pain medications are: She 
sees the bottle with its red cap and the paper towels and cleaning supplies next to it.  
Here again, Lane definitely experienced herself as seeing (the explicitly visual end of the 
continuum) and the seen details were explicitly present to her and far more detailed and clear 
than, for example, the guest rooms experience at sample 11.3. That is, at this beep, Lane saw the 
details of the bottle (its spot in the bathroom, the red cap, the things next to it), whereas, at 
sample 11.3, Lane was somehow aware of some vague details about the guest bedroom and 
bathroom but did not see them. For whatever reason, during ovulation, the details of Lane’s 
experience were clearly present—in this case, seen—whereas, during non-ovulation phases, the 
details of Lane’s experience were sometimes vaguely present in inchoate, non-explicit ways. 
Summary, (the usual analysis, without-medication)  
 At the time of her participation, Lane was between the ages of 25 and 35. She was an 
undergraduate student who also worked full-time. Her Screening responses indicated she 
experienced severe and clinically significant symptoms of PMDD. Indeed, we learned that Lane 
had been medically evaluated many times over the past 10 years for premenstrual distress. 
Within the last year, she had been diagnosed with endometriosis for which she underwent an 
elective tubal ligation surgery. Because endometriosis is associated with atypically high levels of 
estrogen and may also impact ovulation (though research is mixed), Lane’s menstrual cycle and 
associated hormone fluctuations may not have been typical. Thus, it was possible that our 
determinations of cycle phase were not always accurate and/or that, even if we were accurate 
with respect to phase, Lane’s hormones were not at the levels typically expected for each phase.  
 Lane initially participated in the study across three menstrual cycles (11 sampling days, 
66 samples). During that time, her average cycle length was 25 days, estimating ovulation 
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around approximately days 10-14. Consistent with that estimation, the two sampling days 
confirmed by ferning as occurring around ovulation were on cycle days 12 and 15; thus, the test 
kit appeared to be effective at detecting ovulation for Lane.  
 On the basis of those 66 samples, Lane’s experience did seem to fluctuate with her 
menstrual cycle. Specifically, her experiences were notably clearer and simpler around the time 
of ovulation as compared to non-ovulation phases. This observation was supported by the 
exploratory ANOVA showing that experience sample captions were more than half as long for 
ovulation than for other phases. Inner seeings offered a case study in this difference: Inner 
seeings were found to differ in frequency across cycle phases and were most frequent during 
ovulation (occurring in 1/3 of those samples). When inner seeing occurred during ovulation, it 
was clear and detailed with an obvious central figure. In contrast, during non-ovulation phases, 
experiences were sometimes hintily or inchoately visual either without the experience of actually 




Step 2b: DES Sampling & Cycle Tracking (the secondary analysis, including with-
medication samples) 
 Recall that, after 12 days of DES sampling, Lane requested to postpone her participation 
in the study; she said she needed to focus on schoolwork. When Lane returned to the study, she 
explained that she had been newly diagnosed with ADHD and Bipolar II Disorder and was 
prescribed Adderall (a stimulant) and Lamotrigine (an anticonvulsant/mood stabilizer). In 
simplified terms, Lamotrigine dampens brain activity by interfering with intracellular signaling 
pathways (Grunze et al., 1999), whereas Adderall increases the activity of dopamine and 
norepinephrine neurotransmitters to improve attention, motor activity, and cognitive control 
(Arnsten, 2006). Taking these medications, she and we suspected, caused her to stop regularly 
menstruating. 
Though Lane was no longer menstruating, we continued sampling with her for four more 
days (sampling days 13-16 which we will call “with-medication”), amassing an additional 22 
samples, with the recognition that her experiences on those days could not be classified by 
menstrual cycle phase. However, given that we had already captured 12 days of Lane’s without-
medication experience, her experiences on sampling days 13-16 could offer a natural experiment 
into the effects (if any) of biology (in this case, of medications) on inner experience.  
Analysis 2b (the secondary analysis, including with-medication samples) 
Recall that we reviewed and captioned all 16 days of DES sampling together without 
regard for any biological or cycle factors. Then, as we have just seen, we conducted the usual 
analysis for Lane’s first 11 days of sampling. Next, to explore the impact of medication on 
experience, we thoroughly re-reviewed the DES days 13-16 with-medication samples. Our goal 
was phenomenologically to note the overall characteristics of that with-medication “batch” of 
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samples. We noticed that Lane’s with-medication samples seemed to be even more complex and 
messy than even her without-medication non-ovulation samples had seemed before. 
Furthermore, her with-medication samples were often highly unusual by DES standards.  
To explore further these potential differences, we conducted the same ANOVA and chi 
squared analyses as in the usual analysis except that, in this secondary analysis, we included 
Lane’s 22 with-medication samples as a fourth group. Thus, these analyses now compared four 
different biological statuses: 3 without-medication menstrual cycle phases and one with-
medication/amenorrhea state. The exploratory ANOVA comparing sample caption lengths, now 
with four biological statuses instead of the usual three cycle phases, was significant (F(3, 84) = 
4.38, p = 0.007). Inspection showed that ovulation captions were shortest and with-medication 
samples were longest (M = 78.54). Indeed, the average with-medication sample caption was 
considerably longer than the late luteal/premenstrual and traditionally non-symptomatic sample 
captions (M = 57.33 and 61.79 respectively). Thus, consistent with our phenomenological 
observation, this quantitative analysis suggested that the with-medication samples were messier 
and more complex even than non-ovulation samples were before Lane had started medications. 
 We also recomputed the chi-squared tests of independence to explore whether the 
frequencies of experiential phenomena differed across biological status, this time including the 
fourth with-medication state. There were nine “significant” (these were exploratory and so did 
not adjust for multiple tests) findings. Two of those findings were consistent with what had been 
found with the usual analysis: 
 Inner seeing differed by biological status, X2 (3) = 11.88, p = 0.008. Inspection showed 
that, as before, inner seeing was most frequent during ovulation (33.3% of samples) and 
occasional during traditionally non-symptomatic (6.0% of samples) and late 
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luteal/premenstrual (8.3% of samples) phases. Inner seeing did not occur at all during the 
22 with-medication samples. 
 Auditory sensory awareness differed by biological status, X2 (3) = 12.96, p = 0.005. By 
inspection, auditory sensory awareness was most frequent during the late 
luteal/premenstrual phase (16.7% of samples) whereas it was non-existent during all 
states. However, note that, in total, only 2 late luteal/premenstrual phase samples 
contained auditory sensory awareness. 
Seven findings were new with the four-status analysis; four of the findings centered on 
sensory awareness’s being more frequent and/or more vivid in the with-medication phase: 
 Sensory awareness differed by biological status, X2 (3) = 14.54, p = 0.002. By inspection, 
sensory awareness was most frequent during with-medication samples (84.1% of 
samples) especially compared to ovulation (33.3% of samples) and the traditionally non-
symptomatic phase (38.1% of samples). The late luteal/premenstrual frequency was 
intermediate (62.5% of samples). 
 Bodily sensory awareness differed by biological status, X2 (3) = 11.96, p = 0.008. By 
inspection, bodily sensory awareness was most frequent in with-medication samples 
(70.5% of samples) and roughly twice as frequent as the other three cycle phases which 
were similar to each other (28.6% of traditionally non-symptomatic samples, 25.0% of 
ovulation samples, and 37.5% of late luteal/premenstrual samples. 
 Sensory awareness of imaginary bodily sensations differed by biological status, X2 (3) = 
9.32, p = 0.025. By inspection, such experiences occurred in 13.6% of with-medication 
samples but not at all during other states.  
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 “Organismic apprehensions” in the direction of sensations differed by biological status, 
X2 (3) = 9.32, p = 0.025. By inspection, such experiences occurred in 13.6% of with-
medication samples but not at all during other states.  
The remaining three “significant” findings suggested that simple, straightforward experience 
was least frequent in the with-medication samples:  
 Inner speech (among the simplest and most straightforward experiential phenomena) 
differed by biological status, X2(3) = 8.64, p = 0.035. By inspection, inner speech was 
least frequent during the with-medication samples (18.2% of samples) especially 
compared to the late luteal/premenstrual phase (66.7% of samples) and, less so, by 
comparison to the other states (35.7% of traditionally non-symptomatic samples and 
25.0% of ovulation samples).  
 Multiplicity (among the most complex of experiential characteristics) differed by 
biological status, X2 (3) = 8.97, p = 0.030. By inspection, multiplicity was most frequent 
during the with-medication samples (45.5% of samples) and late luteal/premenstrual 
samples (45.8%). It was least frequent during ovulation, occurring in only 4.2% of 
samples. The frequency during the traditionally non-symptomatic phase was intermediate 
(22.6% of samples).  
 Seeing differed by biological status, X2 (3) = 7.84, p = 0.049. It was most frequent during 
ovulation and the late luteal/premenstrual samples (25.0% of those samples) and less so 
during the traditionally non-symptomatic and with-medication samples (4.8% and 4.5% 
of samples respectively).  
Table 8 reproduces Lane’s Table 7 but includes the with-medication samples and with updates to 




Characteristics of Lane’s inner experience overall and by biological status (including with-
medication samples) 
 
a  Note that % need not up add to 100 because a single sample can contain multiple phenomena. 
* “significant” (recall that this analysis did not adjust for multiple tests) at p < .05 








medication Total X2(2) 
N Sampling Days 7 2 2 4   
N Samples 42 12 12 22 88  
 Frequencies (%)a of Experiential Phenomena 
Inner speaking 35.7 25.0 66.7 18.2 34.1 8.64* 
Inner seeing 6.0 33.3 8.3 0.0 8.5 11.88** 
Unsymbolized thinking 42.9 41.7 16.7 29.5 35.8 3.38 
Feeling 14.3 25.0 12.5 13.6 15.3 1.02 
Sensory awareness (SA) 38.1 33.3 62.5 84.1 52.3 14.54** 
Multiplicity 22.6 4.2 45.8 45.5 29.0 8.97* 
“Org app”  41.7 25.0 50.0 63.6 46.0 5.28 
“Org app” sensory 0.0 0.0 0.0 13.6 3.4 9.32* 
Bodily feelings 4.8 8.3 12.5 2.3 5.7 1.74 
Bodily + mental      
    feelings 
4.8 8.3 0.0 4.5 4.5 0.97 
Multiple   SA 23.8 8.3 16.7 45.5 26.1 6.90 
Bodily SA 28.6 25.0 37.5 70.5 39.8 11.96** 
SA imaginary 0.0 0.0 0.0 13.6 8.0 9.32* 
Feeling/sense in    
    specific region 
4.8 16.7 8.3 9.1 8.0 1.87 
Tactile SA 11.9 16.7 16.7 22.7 15.9 1.28 
Auditory SA 0.0 0.0 16.7 0.0 2.3  12.96** 
Seeing 4.8 25.0 25.0 4.5 10.2 7.84* 
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In sum, we observed that, after Lane began taking medications, her experience seemed to 
be messier, more complex, and more unusual than it had been without-medication; this 
observation was confirmed by the exploratory ANOVA (which showed that sample captions 
were longest for the with-medication samples) and by the exploratory chi-squared analyses of 
experiential frequencies (which suggested that with-medication samples more frequently 
included multiple phenomena and nearly-but-not-explicitly sensory experiences, both of which 
are markers of complexity/lack of clarity). Additionally, with-medication samples less frequently 
included inner speaking and inner seeing, both phenomena that are generally clear and 
straightforward. In fact, whereas she had clear and explicit inner seeings during 11.4% of all 66 
without-medication samples, she had no such clear and explicit imagery post-medication but, 
instead, had 3 inchoately but not explicitly visual experiences (accounting for 13.6% of with-
medication samples). The chi squared analyses also revealed that Lane’s experience after she 
began taking medication was dominated by sensory awareness. Whereas Lane’s experience 
without-medication was fairly frequently sensory (41.7% of those samples), her experience with-
medication was almost always sensory (84.1% of with-medication samples), especially with 
respect to her body (70.5% of with-medication samples).  
We have seen that Lane’s without-medication experiences, particularly around ovulation, 
could be clear and straightforward with an obvious central figure. Recall, for example, sample 
5.3 in which Lane was (90% of the experience) wondering whether a man at her office would say 
goodbye before he left while simultaneously (10%) looking for moldy grapes among a bunch. 
This experience was relatively clear and simple with one predominant and well-articulated figure 
(the unsymbolized wondering). We have also seen that Lane’s without-medication non-
ovulation-phase experiences were often more complex and inchoate. Recall, for example, the late 
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luteal/premenstrual sample 10.6: At that moment, Lane was aware of a “collage” of not-well-
articulated rememberings about her high school’s “black market.” Lane’s with-medication 
samples were even more complex than her without-medication non-ovulation samples, especially 
with respect to figure-ground. Sample 13.1 (with-medication) helps exemplify this difference:  
13.1: [Lane is reading a Reddit thread.] At the moment of the beep, she is reading with 
comprehension, “…dress as a woman and just walk around at the mall,” but the reading 
is not very salient (between 5 and 25% of the total experience). Much more salient (70% 
or more of the total experience), she imagines a generic, stereotypical mall and a cross-
dressing man walking through the mall. This imagining has some innerly seen details: 
She innerly sees part of an escalator and a square fixture with water [she understands this 
to be part of a fountain, but she does not see an actual fountain]. She sees this from the 
perspective of being on the second floor of the mall looking down at the main floor. [She 
does not experience herself as in the mall; she just sees from the perspective as if she 
were in the mall.] Though she does not explicitly innerly see the rest of the mall, she 
experientially knows what is there, including a masculine, hairy man wearing a woman’s 
red dress and carrying several (five or so) shopping bags. That is, whereas she innerly 
sees the escalator and fountain, she does not innerly see the man, yet she knows specific 
visual details of the man. Additionally, she knows there are plants, store windows, and 
other people. The plants, windows, and other people are less specified by comparison to 
the man (e.g., she does not know the colors of the other peoples’ clothes like she does the 
man’s dress) but are no less in her experience.  
Sample 13.1 was obviously complex: Lane imagined a highly specific scene with many different 
elements, some of which were explicitly seen and some of which were known (sometimes in 
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elaborate visual detail) but not explicitly seen. Perhaps the most remarkable feature of sample 
13.1 was the seemingly neglected central figure. That is, sample 13.1 was Lane’s private 
illustration of a man wearing a woman’s dress while walking through the mall. Yet, instead of 
innerly seeing the man in the dress (as would be the expected focal point), what she saw were 
insignificant background details—an escalator and part of a fountain. It was as if Lane’s 
experience “missed the point” of her own interest. Sample 16.6 (also with-medication) was 
similar:  
16.6: [Lane is watching a movie scene about a prisoner’s release.] She is thinking about 
how hard it must be to be in prison and away from society for 15 years. This wondering 
is aimed at understanding in a descriptive, rational, cognitive way how that would feel. [It 
is not that she is trying to actually feel how it would feel. She wants to understand 
cognitively how it would feel.] At the same time, she hears music and, in some 
cognitive/mental way, recognizes it as early 90s hip hop. Thus, this is more than simply 
hearing—there is a cognitive recognition accompanying/connected to her hearing. At the 
same time, [the movie is showing a close-up of Denzel Washington with his hair dyed 
gray to appear older.] Lane sees the individual gray hairs (within his otherwise not-gray 
head of hair) and also the uneasy way he’s moving his mouth. These are focused seeings, 
perhaps better-categorized as visual sensory awarenesses.  
As with the man-in-the-dress sample 13.1, Lane seemed to miss the expected figure in 16.6. She 
was trying to glean from the movie what it would be like to return to society after 15 years in 
prison but, instead, focused on relatively unimportant details—90s music and grey hairs. It was 
as if her experience became distracted away from its own purpose.  
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With-medication sample 14.1 was also significant for its lack of clear figure-ground 
qualities. At sample 14.1, Lane’s experience was divided between four separate and 
simultaneous sensations: popping on the right side of her neck [as she rolled her head back], a 
tight knot in her right shoulder, the elastic of her underwear cutting into her thigh, and the fabric 
of her waistband pressing against the skin of her abdomen. These four sensations were more or 
less equally salient. That is, there were essentially four figures of Lane’s experience, as if she 
could not clearly “pick” or “commit herself” to one. Thus, the “messiness” of Lane’s with-
medication samples seemed distinct from (and more severe than) the earlier messiness of her 
without-medication non-ovulation samples, perhaps in large part due to her inability to “snap” to 
a clear and coherent figure.  
 Lane’s with-medication samples were also noted to be highly unusual at times. For 
example, they were sometimes unusually specific, such as at sample 14.3: 
14.3: [Lane’s boss is in the warehouse smoking a cigarette. She has asked him many 
times not to smoke with the door open so she doesn’t have to smell the smoke, but yet, 
the door is open, he’s smoking, and she can smell the smoke in her office.] At the 
moment of the beep, she (mostly) smells cigarette smoke. Simultaneously, she feels a 
headache, a physical sensation with a highly specific shape and location—behind her left 
eye about 1-inch deep approximately aligned with the bottom of her eyebrow and about 
the size and shape of a grape. At the same time, she feels rising anger which is partly 
mental and partly bodily. In her body, she feels two fist-sized regions of inward pulling 
and inward twisting, one on each side of her chest. This is one bodily feeling of anger 
with two distinct regions. The entire smoke smelling-headache-anger experiences 
comprise about 70% of Lane’s total experience at this moment. The other 30% (or maybe 
147 
 
less) involves Lane’s innerly saying in her own voice “LBC” as she sees those letters on a 
package; she understands the letters to refer to the Long Beach (shipping port) Customs. 
In that sample, Lane had two bodily sensations that were highly specific— the headache and the 
anger, both of which had a specified shape, location, and even depth. Such intense specificity is 
rare in DES participants: emotion, when experienced bodily, is generally felt more diffusely.  
 Lane’s with-medication sensations were sometimes unusual in that the sensations 
themselves were imaginary (a difference that was “significant,” X2(3) = 9.32, p = 0.025). See, for 
example, with-medication samples 14.4 and 15.6: 
14.4: Lane takes a deep breath, inhaling through both nostrils. She smells cigarette smoke 
and, simultaneously, feels smoke coming up through her nostrils and moving through a 
specific physical tubelike-pathway [even though there is no such tube in her actual body] 
directly to a grape-sized region behind her left eye. She feels the grape area filling up 
with smoke—not expanding but becoming fuller. [We noted that this is a highly creative 
and highly specific experience. Hard to categorize without losing the richness.] 
15.6 [Lane is brushing her teeth. Yesterday, she had over-flossed a region on the right 
upper side of her mouth and, today, her gums are inflamed in that spot.] At the moment 
of the beep, she feels her soft/tender gums [which are, in fact, being stimulated by her 
toothbrush, though her experience is not of the toothbrush, it’s of her gums.] She 
simultaneously has an imaginary sensation (remembered from earlier) of the same area of 
her gums: She (imaginarily) feels the swollenness of her gums both in her gums and in 
her tongue [At the time this memory refers to, her tongue had been running over that part 
of her gums. At the moment of this beep, her tongue is doing no such thing; she’s re-
experiencing the earlier sensation.] Thus, at this moment, there are two separate 
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sensations of the same area—a real sensation in the gums only (not including the 
toothbrush which is, in fact, touching the gums) and an imaginary (remembered) 
sensation in both the gums and her tongue. At the same time, she hopes her gums don’t 
start bleeding again, a cognitive thought process not in words, pictures, or other symbols.  
Notice in sample 14.4 the highly specific sensation in the imagined “tube” running from her 
nostrils to the “grape” region. And, in sample 15.6, notice the remarkable co-occurrence of one 
real (tender gums) and one imagined (tongue running over swollen gums) sensation in the same 
spot in her mouth at the same moment. Such sensory experiences are unusual by DES standards 
and, by comparison to some of Lane’s other experiences, seemed almost hyper-figural in their 
specificity.   
Summary, Step 2b (the secondary analysis, including with-medication samples) 
 Lane took a break in participation after 12 days of DES sampling. When she returned, she 
reported she had been diagnosed with Bipolar II Disorder and ADHD and had started 
psychotropic medications which (presumably) caused her to stop menstruating. We decided to 
continue sampling with Lane for four more days (sampling days 13-16), amassing an additional 
22 samples (88 grand total). These samples were referred to as her “with-medication” samples.  
We recognized that, given her amenorrhea, Lane’s day 13-16 samples would not be relevant with 
respect to menstruation cycle phase but would be highly relevant with respect to this study’s 
larger question—how do changes in biology (in this case, the onset of medications) impact 
pristine inner experience?  
 Without medication (sampling days 1-12), Lane’s experiences showed a range of 
complexity: least complex in the vicinity of ovulation and more complex elsewhere in her cycles. 
With medications (sampling days 13-16), Lane’s experiences were the most complex she 
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experienced in this study. Lane’s with-medication samples usually contained several 
simultaneous phenomena and were often “messy,” failing to “snap” to a clear, central figure. 
Exploratory quantitative analyses supported this qualitative observation. The ANOVA (now 
conducted with the with-medication samples as a fourth biological state) showed a significant 
difference in caption lengths across phases. With-medication captions were the longest on 
average, suggesting the experiences themselves were the most complex and difficult to neatly 
categorize. Moreover, exploratory chi squared analyses revealed that several markers of 
complexity differed by cycle phases and, by inspection, those more complex phenomena were 
most frequent in the with-medication samples. Sensory awareness was also notably more 
frequent in the with-medication samples, occurring in 84.1% of those samples. Moreover, the 
with-medication sensory awareness experiences were unique, often with highly specific shapes, 
sizes, locations, or movement, and sometimes with imagined sensations.  
 In general, across psychological science, the impact of medications on directly 
apprehended, conscious inner experience is not descriptively known. Studies utilizing methods 
such as DES may shed light on how medications achieve (or not) their desired effect: perhaps 
medications do not “clear up” experience but may actually disorganize and complicate 
experience, and yet, still lead to a desired external behavioral change. Furthermore, such studies 
may illuminate what famously discourages patients with bipolar disorder from consistently 
taking their medications—disorganized/complex experiences may be unpleasant. Though this is 
only a small case study with a number of limitations, Lane’s case suggests that careful studies of 





Chapter 7: Allison 
Allison is a Hispanic female. At the time of sampling, she was between 18 and 25 years 
old and an undergraduate university student.   
Step 1: Screening  
 Allison reported she had regular menstrual periods. She denied any medical conditions, 
behaviors (e.g., shift work), or medications (including birth control) that would alter her 
hormone function. Her screening results indicated normal levels of anxiety and depression.  
 Allison’s responses indicated she experienced clinically significant symptoms of 
Premenstrual Dysphoric Disorder (PMDD). She endorsed 8 of the 11 DSM-5 symptoms of 
PMDD and noted that those symptoms profoundly impacted her functioning at school and work. 
On the Premenstrual Assessment Form (PAF), Allison earned a score of 31, placing her, 
essentially, at the mean of the non-clinical normative sample. On the Visual Analogue Scales of 
PMDD symptoms, she reported that her mood and overall symptoms are, on average, 38% worse 
during the premenstrual phase as opposed to the rest of her cycle. Thus, Allison’s responses on 
self-report measures were mixed; it is possible that, while she experienced a wide range of 
PMDD symptoms, those symptoms were not particularly severe.  
Step 2: DES Sampling & Cycle Tracking 
Allison completed 19 days of natural-environment Descriptive Experience Sampling 
(DES), amassing 96 total beeped experiences (this count excludes day 1 which was discarded as 
training, as is typical of DES). She followed the typical DES sampling-interview procedure that 
is described in Step 2 of the Method section of this paper (Chapter 3). Due to the coronavirus 
pandemic, Allison’s final two sampling days were conducted by Zoom or Skype (as opposed to 
in-person). However, given her substantial practice with the method by that time, we suspect this 
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had little impact on the quality of those interviews. The effects of the pandemic on Allison’s 
inner experience more broadly are, of course, unknown.  
Allison participated in the study across menstrual cycles with an average cycle length of 
approximately 29 days. Allison struggled to develop the habit of taking the ovulation test daily. 
Therefore, she was encouraged to prioritize ovulation testing at least around the time of DES 
sampling days. This was a largely successful improvisation: She provided pictures of her 
ovulation test kit results surrounding 17 of her 20 sampling days. For Allison, the ovulation 
ferning pattern appeared frequently, including on days for which she was clearly not ovulating 
(e.g., the first day of a menstrual cycle). We do not know the explanation for why this occurred. 
It might suggest that Allison had higher baseline levels of estrogen than would be expected for 
typical hormone function. However, it might also be explained by other biological factors, such 
as the levels of sodium and potassium chloride in Allison’s saliva (both of which contribute to 
salivary ferning). Because of this lack of specificity, we considered a number of factors when 
determining when ovulation was likely to have occurred, including day of cycle, test result on 
that day, pattern of test results surrounding that day, cycle length, and so on. For example, for 
Allison’s second menstrual cycle (the first cycle that included a DES sampling day), ferns began 
to appear on her test results as early as cycle day 11. However, around cycle day 19 or 20, the 
ferning pattern became qualitatively different: The ferns were clearer and more plentiful, 
consistent with detection of ovulation. We therefore estimated ovulation for that cycle as around 
cycle day 20 or 21, which included DES sampling day 4. Days 20 and 21 are later than the 
theoretical midpoint of her average cycle length (which would be between days 12 to 16); 
however, this was also one of Allison’s longer menstrual cycles (31 days) and thus, it made sense 
that ovulation would occur somewhat later within that cycle.  
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Using a similar process, ovulation was determined as occurring around cycle days 19-22 
for cycle 3 (which included DES sampling day 8), cycle days 16-17 for cycle 4, and cycle days 
13-16 for cycles 5 and 6 (which included DES sampling days 13 and 17). There were therefore 
four sampling days associated with ovulation; however, those sampling days occurred on 
disparate cycle days. Because we did not use a consistent range of cycle days for Allison’s 
ovulation phase, the cycle days classified within each phase were similarly varied. For example, 
the Traditionally Non-Symptomatic phase generally included cycle days 1-13 (for cycles 1, 3, 5, 
and 6) but also included cycle days 15 and 17. Given that our primary biological marker of 
ovulation (the test kit) was ineffective for Allison, these determinations of cycle phase were 
potentially inaccurate. Moreover, if Allison’s test results really did indicate, for example, 
atypically high baseline levels of estrogen, she may not have been an ideal candidate for the 
present study. Regardless, we made the determinations as best we could—with careful 
consideration, integrating multiple sources of information, and blind to the associated inner 
experience characteristics.  
The top panel of Table 9 displays the breakdown of Allison’s sampling days by cycle 
phase. The bottom panel displays the frequencies of her salient experiential phenomena within 





Characteristics of Allison’s inner experience overall and by cycle phase 
a See Cycle Tracking and DES Sampling section above for explanation of variability in which cycle days were 
associated with each menstrual cycle phase.  
 
b Note that % need not up add to 100 because a single sample can contain multiple phenomena. 
** “significant” (recall that this analysis did not adjust for multiple tests) at p < .01 





Premenstrual Total X2(2) 
Days of Menstrual Cyclea 1-11 and 15-17 13, 21, 22    20-29   
Number of Sampling Days 8 4 7 19  
Number of Samples 36 19 41 96  
Frequencies (%)b of Experiential Phenomena 
Inner speaking 2.8 0.0 0.0 1.0       1.68 
Inner seeing 0.0 2.6 0.0 0.5       2.04 
Unsymbolized thinking 1.4 0.0 6.1 3.1       2.17 
Feeling 22.2 23.7 26.8 24.5       0.23 
Sensory awareness (SA) 48.6 68.4 46.3 51.6       2.74 
Bodily SA 29.2  34.2 34.1 32.3       0.26 
Tactile SA 9.7 10.5 11.0 10.4       0.03 
SA of her own smile 8.3 18.4 2.4 7.8       4.63 
Emotional or SA of face 9.7 26.3 6.1 11.5       5.40 
Visual SA 8.3 15.8 2.4 7.3       3.52 
Taste SA 8.3 10.5 2.4 6.3       1.88 
SA that moves her 11.1 13.2 0.0 6.8       5.28 
Multiplicity 11.1 21.1 14.6 14.6       0.99 
Bodily feelings 6.9 7.9 3.7 5.7       0.59 
Mental feelings 12.5 10.5 20.7 15.6       1.45 
Nothing 9.7 0.0 15.9 10.4       3.53 
Watching TV 11.1 0.0 4.9 6.3       0.18 
Seeing 8.3 10.5 7.3 8.3       0.18 
Hearing 5.6 21.1 0.0 6.3     9.87** 




We followed the usual analysis described in Chapter 3 (Method), Step 2: We first 
reviewed and “captioned” all samples together (blind to their associated cycle phase) and then 
separated sampling days by cycle phase and phenomenologically and quantitatively examined 
differences in experience across phases.  
The Individual (blind to menstrual cycle phase). Overall, Allison’s experience was 
most frequently (51.6% of all samples) populated by sensory awareness, the experience of 
attending to some sensory aspect of her internal or external environment without particular 
regard for the aspect’s instrumentality or function (Hurlburt et al., 2009). Her experiences were 
generally quite simple and driven by internal and external sensations (either for their own sake as 
in sensory awareness or as part of an emotional feeling). It was somewhat more common for 
Allison to have nothing ongoing in experience than it is for the typical DES participant 
(approximately 10% of all of Allison’s samples).  
With Respect to Menstrual Cycle Phase. Allison’s experiences when “binned” by cycle 
phase did not seem (by phenomenological observation) to differ with respect to clarity across 
cycle phases. However, the exploratory ANOVA comparing the average length of experience-
sample captions across cycle phases was significant, F(2, 63) = 4.97, p = 0.009.  Inspection 
showed that ovulation captions were longest on average (65.89, SD = 56.84), especially 
compared to late luteal/Premenstrual phase captions (M = 31.66, SD = 25.98). Traditionally non-
symptomatic phase captions were intermediate (M = 45.14, SD = 40.94). one ovulation sample 
caption included a lengthy note/commentary that rendered the caption an outlier at more than 
three standard deviations above the group mean (271 characters). Therefore, the ANOVA was 
recomputed excluding the commentary from that caption (then only 75 characters); the resulting 
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test was still significant, F(2, 63) = 3.86, p  = 0.025. This suggests that there was indeed some 
aspect of Allison’s experience that differed across phases, but that our phenomenological 
exploration was (for whatever reason) not directly sensitive to it.  
 We then conducted the usual chi squared analyses to test whether the frequencies of 
experiential phenomena differed across cycle phases. For Allison, there was one “significant” 
(recall these were exploratory and so not adjusted for multiple tests) finding: External hearing 
differed across cycle phases (X2(2) = 9.87, p = .007) and, by inspection, was more frequent 
during ovulation (21.1% of samples) especially when compared to the late luteal/premenstrual 
(0.0% of samples) and, less so, to the traditionally non-symptomatic (11.1% of samples) phase.  
Three other findings were suggestive:  
 Emotional or sensory awareness of her face, including of her smile, differed across cycle 
phases. Inspection suggested that it was somewhat more frequent during ovulation 
(26.3% of samples) than in late luteal/premenstrual (6.1%) or traditionally non-
symptomatic (9.7%) phases, X2 (2) = 5.40, p = .067. 
 Sensory awareness that moves her/affects her being differed across cycle phases. 
Inspection suggested it was more frequent during ovulation (13.2% of samples) and in the 
traditionally non-symptomatic phase (11.1% of samples), but somewhat less frequent in 
the late luteal/premenstrual (0.0% of samples), X2 (2) = 5.28, p = .071. 
 Low engagement (i.e., little attention or energy directed toward the phenomenon) differed 
across cycle phases. Inspection suggested it was somewhat more frequent during 
ovulation (15.8% of samples) than during the late luteal/premenstrual (2.4% of samples) 
and traditionally non-symptomatic (2.8% of samples) phases, X2 (2) = 5.38, p = .068. 
Note, however, that all three examples of low engagement during ovulation occurred on 
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the same sampling day and may be more a reflection of Allison on that particular day 
than of her ovulation-phase experiences more generally. 
Overall, Allison’s experience did not seem to differ in dramatic ways across cycle phases. 
Though the exploratory ANOVA comparing caption lengths (a possible indicator of sample 
complexity) was significant, differences in clarity/complexity were not obvious. Moreover, none 
of the major experiential phenomena seemed to differ significantly by phase.  
However, Allison’s sensory awareness experiences did seem to differ in subtle ways 
across cycle phases. For example, Allison had somewhat more frequent awareness of feelings 
(emotion) and sensations in her face, including of her own smile, during ovulation (26.3% of 
samples) especially compared to the late luteal/premenstrual phase (2.4% of samples). That is, 
whereas more than one-quarter of her ovulation samples (26.3%) involved some awareness of 
her face, only approximately 2% of her late luteal/premenstrual phase samples had such a focus. 
Allison’s awareness of her face was almost always sensory in nature. For example, at sample 8.2 
during ovulation, she was drinking coffee and laughing with friends. In her direct experience, she 
felt herself smiling, a physical sensation in her face and cheeks. Allison also sometimes attended 
to her face for its emotional significance; for example, at sample 13.3 also during ovulation, 
Allison was walking into the mall. She felt cold, a bodily sensation, and, simultaneously, happy, 
a mostly bodily feeling that centered on her smile. And, sometimes her awareness of her face 
was not related to smiling but rather, to laughing (samples 4.1, 11.1, and maybe 19.3) or other 
emotion states such as at sample 3.4 when she was playing a video game and felt competitive, an 
emotion experienced in her face which donned a mean/serious/competitive expression.  
Additionally, Allison’s ovulation sensory awarenesses differed from late 
luteal/premenstrual sensory awarenesses in that, around ovulation, Allison’s sensations seemed 
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to “move her” and “affect her whole being” (13.2% of samples compared to 0.0% of Late 
Luteal/Premenstrual samples). That is, in some of Allison’s ovulation-phase samples, sensory 
awarenesses seemed to grab her in ways that were uncommon by DES standards, whereas her 
late luteal/premenstrual-phase sensory awarenesses were typical, experienced as a discrete part 
or facet of her experience. To illustrate, consider the contrast in the following samples. Samples 
9.4 and 10.4 below are from the late luteal/premenstrual phase and are typical sensory 
awarenesses by DES standards. 
9.4: [Allison is lying down.] She feels cold on the surface of her arms. [She is, in fact, 
wearing long sleeves, but that isn’t part of her experience. She doesn’t feel her sleeves—
she feels cold on her arms.] At the same time and equally present, her eyelids feel droopy 
[she’s tired]. Thus, at this moment, there are two separate bodily sensory experiences—
cold arms, droopy eyelids. 
10.4: [Allison is eating a Mexican dish with tortilla chips, sauce, eggs, and sour cream 
(she couldn’t think of the English translation for the dish’s name).] At the moment of the 
beep, she tastes the good taste of the food, [no flavor in particular. It’s a salty dish and the 
salt is cut by the sour cream, but she’s not particularly attending to the saltiness or the 
sour creaminess or any other aspect.] She’s simply tasting what she’s eating, and she 
likes it. At the same time, she feels the soft-yet-still-a-little-hard and cold texture of the 
food, particularly the tortilla chips, which is also good. Thus, Allison’s experience at this 
moment is entirely wrapped up in the sensations of her food—the taste and texture, 
specifically—all of which is apprehended as good/to her liking.  
In contrast, sample 4.2 is from the ovulation phase and represents what we called “sensory 
awareness that moves her, affects her being.” 
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4.2: [Allison is fooling around with filters on Snapchat. At the moment of the beep, she 
applies a filter, is looking at herself, and] feeling adorable, a mushy feeling that is mental 
but also physical, embodied in the way she is her holding her cheeks in her hands [in a 
cutes-y way]. Note that Allison’s experience is about her own feeling of adorable, not 
that the picture of her is adorable; it was decidedly not of noticing/thinking/whatever that 
the picture on Snapchat is adorable, but rather, of her feeling adorable. 
Our understanding of Allison’s experience at 4.2 was unequivocal: This was not a garden-variety 
sensory awareness. A garden variety sensory awareness would have been, as we alluded to in the 
final sentence of the description, “noticing [visually]…that the picture on Snapchat is adorable.” 
Instead, Allison felt adorable in seeing the picture. And the adorable feeling was not discrete; it 
was not faithful to Allison’s experience to call this a mental feeling or a bodily feeling or even a 
visual sensation, for example. Nor would it have been faithful to say that Allison felt some 
adorable but discrete sensation in her face, such as her smile. Her feeling adorable was all of 
those things and, moreover, was embodied, felt in the way she was holding her face in her hands.  
Sample 13.5 was another ovulation example of the way sensory awarenesses seemed to 
grab Allison and affect her whole being. At that sample, Allison was shopping in a clothing 
store. She described herself as “feeling upbeat” while singing and dancing along with the music 
in the store. The interview came to reveal that, by “upbeat,” Allison was not referring to a feeling 
but rather, to the fact that the music was moving her (literally but also, experientially) in 
“upbeat”-esque ways. We understood Allison’s experience to be different from merely “I’m 
singing and dancing along with music”; her experience was not at all that agentic; she did not 
experience herself as singer and dancer; she experienced herself as into the music, consumed by 
the music, and pulled into singing and dancing by its sound. Similarly, at sample 13.4, also while 
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clothes-shopping and also during ovulation, Allison stumbled upon a sweatshirt emblazoned with 
one of her favorite anime characters. She was drawn to the design and colors of the sweatshirt (a 
garden-variety visual sensory awareness) but was also “lit up,” “beaming” in response to the 
sweatshirt which was either a bodily feeling and/or a bodily sensory awareness of her face (we 
could not be sure). Again, we understood Allison’s experience in this sweatshirt sample as more 
than merely “I’m smiling and feeling my smile” (indeed, she had several other experiences that 
were like that); beaming was not a discrete or well-differentiated characteristic of her face; she 
was overtaken by some apparently-not-directly-experienced happiness about the sweatshirt and 
experienced that as beaming.   
 Thus, while there were not obvious and statistically convincing differences in clarity or 
experiential phenomena between Allison’s cycle phases, there were potential subtle differences 
in her sensory awareness across cycle phases. Specifically, compared to the late 
luteal/premenstrual phase, Allison’s sensations around the time of ovulation were more often 
focused on her face and smile and sometimes seemed to grab her/consume her/move her entire 
being. This latter difference was apparently not the by-product of fewer sensory experiences; in 
fact, during the late luteal/premenstrual phase, sensory awareness was still frequent for Allison 
(occurring in 46.3% of those samples) but all were of the typical garden-variety where the 
sensory aspect was but a part or facet of the overall experience (as opposed to something 
affecting her entire being).  
Summary 
 At the time of her participation, Allison was an undergraduate university student between 
the ages of 18 and 25. Her Screening responses indicated she experienced mild but clinically 
significant symptoms of premenstrual distress. She agreed to participate in DES sampling and 
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ultimately did so for 19 days across six menstrual cycles, collecting a total of 96 beeped 
experiences. Her menstrual cycles during that time were regular with an average length of 29 
days. However, the ovulation test kit did not appear to be effective for Allison. The test 
frequently produced what seemed to be “false positive” results, which might have indicated 
atypical hormone function, such as high levels of estrogen. Cycle phases were therefore 
determined by considering the best available evidence, sometimes crudely, with an increased 
potential for inaccurate classifications.  
 Though cycle-phase-related differences in experiential complexity were not 
phenomenologically obvious to us, the exploratory ANOVA of caption lengths suggested such 
differences might well exist (the caption length differences probably do reflect something). 
Cycle-related differences in experience were, for Allison, only suggestive and subtle. It seemed 
that her sensory awarenesses differed somewhat by phase, especially between ovulation and the 
late luteal/premenstrual phase. That is, during ovulation, Allison was more frequently aware of 
her face for (usually) its sensations and (occasionally) its emotional significance. Additionally, 
more than 10% of Allison’s ovulation-phase experiences involved sensory awarenesses that 
seemed to grab her, move her, and affect her whole being. In contrast, this sensory-awareness-
that-moves-her feature never occurred during the late luteal/premenstrual phase despite frequent 
sensory awareness; her sensory awareness during that phase was typical by DES standards with a 





Chapter 8: Lee 
Lee was, at the time of sampling, between the ages of 18 and 25 and an undergraduate 
university student who also worked part-time. She did not identify with any of the available 
categories for ethnicity. 
Step 1: Screening 
 Lee reported she had mostly regular menstrual periods but had experienced at least one 
missed period within the last year. Indeed, Lee missed one menstrual period during the time she 
was engaged in our study. She denied any medical conditions, behaviors (e.g., shift work), or 
medications (including birth control) that would alter her hormone function. Her screening 
results indicated normal levels of anxiety and depression.  
 Lee’s responses indicated she experiences clinically significant symptoms of 
premenstrual distress. She endorsed 6 of the 11 DSM-5 symptoms of PMDD and noted that those 
symptoms profoundly impacted her functioning at school and work as well as tasks of everyday 
living. On the Premenstrual Assessment Form (PAF), Lee earned a score of 26, placing her, 
essentially, at the mean of the non-clinical normative sample. On the Visual Analogue Scales of 
PMDD symptoms, she reported that her mood and overall symptoms were, on average, 66% and 
57% worse respectively during the premenstrual phase as opposed to the rest of her cycle.  
Step 2: DES Sampling & Cycle Tracking 
  Lee completed 21 days of natural-environment Descriptive Experience Sampling (DES), 
amassing 111 total beeped experiences (excluding day 1 beeps which were discarded as training, 
as is typical of DES, and day 9 beeps which occurred around the time of a missed menstrual 
period and therefore could not be classified within any menstrual cycle phase). She followed the 
typical DES sampling-interview procedure that is described fully in Step 2 of the Method section 
of this paper (Chapter 3). She completed her first 13 sampling interviews in-person but, due to 
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the coronavirus pandemic, the remainder were conducted by Skype or Zoom. Given that Lee had 
substantial experience with DES sampling before switching to virtual interviews, it seemed she 
adjusted easily to the virtual environment. However, the impacts, if any, of virtual interviews 
(and of the pandemic more broadly) on Lee’s experience are, of course, unknown.  
Lee participated in the study across a total of eight menstrual cycles. During that time, 
she missed one menstrual period and had an average cycle length (excluding the cycle with the 
missed period) of approximately 34.5 days, therefore estimating ovulation as approximately 
between days 15 and 19. Lee was fairly inconsistent in providing daily pictures of her ovulation 
test results; she failed to provide pictures surrounding 9 of her 21 sampling days. Because we did 
not have ovulation test results for nearly half of Lee’s sampling days, there was a greater 
possibility of inaccurately classifying the cycle phases associated with each sampling day. 
However, as with other participants, we used the best available data and judgment considering a 
number of factors to determine the occurrence of ovulation, including day of cycle, test result on 
that day, pattern of test results surrounding that day, cycle length, and so on, but blind to the 
characteristics of experience.  
The top panel of Table 10 displays the breakdown of Lee’s sampling days by cycle phase. 
The bottom panel displays the frequencies of her salient experiential phenomena within each 






Characteristics of Lee’s inner experience overall and by cycle phase 
 
a See above for explanation of variability in which cycle days were associated with each menstrual cycle phase. 
b Recall that Lee’s day 9 could not be classified within a menstrual cycle phase (due to a missed menstrual period) 
and was therefore excluded from analysis.  
c Note that % need not up add to 100 because a single sample can contain multiple phenomena. 




Premenstrual Total X2(2) 
Days of Menstrual Cyclea 1-15, 21 15-19 22+   
Number of Sampling Days 8 4 7 20b  
Number of Samples 48 24 39 111b  
Frequencies (%)c of Experiential Phenomena  
Inner speaking 27.1 31.3 19.2 25.2 1.29 
Inner seeing 21.9 31.3 35.9 28.8 2.15 
Unsymbolized thinking 21.9 14.6 19.2 19.4 0.55 
Feeling 20.8 12.5 26.9 21.2 1.86 
Sensory awareness (SA) 19.8 20.8 34.6 25.2 2.82 
Inner speech while reading 6.3 8.3 2.6 5.4 1.09 
Inner seeing of words 4.2 4.2 2.6 5.4 0.19 
Inner seeing with SA 5.2 2.1 11.5 6.8 2.43 
Inner seeing in slow motion 0.0 4.2 5.1 5.4 2.40 
Inner seeing notable color 0.0 4.2 7.7 3.6 3.69 
Inner seeing with sound 0.0 8.3 0.0 1.8 7.38* 
Bodily feelings 6.3 0.0 17.9 9.0 6.62* 
Mental feelings 14.6 10.4 6.4 10.8 1.50 
Sensation not integrated with  
    feeling 
4.2 0.0 5.1 3.6 1.20 
Feeling with specific location 3.1 0.0 6.4 3.6 1.81 
Feeling experienced as color 0.0 0.0 5.1 1.8 3.76 
Feeling outside body 0.0 0.0 5.1 1.8 3.76 
Bodily SA 6.3 2.1 10.3 6.8 1.61 
Visual SA 9.4 18.8 21.8 15.8 2.70 
Skillful/creative experience 0.0 0.0 7.7 2.7 5.69 
Unusual by DES standards 8.3 0.0 20.5 9.0 1.44* 
Watching TV/video game 11.5 25.0 9.0 13.5 3.57 
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We followed the usual analysis described in Chapter 3 (Method), Step 2: We first 
reviewed and “captioned” all samples together (blind to their associated cycle phase) and then 
separated sampling days by cycle phase and phenomenologically and quantitatively examined 
differences in experience across phases.  
The Individual (blind to menstrual cycle phase). A notable quality of Lee’s overall 
inner experience in general was its clarity of organization. That is, Lee’s experience was 
generally unified with a clear and single focus. She could (and often did) have several separable 
aspects of experience, but those aspects were almost always connected/of the same rhythm as 
opposed to fragmented or disjointed. To illustrate, consider sample 16.2: 
16.2: [Lee is watching a Red Hot Chili Peppers music video. She used to love this band 
and is now reminiscing.] She hears the Red Hot Chili Peppers playing from the video 
and, at the same time, innerly sees herself sitting on a sofa in her friend’s house watching 
them play on TV. She sees from behind, as if she is in the same room but a few feet 
behind the couch. Part of the inner seeing is in slow-motion: the TV is slowly changing. 
On the TV, she just sees changing colors, not the band or anything else in detail, even 
though she understands it to be the Red Hot Chili Peppers. She sees the rest of the room, 
too, and it seems accurate of her friend’s living room. [In fact, Lee does not recall 
watching the Red Hot Chili Peppers on TV at her friend’s house, so this image is 
apparently her own creation but is the sort of thing that could have happened.] At the 
same time, Lee feels joy, a strong mental feeling. 
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Notice that in that sample, there were several simultaneous aspects of Lee’s experience: hearing 
the real Red Hot Chili Peppers, innerly seeing them on TV, and feeling joy. While these were 
separable phenomena (an external hearing, an inner seeing, and a mental feeling), they were 
connected and unified, all aspects of one coherent reminiscing-about-this-band experience.  
There was only one marked exception to the unity of Lee’s experiences (sample 14.4 
during the Traditionally Non-Symptomatic phase): 
 14.4: [Lee is planning to text a friend who is going through a hard time because of the 
COVID-19 quarantine. She can’t think of what to say in the text.] She experiences her 
mind as full of a jumble of unarticulated thoughts of what she might say, which may have 
included some words or inklings of words or ideas but nothing specific at the moment. 
The jumbledness is by far the most salient aspect of this experience; if words are present, 
they are not nearly as important to her. Simultaneously, Lee experiences her face 
(primarily the region around her mouth) as blank, nothing. This is not a physical 
experience of the sensations or expression of her face—that is, it’s not about a blank 
facial expression—but she somehow (not physical) recognizes or senses the 
nothingness/blankness of her face. [Thus, there is, at the moment of the beep, a 
disconnect between Lee’s mind (jumble of thoughts) and face (blank), but she does not 
directly experience the disconnect. After the beep, she recognizes the disconnect, and was 
believably confident that it was about her mind and face specifically, not about her mind 
and body, for example.] 
That sample was much busier and more fragmented than were Lee’s typical experiences. Though 
the jumble of thoughts and blank face were apparently both spawned by her inability to articulate 
the text message, the two strands of experience were not coherently unified. Her mind was one 
166 
 
thing—busy, full, a jumble of not well-articulated somethings. And her face was quite another 
thing—blank, nothingness. Furthermore, she did not directly experience the two as 
manifestations of her texting trouble, nor did she directly experience their disconnect. They were 
two distinct streams ongoing in parallel. Note the contrast from Lee’s other experiences, 
including in the Red Hot Chili Peppers sample 16.2: In that sample, there were three separate and 
simultaneous phenomena, all clearly unified in one reminiscing-on-my-relationship-with-this-
band experience.  
Lee’s overall inner experience was well-characterized by what DES has called the “five 
frequent phenomena,” or “5FP” (Kühn et al., 2014): inner speaking, inner seeing, unsymbolized 
thinking, feelings, and sensory awareness. Lee experienced each of the 5FP in roughly 20-25% 
of all samples, consistent with the frequencies Hurlburt and Heavey (2008) reported in a 
stratified sample of 30 college students.  
Lee was innerly seeing in 28.8% of all samples, most of which were clear and detailed. 
Lee’s inner seeings sometimes including a sensory awareness. For example, at the moment of 
sample 5.3, a song came on the TV that made Lee feel happy. Apparently as her own illustration 
of happiness, she innerly saw the bright and shiny pink, blue, and yellow colors of balloons in a 
room of people dancing. Her experience was not of innerly seeing a party, it was of innerly 
seeing and being drawn to the bright colors of the balloons that happened to be at a party (which 
DES calls sensory awareness). Sometimes Lee’s inner seeings were in slow motion. For 
example: 
6.2: [Lee is in class and planning to go to the library after.] At the moment of the beep, 
she innerly sees the unfolding, in-slow-motion (slower than normal walking pace) view 
of approaching the university’s library from its east side. She sees in detail the entire 
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scene: the library, the trees, the path, the dirt and rocks, the tables and chairs outside, the 
food trucks that are usually there in the morning. (She does not see people, however.) The 
seeing is in accurate and realistic color [as if she had taken a video]. She sees from the 
perspective of walking toward the library but does not feel herself moving towards the 
library. [It’s also not the case that the imaginary walker is not her; it’s that the ‘walker’ is 
no one, it doesn’t matter as far as her experience is concerned.]  
On two occasions (both on sampling day 3 during Ovulation), Lee’s inner seeings included 
sound like a movie playing in her mind. At sample 3.6, she innerly saw a pot of macaroni and 
cheese being stirred. She heard the sloshing sound as it was stirred. (Also note that, like sample 
5.3 of the balloons, the macaroni was seen in hypervivid color, a sensory awareness). Consider 
also the sound within an inner seeing from sample 2 on that day:  
3.2: [Lee is reading about Miranda v. Arizona and has just read about the “right to remain 
silent.” Apparently spawned by those words,] Lee innerly sees a “cop” [her word] 
handcuffing a “victim” [also her word even though, presumably, someone being 
handcuffed would more aptly be called a “suspect” or “perpetrator”]. She innerly sees the 
cop straight on from eye level, but he is looking down and his stereotypical police hat 
obscures most of his face. She can see that he has dark hair, a mustache, and is wearing 
glasses. She sees the top of the victim’s head but nothing really of his face. She sees his 
hands in handcuffs raised up by his face. The inner seeing is not in motion, yet 
simultaneously, she innerly hears the cop say, “You have the right to remain silent.” It’s a 
generic male cop’s voice with a stern tone that she knows to belong to the cop even 
though she does not see the cop’s mouth moving. Thus, this is a very clear, realistic inner 
seeing with sound of a police officer reviewing someone’s Miranda rights. 
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Thus, for Lee, inner seeing was frequent with similar characteristics across all menstrual 
cycle phases (with the possible exception of inner seeings including sound which may have been 
more frequent around Ovulation). Her inner seeings were usually clear, detailed, and could be 
quite elaborate, including with details such as slow motion, innerly seen words, or embedded 
sensory awarenesses of hypervivid color.  
Lee was innerly speaking in 25.2% of all samples. Her inner speech was sometimes in 
accompaniment with reading or writing. For example: 
20.4: [Lee is typing.] She innerly says in her own voice at a faster than conversational 
speed, “it helps them gain” [In fact, she’s trying to remember that phrase so she can type 
it later, but the remembering aspect is not directly experienced.] 
Other times Lee’s inner speech was more self-generated, like a running commentary. For 
example:  
21.5: [Lee is watching a TV show. On the show, they’re holding up a lychee fruit and 
referring to it as a nut.] Lee (60 or 70% of the total experience) thinks that lychees are 
fruit, [not nuts]. That is, she knows that lychees are fruit and directly experiences that 
knowledge without explicit words, pictures, or other symbols at the moment. At the same 
time, she (30 or 40%) innerly says in her own voice in an incredulous tone, “What the 
heck are lychee nuts?” 
In 25.2% of all samples, Lee’s experience included sensory awareness, the focus on some 
sensory aspect without particular regard for instrumentality. She was most often drawn to visual 
characteristics (17.5 of 28 sensory awarenesses, or 62.5%) such as color. For example: 
9.4: [Lee is watching a movie. The scene is of waves crashing on a beach.] She sees the 
whole scene but, mostly, is noticing/drawn to (equally) the bubbly texture and white 
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color of the seafoam produced by the waves. [She is not following the plot of the movie 
at this moment.] 
Similarly, at sample 21.1, she noticed the blue aura surrounding the main character on a TV 
show; at sample15.3, she was drawn to the weird appearance of Mr. Potato Head’s eyes in an 
Instagram video; and, at sample 9.6, she noticed the braided hairstyle of a character in a movie.  
Lee could also attend to non-visual sensations, such as physical sensations in her body (7.5 of 28 
sensory awarenesses, or 26.8%). For instance: 
5.6: [Lee is really warm. She’s wearing too many layers of clothing.] She feels a spark-y 
hot sensation “sprinkling” on the surface of and inside her torso (below neck, above 
waist, not including arms). Sprinkling is intended to convey that the sparky sensation 
sprinkles/peppers her body not all at once but like rain drops. The sprinkly-sparky 
sensation rises in patches and then fades, immediately followed by a cooling sensation. 
Thus, there will be a patch in her lower left torso followed by cooling, then another patch 
near her belly button followed by cooling; it’s not necessarily one patch at a time; there 
can be several simultaneous sensations. At the same time, she knows she wants to change 
her clothes. Perhaps it could be said that she is thinking she wants to change her clothes, 
but it felt more faithful to Lee to say she knows (thus this aspect is apparently something 
cognitive but short of an unsymbolized thought process).  
Lee had unsymbolized thoughts in 19.4% of all samples. Her unsymbolized thoughts 
were generally straightforward and uncomplicated, of the garden-variety typically seen in DES. 
For instance, at sample 15.2, she heard her mom’s work phone ringing and wondered (a directly 
experienced thought process not in words, pictures, or other symbols) whether she should bring 
her mom the phone. Similarly, at sample 8.6, she was planning a karaoke gathering for her 
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birthday and was thinking without words, pictures, or other symbols, who she needed to text with 
directions to the venue. At the moment of the beep, she was specifically wondering about her 
friend, Shannon. 
Finally, Lee had feelings (the direct experience of emotion) in 21.2% of all samples, 
roughly half of which were experienced in her body and half mentally with no bodily 
component.  
With Respect to Menstrual Cycle Phase. We did not observe phenomenologically that 
there were any differences in clarity between Lee’s cycle phases and the non-significant 
ANOVA of caption lengths supported that observation, F(2, 109) = .538, p = .586.  
We also conducted the usual exploratory chi squared tests to determine whether the 
frequency of phenomena differed across phases. For Lee, there were two “significant” (recall 
that these were exploratory and thus did not correct for multiple tests) findings:  
 Experiences considered “unusual by DES standards” differed across cycle phases (X2(2) 
= 7.02, p = 0.03). This “unusual” category includes the following: feelings experienced in 
color; feelings experienced outside her body; feelings with non-integrated sensations; 
imaginary sensations; and one particularly unusual example of innerly seen words. By 
inspection, these “unusual” experiences were entirely absent during ovulation but 
frequent during the late luteal/premenstrual phase (20.5% of samples) and occasional 
during the traditionally non-symptomatic phase (6.3% of samples).  
 Inner seeings including sound differed across cycle phases (X2 (2) = 7.38, p = 0.025). In 
fact, inner seeings with sound only occurred only twice, both around ovulation; however, 
both instances were on sampling day 3; thus, it is difficult to determine whether sound in 
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inner seeings was a characteristic specific to ovulation broadly or just somehow specific 
to Lee on that sampling day. 
 Bodily feelings (emotional, not only sensory) differed across cycle phases (X2 (2) = 6.62, 
p = 0.036).  By inspection, bodily feelings were entirely absent during ovulation but 
occurred moderately frequently in the late luteal/premenstrual phase (17.9% of samples) 
and, less so, in the traditionally non-symptomatic phase (6.3% of samples).  
There was one other finding that was suggestive: Experiences were coded as “skillful/creative” 
(explained more fully below) in 3 of the 39 late luteal/premenstrual samples (7.7%), but not at all 
during either of the other two cycle phases (X2 (2) = 5.69, p = 0.058).  
With Respect to Menstrual Cycle Phase. As we have seen, the characteristics and 
frequencies of Lee’s experience were generally consistent across her menstrual cycle; for 
example, the 5FP were common for Lee and each occurred at roughly the same frequency within 
each cycle phase and overall. Lee’s feelings (emotion) were one notable exception. That is, 
whereas bodily feelings occurred in 9% of all samples, there were no instances of bodily feelings 
during ovulation compared to 17.9% of late luteal/premenstrual samples and 6.3% of 
traditionally non-symptomatic samples. This was a “significant” (albeit exploratory) difference: 
X2 (2) = 6.62, p = 0.036. In contrast, mental feelings occurred at roughly the same frequency 
overall (10.8% of samples) as within each phase (14.6% of traditionally non-symptomatic 
samples, 10.4% of ovulation samples, and 6.4% of late luteal/Premenstrual samples).   
In addition, Lee’s experiences were notably more unusual by DES standards in the late 
luteal/premenstrual phase (and less so, during the traditionally non-symptomatic phase) by 
comparison to ovulation, a difference that was “significant” (X2 (2) = 7.02, p = 0.030). Those 
“unusual” experiences were so striking that we created a category to capture them, which 
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included unusual feelings (feelings in color, outside her body, and non-integrated with 
sensations), imaginary sensations, and one particularly unusual example of innerly seen words.   
Let us first consider feelings. Feelings are among the most difficult phenomena for DES 
participants to describe. However, when feelings occur, they generally take one of two forms: 
They are experienced “mentally” (there is clearly an emotion ongoing but without any 
experienced bodily aspect) or “bodily) (there is clearly an emotion ongoing and it includes 
experienced internal bodily characteristics/sensations). Lee had typical feelings of those kinds; in 
fact, during ovulation, for example, when feelings were present, they were only and always of 
the garden-variety of mental feelings.  In contrast, in two of Lee’s 39 late luteal/premenstrual 
samples, feelings were experienced as outside her body/engulfing her and in color (though not 
visually, not seen). In sample 5.3 (mentioned above for its sensory awareness of the color of 
balloons), Lee felt happy, a “sparky”/energized feeling that had begun (before the beep) in the 
center of her chest and was, at the moment of the beep, radiating throughout the entire inside of 
her body and also outside her body in a yellow, dome-shaped “aura.” Lee did not see a yellow 
dome and yet, without a doubt, her happy feeling included being surrounded in a yellow, dome-
shaped aura. In fact, the domedness of it was quite specific: an egg-like shape with his ‘edges’ 
roughly six inches away from Lee’s body. See also Late Luteal/Premenstrual sample 6.6, in 
which Lee felt an emotion that, again, had specific color and engulfed her (though not in a 
specific shape as with the dome in sample 5.3): 
6.6: [Lee has been texting her boyfriend’s sister, reminiscing on how they both 
(separately—they did not know each other then) had been mega-fans of the band One 
Direction. They are recounting embarrassing moments, such as crying about the band.] 
At the moment of the beep, Lee (90% of the total experience) feels 
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happy/funny/laughing, an emotional experience. She feels the corners of her mouth and 
cheeks pulling and tight (but not uncomfortably so) as she laughs aloud. At the same 
time, she experiences this happy/funny/laughing feeling outside of her and engulfing her 
entire body. The engulfing feeling is understood to be static-y and orange-ish/yellow-ish 
in color. Her description is not metaphorical: The feeling is definitely present and has 
those visual and sensory qualities even though she does not directly experience the 
qualities in the expected way (e.g., she does not see orange-ish/yellow-ish). At the same 
time, (10%) she sees and reads her friend’s text message, HAHAHA. She reads it exactly 
as HAHAHA even though she suspects the actual text may have included more iterations 
of HA (e.g., HAHAHAHAHA) or had typos/insertions (e.g., HAJHAKSA).  
Lee’s feelings were also at times unusual in their failure to integrate physical sensations (what 
we called “non-integrated feelings”: 3.6% of all samples), meaning she had a mental feeling and, 
in parallel but not connected to the mental feeling, a physical sensation. Again, this never 
occurred during ovulation, but did occur in both the traditionally non-symptomatic (4.2% of 
samples) and late luteal/premenstrual phases (5.1% of samples). Typically, when people 
experience emotion, their physical sensations are integrated with/part of the emotion (what DES 
calls a “bodily feeling”). Lee, in contrast, could have a purely mental feeling and, in tandem, a 
physical sensation that certainly seemed like it ought to be related to the feeling but was 
decidedly not or, at least at the moment, not yet. For example, see sample 21.4 during the late 
luteal/premenstrual phase:  
21.4: [Lee is watching a TV show. An unfamiliar voice indicates that a new character has 
arrived in the scene. Lee looks around the scene and] notices that there’s a man hiding in 
a dark doorway. She feels really, extremely startled/scared by this man. This is an 
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entirely mental feeling. Separately [but apparently also spawned by the startling man], 
she feels a static-electricity-like sensation in her abdomen. It’s a light, not painful 
sensation. Thus, at this moment, Lee experiences an emotion that, though mental, is 
strong and clear. And, in tandem, she experiences a bodily sensation that is likely related 
to the startled feeling but not (or perhaps not yet?) fully integrated. 
See also sample 14.3 during the traditionally non-symptomatic phase:  
14.3: [Lee is watching the news. A song played as the station went to commercial and it 
was familiar to Lee, somehow reminding her of her younger years, yet not bringing her 
back to any specific memory, age, or time.] She feels nostalgic, a mental feeling, and, at 
the same time, has chills on the left side of her abdomen (a physical sensation). The 
nostalgia and chills are not, at the moment, two aspects of the same thing (the feeling) but 
yet, they are not entirely separate. [Perhaps if the beep had occurred slightly later, the 
chills would have been experienced as part of the nostalgia.] 
Lee’s non-integrated feelings were fairly unusual by DES standards and, like the other unusual 
characteristics of her feelings, they occurred most frequently in the late luteal/premenstrual 
phases and not at all in the ovulation phase.  
Imaginary sensations were another of Lee’s unusual-type experiences. Sensory 
awarenesses of imaginary sensations occurred in three total samples (two during the late 
luteal/premenstrual phase and one during the traditionally non-symptomatic phase). For example, 
see sample 5.1 from the late luteal/premenstrual phase: 
5.1: [Lee is watching TV. Before the beep, she cut fuzz balls off of her blanket and is 
now,] at the moment of the beep, rubbing the fuzz balls between her fingers. She feels the 
rubbing sensation in her fingers, a tactile sensation like cotton balls rubbing together. 
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Simultaneously, Lee hears the sound of the fuzz balls rubbing [even though, in reality, 
there is no such sound. That is, another person in the room would not hear the fuzz balls.] 
The sound is difficult for Lee to describe but is intensely negative/unnerving and is 
specifically located in/connected somehow to the space between her back teeth. She hears 
the fuzz ball sound specifically in the space between her back teeth. Lee is, in fact, 
grinding her teeth at the moment, and the physical feeling of grinding is also part of her 
experience. [Lee maintained that, even though the sound seemed to be located in the 
place where she was grinding her teeth, the sound was not of teeth grinding; it was of the 
fuzz balls.] This entire experience is intensely uncomfortable/unnerving for Lee [and yet 
she continues to consciously, not mindlessly, rub the fuzz balls together.] 
This fuzz-ball sample is extremely unusual by DES standards for several reasons: (1) the 
imaginary sound, (2) the specific and seemingly mismatched location of the imaginary sound, 
and (3) Lee’s conscious, deliberate rubbing action to create the sound even though it bothers her 
(an example of what DES has called “the doing of sensory awareness”).  
Sample 7.5 (during the traditionally non-symptomatic phase) also included an imaginary 
sensory awareness: Lee had been reminded of a rambutan (a fruit similar to a dragon fruit) and, 
at the moment of the beep, imaginary felt herself tossing a rambutan around in her mouth with 
her tongue. She did not, in fact, have a rambutan in her mouth, but felt the smoothness of the 
rambutan on her tongue as if she did. Like feelings in color, imaginary sensations are not 
unheard of among DES participants but are rare enough to be considered unusual.  
We also included in the “unusual by DES standards” category a particularly unusual example of 
innerly seen words.  
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15.1: [Lee is trying to remember something, but she doesn’t know what it is, only that it 
is important.] She innerly sees important in a standard computer font, all lowercase, 
white lettering against black, no explicit borders. The word important is big—not big like 
a billboard but big enough to fill a piece of printer paper. At the same time, she innerly 
says in her own voice repeatedly “important… [1 second or so pause] …important.” This 
inner speaking is more or less mindless and much less prominent compared to the inner 
seeing.  
The most striking characteristic of sample 15.1 was not that Lee innerly saw a word (she did so 
in 3.6% of all samples, at least once in each of the three menstrual cycle phases) but rather, the 
choice of word. That is, Lee innerly saw a word that conveyed a sort of meta-commentary on her 
current situation. Important was not the word or even part of the sentence or whatever it was she 
was trying to remember; important was a comment on her own memory-failing; she was trying 
to remember something important. For a more typical inner seeing of words (by DES and Lee’s 
standards), see sample 12.3 during the Traditionally Non-Symptomatic phase:  
12.3: [Lee is in class. Her teacher is talking about Utah.] She innerly sees the word Utah 
in white, normal computerized font against a black background. The U is capitalized and 
the rest of the word is lowercase. The letters are relatively big—bigger than 12-pt font on 
a page but not as big as the text on a billboard. [Her experience is not at all about the state 
Utah or any other connotations—trees, Salt Lake City, her memories there, etc. It’s just 
about the word Utah.] 
Notice that in sample 12.3, the content of Lee’s inner seeing is coherent; she seems to be 
illustrating her situation. Her teacher is talking about Utah and she sees the word Utah. However, 
in sample 15.1, it would have been more typical/expected for Lee to see something related to 
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what it was she was trying to remember (as that was the crux of the situation). Instead, she sees 
important, a meta-commentary on the situation.  
We have seen that Lee’s non-ovulation (especially, late luteal/premenstrual) experiences 
were often remarkable and unusual. Consistent with that, in three of Lee’s 111 total samples 
(2.7%), all during the late luteal/premenstrual phase, her experiences were coded as 
“skillful/creative” (X2 (2) = 5.69, p = 0.058), another somewhat “unusual” quality. In DES, 
experiences are considered “skillful/creative” if they contain a quality/element/characteristic that, 
on its face, may seem artifactual, but, upon closer examination, is rather savvy. To illustrate, 
consider sample 4.4: 
4.4: [Lee has just read on social media, “Have you ever been attracted to somebody’s 
voice?” Before the beep, she thought, Yes.] At the moment of the beep, she innerly hears 
a man’s voice. She attends to the vocal characteristics of the voice—it’s warm and 
comforting. She experiences the innerly heard man’s voice to be speaking words, but the 
words are not important to her experience; that is, she understands him to be speaking 
probably in words, but she doesn’t hear specific words or comprehend any meaning. The 
words are unimportant; her experience is aimed at how his voice sounds. At the same 
time, Lee innerly sees a black silhouette stepping into a room. [After the beep and in the 
interview, Lee speculates that the silhouette is a man and, indeed, he is shaped more like 
a man than a woman, but her experience is not of seeing a man. It’s of seeing a 
silhouette.] The silhouette is seen from the side, stepping into a room with the door 
opening away from the room. The inner seeing is entirely flat, all aspects are of the same 
dimension; the background, the door, and the silhouette are all on the single flat “canvas” 
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so to speak. The inner seeing is dark: the silhouette and door are both black and set 
against a dark purple background.  
On its face, several aspects of this experience appeared to be unclear or poorly articulated: She 
heard a voice but no words and saw a silhouette instead of seeing a man. However, upon closer 
examination, these were (we thought) highly skillful improvisations. That is, Lee was apparently 
trying to recreate attraction to a voice (the question that spawned her experience) and so heard a 
voice speaking words (as voices do) but also experientially discarded or ignored or denied the 
words because her experience was not about what the man said but about how his voice sounded. 
Moreover, she was apparently not aware of or interested in whom the voice belonged to and, 
therefore, instead of seeing someone specific or even seeing a man generally, she created an 
extremely vague silhouette of a generic man to be the voice’s owner. Similarly, consider sample 
11.4: 
11.4: [Lee is half-asleep on the couch.] At the moment of the beep, she is immersed in 
(somehow both a part of and listening to) an inner debate. There are no words or sounds 
even though she definitely experiences herself as listening [which would seem to imply 
sound]. Moreover, the debate has no content—she doesn’t know now in the interview and 
didn’t know at the time what the debate was about [even in general—e.g., politics, 
favorite foods, etc.]. However, she does clearly apprehend that there are two sides—more 
like two different ideas as opposed to, say, Person A vs. Person B—and she apprehends 
those sides as passionately and frustratedly advancing their respective points. Both sides 
are frustrated and passionate, which are not meant to be synonymous; she apprehends 
passion distinctly as something like the gusto behind their position and frustration as 
something like trying to win. Additionally, Lee herself feels frustrated, an empathic, for-
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the-debaters frustration. She does not experience herself as with a particular side of the 
debate—she’s more witness than debater. Thus, at the moment of this beep, Lee 
apprehends a debate without any content; it was rather like the experienced affective 
bulwark of a debate. 
As with the attractive voice in sample 4.4 above, the inchoate/undifferentiatedness of Lee’s 
experience in sample 11.4 seemed to be skillful. She was apparently not interested in any 
particular debate or even debate topic; rather, she was, for whatever reason, interested in the 
affective atmosphere and back-and-forth of a debate. Skillfully, then, she experienced that 
affective atmosphere perfectly void of the not-important-to-her details: There were no specified 
debaters; no specified topic; no specified words, even. There was only the feel, of which she was 
entirely immersed: She sensed the debaters’ emotions with fine-grained distinction (i.e., passion 
versus frustration) and she herself felt empathically, vicariously frustrated.   
Summary 
 At the time of her participation, Lee was an undergraduate university student between the 
ages of 18 and 25. Her Screening responses indicated she experienced clinically significant 
symptoms of premenstrual distress. She agreed to participate in DES sampling and ultimately did 
so for 21 days across eight menstrual cycles, collecting a total of 111 beeped experience samples. 
Her menstrual cycles were generally regular with an average length of 34.5 days, though she 
missed one menstrual period during her participation. Because she was inconsistent in providing 
daily ovulation test results, her cycle phases were estimated more crudely (usually based on 
average cycle length and cycle day of sampling, sometimes including a test result) and were 
therefore more vulnerable to inaccuracies. However, even with that crude estimation, there 
appeared to be some cycle-related differences in experiential frequencies. Whereas Lee’s most 
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frequent phenomena (conveniently DES’s “five frequent phenomena,” or “5FP”) did not differ 
by cycle phase, her more unusual experiences did. Specifically, unusual experiences (such as 
feelings experienced in color, outside one’s body, or non-integrated, imaginary sensations, and 
innerly seen words) occasionally occurred during non-ovulation phases (especially the late 
luteal/premenstrual phase) but never during ovulation. Ovulation was therefore unremarkable in 
some respects (especially regarding feelings) compared to other cycle phases, whereas the late 




Chapter 9: Cat 
Cat is an Asian female. At the time of her participation, she was between 18 and 25 years 
old and a full-time undergraduate university student. 
Step 1: Screening  
Cat’s screening results indicated she was appropriate for the study. She reported she had 
regular menstrual periods and denied any medical conditions, behaviors (e.g., heavy alcohol use, 
shift work), or medications (including birth control) that would alter her hormone function. Cat’s 
responses indicated she experienced clinically significant symptoms of Premenstrual Dysphoric 
Disorder (PMDD). She endorsed 6 of the 11 DSM-5 symptoms of PMDD and noted that those 
symptoms profoundly impacted her functioning at work, socially, and even with respect to 
activities of daily living. On the Premenstrual Assessment Form (PAF), Cat earned a score of 43, 
which translates to a z score of 1.3 and therefore placed her score higher than approximately 80% 
of those in the normative, non-clinical sample. On the Visual Analogue Scales of PMDD 
symptoms, she reported that her mood symptoms were, on average, 83.75% worse during the 
premenstrual phase as opposed to the rest of her cycle. She reported all PMDD symptoms (mood 
and behavioral) were, on average, 77.73% worse during the premenstrual phase as opposed to 
the rest of her cycle.  
Step 2: DES Sampling & Cycle Tracking 
Cat participated in the study across nine menstrual cycles. She completed 21 days of 
natural-environment DES sampling amassing a total of 126 beeped experiences (this count 
excludes day 1 which was discarded as training, as is typical of DES).  Cat completed her first 7 
sampling interviews in-person but, due to the coronavirus pandemic, the remainder of her 
sampling interviews were conducted over Skype or Zoom. Cat demonstrated skill at 
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apprehending and describing experience from very early in the process and seemed to acclimate 
easily to the virtual interview environment. However, the impact, if any, of virtual interviews 
(and of the pandemic more broadly) on Cat’s inner experience are, of course, unknown.  
Cat provided ovulation test results around all but three of her 21 DES sampling days; 
however, the days she missed were easily classified without those results (e.g., Sampling day 12 
occurred on the 3rd day of that menstrual cycle, therefore clearly in the traditionally non-
symptomatic phase). Moreover, the ovulation test kit appeared to be effective for Cat; that is, the 
ferning pattern showed up predictably, including clear ferns or at least some ferns (an indicator 
that ovulation was maybe/probably occurring or about to occur) on each of the six days 
identified as occurring in the ovulation phase. Across all nine cycles, Cat’s average cycle length 
was 29.5 days, therefore estimating ovulation around days 13-17. Consistent with that 
estimation, the six sampling days we identified by ferning as occurring in the ovulation phase 
occurred between cycle days 13 and 18.  
The top panel of Table 11 displays the breakdown of Cat’s sampling days by cycle phase 
as determined by the day of her menstrual cycle and the results of the ovulation test kit. The 
bottom panel displays the frequencies of Cat’s salient experiential phenomena within each cycle 





Characteristics of Cat’s inner experience overall and by cycle phase 
 
a Note that % need not up add to 100 because a single sample can contain multiple phenomena. 
* “significant” (recall that this analysis did not adjust for multiple tests) at p < .05 
** “significant” (recall that this analysis did not adjust for multiple tests) at p < .01 
 





Premenstrual Total X2(2) 
Days of Menstrual Cycle 1-12, 19-20 13-18 21+   
Number of Sampling Days 8 6 7 21  
Number of Samples 48 36 42 126  
Frequencies (%)a of Experiential Phenomena 
Inner speaking (IS) 33.3 27.8 35.7 32.5 0.58 
Inner seeing 2.1 2.8 4.8 3.2 0.55 
Unsymbolized thinking 3.1 5.6 3.8 4.4 0.31 
Feeling 2.1 2.8 13.1 6.0 5.76 
Sensory awareness (SA) 64.6 51.4 48.8 55.6 2.61 
IS while reading or writing 21.9 12.5 16.7 17.5 1.28 
Bodily feelings 2.1 0.0 9.5 4.0 5.34 
Mental feelings 0.0 2.8 3.6 2.0 1.63 
Tactile SA 31.3 19.4 19.0 23.8 2.37 
Visual SA 14.6 15.3 19.0 16.3 0.36 
Bodily SA 16.7 8.3 10.7 12.3 1.47 
Multiple connected SA 10.4 13.9 7.1 10.3 1.51 
Multiple separate SA 6.3 2.8 2.4 4.0 1.07 
Physical action 8.3 29.2 9.5 14.7 8.47* 
SA of her physical action 8.3 5.6 2.4 5.6 1.51 
Emphasis on movement 5.2 6.9 9.5 7.1 0.63 
Aware of her destination/goal 14.6 15.3 14.3 14.7 0.02 




We followed the usual analysis described in Chapter 3 (Method), Step 2: We first 
reviewed and “captioned” all samples together (blind to their associated cycle phase) and then 
separated sampling days by cycle phase and phenomenologically and quantitatively examined 
differences in experience across phases.  
The Individual (blind to menstrual cycle phase). In general, Cat’s experience was 
dominated by sensory awareness, which occurred in more than half of all samples (55.6%) and in 
a variety of ways (bodily, tactile, visual, etc.). She also frequently engaged in inner speech 
(31.0% of all samples), especially along with reading or writing (22 of 39 inner speaking 
samples, or 56.4%).  
Cat was consistently able to make fine experiential distinctions, especially regarding 
sensations. For example, note the skill with which Cat differentiated related sensory aspects in 
this excerpt of sample 16.4: 
16.4: Cat notices the text [that she’s currently reading] standing out. [In fact, the current 
text is red whereas the previous text was black, and it is the redness that causes the text to 
stand out, but her experience is not about the redness.] She’s noticing the standing-out-
ness (which happens to be caused by a difference in color). This is purely visual 
experience, nothing analytical, a visual noticing of standing-out-ness.  
Sample 12.4 was another example of the fine-grained distinctions within Cat’s 
experience. At the moment of that beep, there were two parallel strands in Cat’s experience: 
innerly speaking the words that she was typing and seeing the letters that she typed appear on the 
screen. Cat was believably clear that the inner speaking was of words whereas what she saw 
appear on the screen were letters.  
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With Respect to Menstrual Cycle Phase. While reviewing Cat’s samples, we noticed 
that there seemed to be differences in the complexity of her experience across sampling days. 
That is, on some sampling days, Cat’s experience seemed overall clear whereas, on other 
sampling days, her experience seemed “messy” and unfocused. The usual exploratory ANOVA 
of caption character counts supported that observation, showing that caption lengths differed 
across cycle phases, F(2, 123) = 3.06, p = 0.050. Inspection, justified by considering the analysis 
exploratory, showed that the ovulation caption mean (67.31 characters) was the largest, the 
traditionally non-symptomatic caption mean was smallest (48.48 characters), and the late 
luteal/premenstrual caption mean was intermediate (65.27 characters). This suggested that Cat’s 
experiences around the time of ovulation may have been more complex than during the other 
cycle phases, though the differences were not as phenomenologically obvious as they had been 
with other participants. 
We then conducted the usual exploratory chi squared analyses to examine whether the 
frequency of a phenomenon differed across cycle phases. There were two “significant” (recall 
these analyses were considered exploratory and so did not adjust for multiple tests) findings: 
 Cat’s direct experience of her own physical action(s) differed across phases, X2(2) = 
8.47, p = 0.015. By inspection, those experiences were more frequent during ovulation 
(29.2% of samples) than in other cycle phases (8.3% of traditionally non-symptomatic 
samples and 9.5% of late luteal/premenstrual samples).  
 Cat’s TV-watching differed across phases, X2(2) = 11.13, p = 0.004. Watching TV 
occurred in far fewer (in fact, none) of her ovulation samples (0.0% of samples) as 
compared to the late luteal/premenstrual phase (19.0% of samples) and the traditionally 
non-symptomatic phase (4.2%).  
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 Two other findings were suggestive: 
 Feelings seemed to differ slightly across cycle phases, X2 (2) = 5.76, p = .056. By 
inspection, feelings were more frequent during the late luteal/premenstrual phase (13.1% 
of samples) than during ovulation (2.8% of samples) or the traditionally non-symptomatic 
phase (2.1% of samples).  
 Similarly, bodily feelings seemed to differ slightly across cycle phases, X2 (2) = 5.34, p = 
.069. By inspection, bodily feelings were most frequent during the late 
luteal/premenstrual phase (9.5% of samples), whereas they were nonexistent during 
ovulation and rare during the traditionally non-symptomatic phase (2.1% of samples).   
 
Thus, on the basis of 21 days of natural-environment sampling and careful description of 
126 individual moments of private inner experience, it seemed that Cat’s experience, too, 
differed somewhat across cycle phases. Specifically, her experiences during Ovulation seemed to 
be somewhat more complex than during other phases. This complexity involved, at least in part, 
to the busyness/fragmentedness of those experiences. That is, whereas the majority of Cat’s 
beeps were simple and straightforward with generally one or perhaps two simultaneous 
phenomena, some of Cat’s beeps stood out as “busy,” and those seemed to occur most frequently 
during ovulation. For example, consider two samples from sampling day 4 during the 
traditionally non-symptomatic phase. These samples are typical of Cat with a single, specific, 
finely distinguished sensory awareness: 
4.1: [Cat is eating pasta.] She (60% of the total experience) notices the savory taste. This 
is more about the savoriness than about the taste generally. At the same time, she (40%) 
notices the chewy texture of the pasta between her top and bottom teeth [as she chews]. 
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Thus, her experience at this moment is captured by two simultaneous and related sensory 
awarenesses. 
4.4: [Cat is working on a homework assignment for her Chinese class. Chinese is not her 
native tongue; she is learning it as a foreign language. The assignment asks her to 
translate an English sentence into Chinese.] At the moment of the beep, she is innerly 
speaking in Chinese the translated sentence, and the beep interrupts her somewhere in the 
middle of the sentence. It’s a smooth process—Cat has easily translated the sentence and 
more or less fluently says it in her inner voice. 
In contrast, ovulation samples 9.3 and 9.5 were much busier:  
9.3: [Cat is exercising.] At the moment of the beep, she’s doing jumping jacks and 
experiences herself doing them. Most salient, she innerly counts the reps in her own 
voice, saying, at the moment of the beep, “…12...13...14…” Her experience is of 
speaking just as she would if speaking aloud with a normal, conversational tone and 
inflection. At the same time, she feels her heart beating in her chest. [It’s beating fast, but 
she isn’t particularly noticing the fastness at the moment of the beep—just feeling the 
heartbeat.] Also, at the same time, she feels herself breathing and notices that she’s 
breathing heavily through her nose. Thus, whereas she does not directly notice the 
quickness of her heart beep, Cat does in some sensory way notice/recognize the qualities 
of her breath—that it’s heavy and that it’s through her nose [which is not how she 
typically breathes.] This is more than merely the sensation of breathing.  
9.5: [Cat is singing along aloud to a Broadway song.] At the moment of the beep, there 
are several simultaneous and equally present strands in her experience. She is singing 
“not what I asked for” and is attending to/aware of the words [more to the words 
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themselves than to the message of the song.] At the same time, she feels vibration in her 
throat as she attempts to get the melody right—that is, this is a bodily sensation that she 
experiences as melody-related. Also, at the same time, she recognizes when to start and 
stop (an aspect of the rhythm), which is a cognitive/analytical experience. Thus, this is 
different than the bodily sensation in her throat—the rhythm experience is some sort of 
cognitive noticing/knowing when to start and stop [which is her attempt to get the rhythm 
right], whereas the throat vibration is sensory, not at all cognitive. Cat is trying to convey 
sadness in her voice. [She does not feel sad, but she experiences herself as trying to put 
sadness into her performance.] [Notice that Cat is really engaged in this “performance” 
almost as if rehearsing, even though, she said, she was just singing for fun.] 
In “simple” samples (such as the traditionally non-symptomatic day 4 samples before), Cat was 
focused singularly with one or two related phenomena clearly dominant. In contrast, in more 
“complex” samples (such as the ovulation day 9 samples before), Cat’s experience was split 
between several simultaneous phenomena that were related but highly distinct; for example, in 
9.5, her experience included words, bodily sensations, a thought process about rhythm, and the 
conveyance of emotion. Such experiences were clearly “busy” by Cat’s usual standards.  
The complexity of Cat’s ovulation-phase experiences may also have involved the 
difficulty in categorizing her physical experiences (specifically, her sometimes hyper-focus on 
seemingly mundane physical actions) which was more common during ovulation.  
Summary 
 At the time of her participation, Cat was an undergraduate university student between the 
ages of 18 and 25. Her Screening responses indicated she experienced clinically significant 
symptoms of premenstrual distress. She agreed to participate in DES sampling and ultimately did 
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so for 21 days across nine menstrual cycles, collecting a grand total of 126 experience samples. 
During that time, her menstrual cycles were regular with an average length of 29.5 days. She 
consistently provided ovulation test results, and the ovulation test proved effective, identifying 
ovulation around expected times on six occasions.   
 We observed that Cat’s experiences seemed to have been more complex around the time 
of ovulation than during other cycle phases. The exploratory ANOVA comparing caption lengths 
supported that observation: Caption lengths differed across cycle phases and, by inspection, were 
longest during ovulation. Whereas Cat’s experiences were usually simple with one or perhaps 
two straightforward and focused phenomena, Cat’s ovulation-phase experiences were more often 
busy, with multiple different phenomena present, and sometimes including an unusually specific 




Chapter 10: Across-Participant Discussion 
 The link between mind and biology is well accepted; yet, the specifics of that link, 
including how changes in biology affect directly apprehended conscious experience (“pristine 
inner experience”) are not well-known. This is perhaps because researchers primarily study inner 
experience in temporally and experientially unspecific ways, such as with retrospective self-
report questionnaires. The present study sought to rectify that by using a highly temporally and 
experientially specific, beeper-driven method to explore inner experience. 
We aimed to explore inner experience in situations where biological aspects varied 
substantially. We could, for example, have administered psychoactive drugs and observed inner 
experience both before and after such administration. That would have had the advantage of 
knowing precisely what biological change had occurred but would have had the disadvantage of 
our administration of a foreign, unnatural agent. We could have starved participants and 
investigated inner experience before and during such privation. Beyond the ethical issues, we 
would have been investigating an unusual, unnatural biological condition. Instead of such 
unnatural manipulations, we chose to explore the potential inner experiential changes of women 
as they underwent the natural biological cycles of menstruation. We focused on menstruation 
because menstrual-cycle-related changes in biology (especially, in ovarian hormones) are 
thought to cause experiential changes (i.e., premenstrual distress) in some women.  
We identified women who were generally healthy and who, by self-report screening, 
endorsed clinically significant levels of premenstrual distress. We engaged five of those women 
in approximately 20 days each of Descriptive Experience Sampling (DES) distributed across the 
phases of their menstrual cycles, thereby allowing for experiential differences (if any) to emerge 
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Figure 7 (reproduced) 




Because we wanted to sample experience within different phases of the menstrual cycle, 
we needed to track participants’ positions within their menstrual cycles and did so using a daily 
at-home ovulation microscope test. The test detected a “ferning” pattern in dried saliva that has 
been shown to be indicative of ovulation. We aimed to sample more frequently in cycle phases 
associated with pronounced changes in hormone activity—specifically, the estrogen peak at 
ovulation and the progesterone rise and withdrawal in the late luteal/premenstrual phase. On 
occasion, the ovulation test helped us to do so: If the test detected ovulation and the participant 
was willing, we scheduled an additional immediate DES sampling day to capture experiences in 
the very brief (1-2 day) ovulation phase. However, sampling days were actually predominantly 
(an estimated 90% of the time) selected based on schedule availability, thereby keeping me blind 
to cycle phase throughout most sampling. Then, when a participant was nearing the end of her 
participation, I reviewed her sampling days to determine whether additional sampling was 
needed in any particular phase. For two participants, we agreed to sample once or twice more 
during a particular phase or phases and waited until cycle tracking data suggested that the 
identified phase was occurring; however, for most, it seemed we had captured an adequate 
number of experiences within each cycle phase by convenience-scheduling alone.  
Thus, for all DES sampling, description, review, captioning and coding of experiences 
samples, I was largely (and RTH, entirely) blind to the associated menstrual-cycle phase. Only 
then did we separate sampling days by menstrual cycle phase so we could explore differences, if 
any, in inner experience across phases. Sampling days were separated into one of three cycle 





Table 5 (reproduced) 
Menstrual Cycle Phase Classifications  
Phase Classification Part(s) of Typical Menstrual Cycle Biological (Hormonal) Associations 
“Traditionally Non-
Symptomatic”  
Follicular (beginning of cycle to 
ovulation) and Early Luteal (immediately 
post-ovulation to late luteal) phases; 
theoretically days 1-13 or 14; and 15 or 
16-21 
Estrogen and progesterone 
remain relatively stable; 
fluctuations, if any, are minor 
and gradual 
“Ovulation” Theoretical midpoint of cycle; 
theoretically 1-2 days surrounding day 14 
Rapid spike in estrogen 
“Late 
Luteal/Premenstrual”  
Final 7-10 days of cycle, generally 
considered days 21+ 
Withdrawal of progesterone 
 
 
Phase classifications were determined by considering the ovulation ferning test result on 
that day, the pattern in ovulation test results around that day, day within the cycle, and length of 
the cycle. Sometimes, those considerations made phase classification easy: For example, if a 
participant was midway through a cycle and the ovulation test clearly showed ferning (both 
indicators of ovulation), we could confidently identify the ovulation phase. Other times those 
considerations were not easy: For example, if a participant failed to provide the ovulation test 
result on that day or if the ovulation test had proven ineffective for her (e.g., no or excessive 
“positive” results). This was often the case for two of our participants (Allison and Lee) and, 
because of unavailable of unhelpful data, their phase classifications sometimes had to be made 
quite crudely, based on the cycle day and length of cycle alone, for example.  
We explored possible differences in inner experience across phases first 
phenomenologically and then using exploratory quantitative analyses. We knew we wanted to 
assess differences or changes in experience across the menstrual cycle, but the specifics of that 
assessment were not planned. Instead, the analyses developed organically while trying to make 
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sense of the first participant, Candy’s, inner experience across cycle phase. To observe 
phenomenological differences in experience across cycle phase, we needed to reconsider all 
samples separated by cycle phase. However, we could not visualize and/or recall each 
participant’s 100 or more experiences simultaneously, so, instead, we relied on the much-briefer 
sample “captions” which, recall, were attempts to convey in a few words the salient phenomena 
and other relevant characteristics present in each experience. Captions are a routine aspect of 
DES characterizations and serve as signposts that point back to and reawaken investigators to the 
experiences themselves. For each participant, we created a table that displayed their sample 
captions “binned” by cycle phase. For the first participant, Candy, we observed that ovulation-
phase captions seemed much longer especially by comparison to her late luteal/premenstrual-
phase captions. Our attempt to quantitatively test that observation with Candy became standard 
procedure for all participants: We conducted an exploratory single-factor ANOVA comparing 
caption lengths across cycle phases. Because this analysis was exploratory, a “significant” 
statistic indicated only that differences were relatively large. Finally, we conducted chi-squared 
analyses to test whether the frequencies of individual phenomena differed across cycle phases. 
As with the ANOVA, those chi-squared analyses were exploratory and did not adjust for 
multiple tests, therefore, “significant” implied only that the differences were relatively large. 
Though our primary interest was in within-person cycle-related fluctuations in 
experience, we are able to make across-person observations about experience in general (given 
that we collected, on average, more than 100 samples of experience for each of our five 
participants). Table 12 below compares the frequencies (across all samples, ignoring menstrual 





















First, note that, as DES studies consistently find, differences between participants were 
much greater than differences within participants across cycle phases. There were some 
commonalities between participants, however. For example, sensory awareness was frequent in 
our sample (occurring between 19% and 55% of the time). That is more frequent than might be 
expected from our previous DES research (e.g., Heavey & Hurlburt, 2008), although we should 
be reluctant to make too much of this given the limitations of our small sample. Furthermore, 
visual sensory awareness was not especially frequent in our sample, though it is the most 
common form of sensory awareness found in other DES studies. Inner speaking was also 
 Candy Lane Allison Lee Cat 
N Sampling Days  20 16 19 21 22 
N Samples 112 88 96 117 126 
Frequencies (%) 
Inner speaking (IS) 27.2 34.1 1.0 25.2 32.5 
Inner seeing 8.0 8.5 0.5 28.8 3.2 
Unsymbolized thinking 1.3 35.8 3.1 19.4 4.4 
Feeling 9.8 15.3 24.5 21.2 6.0 
Sensory awareness (SA) 19.2 52.3 51.6 25.2 55.6 
Bodily feelings 9.8 5.7 5.7 9.0 4.0 
Mental feelings 0.9 2.3 15.6 1.8 2.0 
Bodily SA 6.3 39.8 32.3 6.8 12.3 
Tactile SA 0.0 15.9 10.4 2.7 23.8 
Visual SA 11.2 3.4 7.3 15.8 16.3 
IS while reading/writing 6.7 5.7 0.0 5.4 17.5 
Nothing 17.0 0.0 10.4 1.8 0.0 
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frequent for four of our five participants (occurring between 25 and 34% of the time), though the 
fifth participant (Allison) almost never engaged in inner speaking (1% of her samples).  
Cycle-related Findings  
Turning to the study’s main finding, inner experience did, indeed, fluctuate across the 
menstrual cycle for each of our five participants. This is quite remarkable given that our timing 
delineations of cycle phase were sometimes crude. It suggests that, at least among these women, 
the experiential changes were substantial, perhaps even more pronounced in reality than could be 
grasped by our method. It was also quite remarkable that we were able to quantitatively 
“confirm” differences in experience across phases by analyzing sample captions. Recall that 
sample captions are a routine step in DES characterizations and that we had not intended or 
suspected to consider captions in our analysis given that they are but an imperfect “snapshot” of 
the experiences themselves. Thus, the fact that differences were apparent even in the captions 
suggests that those fluctuations in experience may be quite robust. For some participants (e.g., 
Candy, Lane, Cat), a “significant” ANOVA comparing caption lengths seemed to suggest 
variation in experiential complexity such that longer captions signified messier or more complex 
experience and shorter captions signified clear and straightforward experience. However, a 
“significant” ANOVA did not only point to complexity (e.g., Allison’s ANOVA was significant 
but there did not seem to be differences in experiential clarity/complexity across her cycle 
phases) or, even if it did, the nature of clarity/complexity differences varied by participant. For 
example, both Candy and Lane’s ANOVAs were significant but, whereas Candy’s “complexity” 
referred to a lack of clear figure-ground, Lane’s “complexity” involved inchoately or hintily 
formed phenomena.  
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Perhaps surprisingly, our participants’ experiential fluctuations were not primarily 
centered on differences in the frequency of particular “content” (e.g., it was not the case that we 
found, for example, imagery was more frequent during ovulation). Instead, fluctuations usually 
involved the experiential “process” (as is consistent with what Hurlburt (1993) found among 
mood-cycling patients). For example, several of our participants exhibited a continuum of 
complexity and/or clarity in experience. For Candy, experiences in the ovulation phase were 
more often unclear with not-fully-figural phenomena, whereas during other cycle phases, her 
experiences were generally clear and straightforward with one (or maybe two) phenomena. For 
Cat, by contrast, ovulation-phase experiences were more often “busy” with multiple 
simultaneous phenomena and sometimes an unusually specific focus on her physical actions, 
whereas those characteristics were less common during other cycle phases. Lane’s experience 
around the time of ovulation also differed from other phases, but the direction was different from 
that of Candy and Cat: Lane’s experiences during ovulation were more clear and more 
straightforward than during other cycle phases, especially the late luteal/premenstrual phase.  
Those observations point to the second main finding: Ovulation seemed to be the time of 
most experiential difference. This finding should be considered only suggestive and requires 
further examination. Our exploratory quantitative analyses showed that there were differences 
across phases; they could not show which phase was the most different. However, as we have 
just seen, experiences during ovulation seemed phenomenologically (and with support from 
quantitative analyses) to differ in clarity/complexity from experiences in the other two phases for 
Candy, Lane, and Cat. Experiences during ovulation were prominent in other ways for the 
remaining two participants. Though Allison’s experiences did not differ across phases with 
respect to clarity, they did differ specifically with respect to sensory awareness. By comparison 
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to the other cycle phases, Allison’s ovulation-phase sensory experiences were more frequently 
focused on her face and more likely to “grab” her attention beyond what is typical of sensory 
awareness. Lee was perhaps the exception to this importance-of-ovulation characteristic. Lee’s 
experiences were sometimes highly unusual by DES standards (e.g., feelings experienced in 
color or bizarre imaginary sensations), and the frequency of those unusual experiences did 
fluctuate across her cycle, occurring most often in the late luteal/premenstrual phase (20.5% of 
those samples) whereas not at all during ovulation (0.0%). We could, therefore, have concluded 
that Lee’s experience differed most (was most unusual) in the late luteal/premenstrual phase; 
however, given that she had a small number of highly unusual experiences in the traditionally 
non-symptomatic phase as well (8.3% of those samples), perhaps it would have made more sense 
to conclude that her experience differed the most during ovulation (it was the least unusual, most 
normal). The choice between those seemed fairly arbitrary, and neither option changed the 
primary finding: Her experience differed in a fairly remarkable way across the menstrual cycle.  
Other (non-cycle-related) Findings 
 Finally, Lane’s participation demonstrated that experience fluctuated not only across the 
biological process of menstruation (as we have seen above) but also in response to the biological 
changes caused by medication. Partway through her participation, Lane was diagnosed with 
ADHD and Bipolar Disorder and began taking psychotropic medications. Her characterization 
therefore included a secondary analysis comparing her experience with medication (sampling 
days 13-16; 22 samples) to those without medication (sampling days 1-12, 66 samples). Recall 
that without medication, Lane’s experiences during non-ovulation phases (especially the late 
luteal/premenstrual phase) were complex and disorganized by comparison to ovulation, which 
was much clearer and simpler. Now we observed that Lane’s with-medication experiences were 
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even more complex and disorganized than her without-medication samples had been (including 
by comparison to her late luteal/premenstrual samples). For example, Lane’s experience while on 
medication frequently contained multiple disjointed phenomena (45.5% of with-medication 
samples compared to only 23.5% of all without-medication samples and 45.5% of late 
luteal/premenstrual without-medication samples). Moreover, those phenomena were often 
inchoate and poorly differentiated (63.6% of with-medication samples compared to 40.2% of all 
without-medication samples and 50.0% of late luteal/premenstrual without-medication samples). 
Traditionally clear and straightforward phenomena like inner speaking and inner seeing were less 
common after Lane began taking medications. Instead, her with-medication samples were 
dominated by sensory awareness (84.1% of with-medication samples compared to 41.7% of all 
without-medication samples). And Lane’s with-medication samples were less straightforward 
(more unusual) than her without-medication samples, including with imaginary sensations 
(13.6% of with-medication samples), an experience that never occurred in her without-
medication samples. 
Significance 
Recall that our use of the Descriptive Experience Sampling (DES) method was intended 
to be an improvement upon the more-typical methods of retrospective questionnaire and clinical 
interview, which are temporally and experientially nonspecific. DES, in contrast, is highly 
experientially and temporally specific, focused in a principled manner on apprehending pristine 
inner experience (that which is directly present in the “footlights of consciousness” at a precise 
moment in time). Diagnostic criteria and clinical descriptions often refer to pristine inner 
experiences (e.g., the notion that women with PMDD frequently feel irritable), yet pristine inner 
experiences are rarely researched with the care required. Perhaps not surprisingly, then, our 
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participants’ pristine inner experiences as apprehended by DES did not mirror the diagnostic 
expectations for premenstrual disorders. Though all participants reported prior to DES sampling 
that they experienced distressing premenstrual symptoms (such as irritable mood, bloating, 
cramping, food cravings, trouble sleeping, and so on), we saw very few examples of such classic 
premenstrual symptoms among their DES samples. This highlights that different methods 
capture different things. Experientially and temporally nonspecific methods, such as clinical 
interviews or self-report questionnaires, cannot possibly capture the symptoms they do not 
inquire about—those that are pre-defined by theory or observation—and are notoriously 
susceptible to the influence of biases and heuristics. In contrast, experientially and temporally 
specific methods like DES capture pristine inner experiences “in the wild” that have been 
perhaps elusive, overlooked, or misunderstood (such as Lane’s almost-visual experiences around 
ovulation or Lee’s unusual imaginary sensations in the late luteal/premenstrual phase). 
These results highlight another fundamentally important aspect of the DES method—its 
idiographic nature. All of our participants showed difference across phases, but because those 
differences were in different directions for several participants, group means would have shown 
no difference across phases. For example, Lane’s more-complex ovulation-phase experiences 
would have “cancelled out” Candy’s less-clear ovulation-phase experiences. Most of 
psychological science relies on group means. It is well known but largely overlooked that a 
difference between group means does not at all imply that every individual, or even that the 
average individual, behaves in the same way as the group mean. The DES idiographic approach 
demonstrates the not-so-well-known fact that the group mean does not necessarily behave in the 
same way as any individual. 
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We make two final observations. First, we did not find, as the premenstrual distress 
literature would suggest, that experience differed most notably in the late luteal/premenstrual 
phase—if anything, across participants, experiences were most unusual during the ovulation 
phase. That finding is not surprising from a basic biological perspective: The rise and fall of 
estrogen around ovulation is as rapid, if not more rapid, than the progesterone rise and fall of the 
late luteal/premenstrual phase. It makes sense, therefore, to assume that, if the rate of change of 
hormone levels affects inner experience, ovulation would be a time of impact. If and how our 
participants’ ovulation-phase fluctuations in experience relate to premenstrual distress remains to 
be determined. Only a minority of women report that their PMS-like symptoms begin around 
ovulation (and Lane was the only of our participants anecdotally to mention ovulation symptoms 
prior to her sampling). Is that evidence that experiential changes around ovulation are not 
noticeable? Or, if noticed, not perceived as distressing? Or is it merely an artifact of the typical 
assessment methods? Perhaps the changes associated with ovulation are difficult to “catch” or 
describe and therefore require an iterative method like DES. In addition, recall Bosman and 
colleagues’ (2016) review of premenstrual symptom questionnaires: They found that most 
studies analyzed daily reports only for the late luteal/premenstrual phase, completely 
disregarding other times in the cycle including ovulation. Perhaps ovulation-phase changes are 
not actually absent but merely overlooked.   
Second, the observation that our participants’ experience often fluctuated in terms of 
clarity and complexity is significant for the intersection of biological and psychological research. 
The possibility that biological agents and natural fluctuations can clarify or obscure inner 
experience is not unheard of. For example, decreases in the level of blood sugar lead to fogginess 
and disorientation, and one of the DSM-5 criteria for PMDD is difficulty concentrating. Yet, to 
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our knowledge, no other study has demonstrated in the level of detail of the present study what 
are the characteristics of the disorganization/organization of directly apprehended conscious 
experience, and certainly no existing diagnostic criteria or assessment instruments inquire about 
such experientially specific symptoms as “messy” or “multiple” experience. Note also that our 
study (using DES) did not inquire specifically about “messy” or “multiple” experience either; we 
inquired about inner experience and then discovered messiness and multiplicity. As another 
example, psychiatric patients often describe feeling “cognitively sluggish” or “like a zombie” 
while taking psychotropic medications. Lane’s sampling would suggest that perhaps the 
experiential correlate of that “zombie”-ness is a more chaotic and less clearly figural world. Of 
course, hers is only a single case study with many uncontrolled factors and additional research 
into the experiential effects of medication are sorely needed.  
Limitations and Future Directions  
 The present study was exploratory in the truest sense of the word—a traveling into 
unfamiliar territory (in this case, each participant’s private inner experience) with the goal of 
learning about and sensitizing ourselves to the landscape. This study demonstrates that long-
duration DES studies of inner experience are possible (even though they are labor and skill 
intensive). It demonstrates the potential importance of studies that investigate phenomena in high 
fidelity: For example, there is nothing in the premenstrual-distress literature that suggests that 
among women who report premenstrual distress, some have inner experience that is clearer 
around ovulation, whereas others have inner experience that is less clear. However, this was a 
small study with substantial methodological limitations. It calls therefore for next steps—
continued exploration but also mapping and excavation. And those next steps should improve 
upon our initial exploration in several ways. Of course, our sample size was extremely small, and 
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similar or improved versions of this procedure should be carried out with more women. 
However, we do note that the present sample size is consistent with recommendations for 
idiographic qualitative research [Robinson (2014) suggests 3-16 participants for such studies]. In 
addition, our method for detecting ovulation was not effective for all participants; future studies 
should consider using more accurate (and likely, more invasive or time-consuming) methods to 
ensure that cycle phases are correctly classified. Moreover, though we tentatively assumed 
relative hormone levels (e.g., low progesterone in late luteal/premenstrual), we did not directly 
measure hormone levels. Future studies should consider doing so, such as through blood tests. 
And, whereas we were able to say only that experience differed across phases, future studies 
should employ analyses (e.g., time-series) that might be able to “pin down” exactly which day 
and/or phase marks the time of most change. Finally, while we chose to focus on women who 
reported significant premenstrual distress, future studies might consider doing just the opposite. 
Perhaps inner experience fluctuates with the menstrual cycle as much as or even more in women 
who do not notice or report premenstrual symptoms. Above all, we hope that psychological 
science will come to share the values that uphold this study—basic scientific description, 
engaging with participants as individuals, and attempting despite the intensity of the work 





Health & Eligibility Questionnaire 
Please note that these questions are personal because we will ask about your health and your 
menstrual cycle.  You are given the option to respond with Prefer Not to Say; however, selecting 
that response option may mean that we are unable to determine your eligibility for the study. 
Any information you provide will be kept confidential as outlined in the consent form.   
 
What is your gender? 
 Male     
 Female     
 Prefer Not to Say     
 
Have you been on birth control pills or depo-provera or any other type of hormonal 
contraception in the last 3 months? 
 Yes     
 No     
 Prefer Not to Say     
 
What is the brand of pills or contraception you are using?  
Note: Please write "Prefer Not to Say" if you do not want to answer. Please write "N/A" if this 





Have you ever tried the pill Yasmin?  
 Yes     
 No     
 Prefer Not to Say     
 
Generally, what effects did you experience from taking Yasmin? 
 Good effects - improvements in symptoms     
 Bad effects - worsening of symptoms     
 No noticeable changes in symptoms     
 Don't remember or Prefer Not to Say    
 
Do you have regular menstrual cycles? We define regular menstrual cycles as having a period 
about every 22-32 days for the past 6 months. 
 Yes     
 No     
 Prefer Not to Say     
 
Please describe how you consider your menstrual cycles to be irregular.  





Have you skipped any periods in the past year? 
 Yes     
 No     
 Prefer Not to Say     
 
How many skipped periods occurred consecutively? 
Note: Please write "Prefer Not to Say" if you do not want to answer. 
________________________________________________________________ 
 
What was the date of your most recent period? By "date," we mean the first day of menstrual 
bleeding. If you are not sure, please guess to the best of your ability. 
________________________________________________________________ 
 
What was the date of your second most recent period? By "date," we mean the first day of 
menstrual bleeding. If you are not sure, please guess to the best of your ability. 
________________________________________________________________ 
 
Have you been pregnant within the last year? 
 Yes     
 No     




Have you breastfed within the last 6 months? 
 Yes     
 No     
 Prefer Not to Say     
 
Do you currently suffer from anorexia nervosa? 
 Yes     
 No     
 Prefer Not to Say     
 
Have you ever been diagnosed or treated for anorexia nervosa? 
 Yes     
 No     
 Prefer Not to Say     
 
When (roughly how many months/years ago) were you diagnosed and/or treated for anorexia 
nervosa?  





Do you have any medical diseases or illnesses, such as diabetes, gestational diabetes, thyroid 
disorder, metabolic disorder, asthma, or any other chronic medical or genetic condition?  
 Yes     
 No     
 Prefer Not to Say     
 
Which conditions? 
Note: Please write "Prefer Not to Say" if you do not want to answer. 
________________________________________________________________ 
 
How often do you have a drink containing alcohol? 
 Never     
 Monthly or less     
 Two to four times a month     
 Two to three times a week    
 Four or more times a week   




How many drinks containing alcohol do you have on a typical day when you are drinking?  
Note: A standard drink would be 1 beer (12 oz.), 1 glass of wine (5 oz.), 1 shot of liquor. 
 1 or 2     
 3 or 4     
 5 or 6     
 7 to 9    
 10 or more   
 Prefer Not to Say   
 
Are you currently taking any sort of steroid medication? Steroid medication can be taken in pill 
form or as an injection and can be used to treat several things like asthma, arthritis or 
inflammation. 
 Yes     
 No     
 Prefer Not to Say     
 
Please record the steroid medications and dosages. 





Are you currently taking any antibiotic medications (e.g., to treat acne)? 
 Yes     
 No     
 Prefer Not to Say     
 
Please record the antibiotics you are taking and how long you have been taking them.  
Note: Please write "Prefer Not to Say" if you do not want to answer. 
________________________________________________________________ 
 
Are you currently prescribed an antidepressant medication? 
 Yes     
 No     
 Prefer Not to Say     
 
Please record the name and dosage of the antidepressant you are currently taking.   
Note: Please write "Prefer Not to Say" if you do not want to answer. 
________________________________________________________________ 
 
Have you ever been prescribed an antidepressant medication? 
 Yes     
 No     




Please record the name of the antidepressant you were prescribed and roughly when (how many 
months/years ago) you were prescribed it.  
Note: Please write "Prefer Not to Say" if you do not want to answer. Please write "N/A" if you 




Do you regularly work a 2nd or 3rd shift (3-11 PM or midnight to 8 AM)? 
 Yes     
 No     
 Prefer Not to Say     
 





What is your ethnicity? 
 Asian/Pacific Islander     
 Black or African American     
 Hispanic or Latino     
 Native American/Alaska Native    
 White or Caucasian   
 Other   
 Prefer Not to Say   
 
What is the highest level of education you have received? 
 Some high school     
 Graduate high school     
 GED or Adjusted high school diploma     
 Some college    
 Associate's (two-year) college degree   
 Bachelor's (four-year) college degree   
 Some graduate school   
 Master's degree   
 Doctorate degree   




What is your current employment status? 
 Unemployed     
 Part-time (20 hours or less per week)     
 Full-time (approximately 40 hours or more per week)     
 Prefer Not to Say    
 
What is your first name? ________________________________________________________ 
 
What is the best phone number to reach you at? _____________________________________ 
 
What is the best e-mail address to reach you at? _____________________________________ 
 





DSM-5 PMDD Symptom Checklist 
In the majority of your menstrual cycles, do you experience the following symptoms 
(a) during the final week before menses (bleeding)  
(b) that improve during menses  
(c) and are mostly absent in the weeks after menses: 
*Check yes only if (a), (b), and (c) are all true for that symptom.  
 
1. Mood instability: mood swings, feeling suddenly sad or tearful, or increased sensitivity to 
rejection 
2. Irritability or anger or increased conflicts with others 
3. Depressed mood, feelings of hopelessness, or self-deprecating thoughts 
4. Anxiety, tension, and/or feelings of being keyed up or on edge 
5. Decreased interest in usual activities (e.g., work, school, friends, hobbies) 
6. Difficulty concentrating 
7. Lack of energy, easily fatigued, lethargy 
8. Change in appetite: overeating or specific food cravings 
9. Sleeping significantly more or less than usual 
10. A sense of being overwhelmed or out of control 
11. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, bloating, 





How seriously do these symptoms interfere with your: 
1. Work    Not at all  Mildly Moderately Severely N/A   
2. School    Not at all  Mildly Moderately Severely N/A 
3. Social activities  Not at all  Mildly Moderately Severely N/A 
4. Relationships with others Not at all  Mildly Moderately Severely N/A 
5. Daily activities of living  Not at all  Mildly Moderately Severely N/A 
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2021    Doctor of Philosophy in Clinical Psychology 
    University of Nevada, Las Vegas (APA-Accredited) GPA: 4.00 
Advisor: Russell T. Hurlburt, Ph.D.   
Dissertation: Is Pristine Inner Experience Linked to Biology? 
 
2019    Master of Arts in Clinical Psychology  
University of Nevada, Las Vegas (APA-Accredited) GPA: 4.00 
Advisor: Russell T. Hurlburt, Ph.D.   
Thesis: Exploring the Pristine Inner Experience of 
Individuals in Psychotherapy 
 
2015    Bachelor of Science in Psychology 
    Bachelor of Arts in Honors 
    University of North Dakota    GPA: 4.00 
Advisor: Andre Kehn, Ph.D. 
Honors Thesis: The Child Credibility Assessment Scale: Validity 
and Credibility in Child Sexual and Non-Sexual Abuse Cases 
 
 
SCHOLARSHIPS, GRANTS, HONORS, AWARDS 
 
2018-2019   UNLV Graduate College Summer Doctoral Fellowship ($7,000) 
UNLV GPSA Research Grant ($480) 
American Group Psychotherapy Assoc. Foundation Scholarship ($209) 
 
2017-2018   UNLV’S The PRACTICE Clinic Charles Schwab Scholarship ($3,077) 
    UNLV Graduate College Summer Access Grant ($2,000) 
UNLV GPSA Research Travel Grant ($550) 
     
2016-2017 UNLV Graduate College Summer Doctoral Fellowship ($7,000)  
 UNLV GPSA Research Travel Grant ($500) 
 
2012-2015 North Dakota Academic & Burgum Presidential Scholarship ($34,000) 
UND Department of Psychology Undergraduate Travel Award ($250)  
 UND Dept. of Psychology Outstanding Undergraduate Student ($250)  
 UND Dept. of Psychology Outstanding Undergraduate Student ($250)  
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Fargo VA Healthcare System (APA-Accredited) 
Fargo, ND 
August 2020 – August 2021 
Training Director: Jessica Gustin, Ph.D. 
 
Description:  The Fargo VAHCS is a Joint Commission-accredited medical/surgical center with 36 
acute care beds, a 38-bed Community Living Center, Primary Care and Specialty Clinics, 
and 10 Community Based Outpatient Clinics, serving over 34,000 veterans in North 
Dakota and northwest Minnesota. 
 




Activities: Inpatient Psychology (4-month clinical rotation on medical service units, acute inpatient 
psychiatric unit, and transitional care/nursing home unit) 
 Brief, behavioral-based counseling 
 Long-term supportive therapies  
 Weekly inpatient psychiatry group psychotherapy  
 Participation on interdisciplinary treatment teams 
Outpatient General Mental Health Services, including Trauma Team (year-long) 
 Maintain a caseload of outpatient psychotherapy clients 
 Maintain a small but consistent (1-2 veterans) caseload for evidence-
based treatment of trauma, including Prolonged Exposure and Cognitive 
Processing Therapy 
 Participation on multidisciplinary treatment team for consultation and 
staffing of trauma treatment referrals 
Primary Care Mental Health Integration (4-month clinical rotation) 
 Brief, behavioral-based counseling for health psychology concerns (e.g., 
illness anxiety, coping, chronic pain) 
 Participation on Interdisciplinary Chronic Pain Team  
 Specialized assessments in psychological fitness for organ transplant 
Psychological Assessment Services (year-long involvement) 
 Conduct psychological assessments for general mental health, 
personality, and cognitive concerns 
 Specialized assessments in decisional capacity 
   
Orientation: Integration of evidence-based interventions, in particular, Interpersonal Process, 
Dialectical Behavior Therapy, and trauma-focused treatments 
 
 
SUPERVISED PRACTICUM EXPERIENCES 
 
The Evidence Based Practice of Nevada (EBP) – Group Private Practice 
Henderson, NV 
August 2019 – May 2020 
Supervisor: Whitney Owens, Psy.D., Owner 
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Description:  The EBP is a group private practice whose mission is to address the behavioral healthcare  
crisis in Nevada by 1) providing state-of-the-art, evidence-based behavioral healthcare 
for children, adolescents, adults, and families and 2) providing state-of-the-art training in 
empirically supported behavioral health practices to trainees of all levels.  
 
Emphases: Adults; couples; third-wave cognitive behavioral therapies; personality disorders 
 
Activities: Individual therapy: Maintained a caseload of 10-15 adult individual and couples therapy 
patients. 
 Radically-open DBT group therapy: Co-facilitated (with Dr. Owens) a 30-week weekly 
RO-DBT group for issues of overcontrol.  
 Program development/Outreach: Served as a mentor-coach for a yoga teacher in Rwanda, 
Africa as part of a research study examining the effectiveness of a trauma-informed 
wellbeing program. 
Consultation: Attended weekly DBT consultation group consisting of community 
professionals in psychology and social work. 
Supervision: Weekly individual supervision 
   
Orientation: Integration of evidence-based interventions, in particular, Interpersonal Process, RO-
DBT, traditional DBT, and Acceptance and Commitment Therapy (ACT) 
 
 
The PRACTICE – Community Mental Health Clinic located on UNLV Campus 
University of Nevada, Las Vegas 
August 2019 – December 2019 
Supervisor: Michelle G. Paul, Ph.D. 
 
Description:  The PRACTICE is the training clinic of the UNLV psychology department, providing 
sliding-scale individual, family, and group therapy and psychological assessment to 
children and adults in the Las Vegas metropolitan area as well as telehealth services to 
children and adolescents in rural Nevada.  
 
Populations: Adult college students referred from university Disability Resource Center and Academic 
Success Center for personality, learning, and attentional disorders 
 
Activities: Psychological assessment and testing: Completed comprehensive psychodiagnostic 
assessments; wrote integrated reports including recommendations for university 
accommodations; provided therapeutic feedback 
 
 
Southern Nevada Adult Mental Health Services (SNAMHS) – State Agency (Inpatient & Forensic) 
Las Vegas, NV 
August 2018 – August 2019 
Supervisor: Shera D. Bradley, Ph.D., Director of Forensic and Civil Psychology Services 
 
Description:  SNAMHS is a state agency that provides services for individuals with serious mental 
illness. It has two hospitals: Rawson-Neal Psychiatric Hospital provides inpatient 
services to adults who are generally admitted via involuntary admission (average length 
of stay = a few weeks). Stein Hospital is a secure forensic facility that houses patients 
who have been found incompetent to proceed with their legal cases or who have been 
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found permanently incompetent and are deemed dangerous and thus committed to the 
hospital for up to 10 years.  
 
Emphases: Forensic assessment; adult offenders; serious mental illness; personality disorders; 
substance abuse; assessment of malingering 
 
Activities: Forensic evaluation: conducted interviews and evaluations under live-supervision and 
wrote court-ordered evaluations of competency to stand trial, violence risk, and risk to re-
offend 
Brief intervention, involving primarily modified DBT skills coaching and for behavioral 
disturbances  
Long-term individual therapy utilizing DBT and ACT skills for serious mental illness 
Behavior modification: Developed, maintained, and monitored individual positive 
behavior support plans and individualized token economies 
Consultation: Responded to psychological consult requests for various needs (e.g., 
behavior plans, functional assessments, staff educations, etc.) 
Psychological assessment and testing: Conducted and wrote integrated reports for brief, 
targeted assessments aimed at clarifying questions of psychopathology, intelligence, 
memory, personality, and malingering 
Supervision: Weekly individual supervision; weekly live supervision 
 
Orientation: Integration of evidence-based treatments with an emphasis on DBT and ACT. 
 
 
The PRACTICE – Community Mental Health Clinic located on UNLV Campus 
University of Nevada, Las Vegas 
August 2017 - August 2018 
Primary Supervisor: Noelle Lefforge, Ph.D., Assistant Director of Clinical Services and Research 
 
Description:  The PRACTICE is the training clinic of the UNLV psychology department, providing 
sliding-scale individual, family, and group therapy and psychological assessment to 
children and adults in the Las Vegas metropolitan area as well as telehealth services to 
children and adolescents in rural Nevada.  
 
Emphases: Generalist; adults, children, and teens; individual and group psychotherapy for mood and 
anxiety disorders; suicidality 
 
Activities: Individual therapy: Maintained a caseload of 4-7 weekly individual patients with a broad 
range of presenting concerns. 
 Skills group therapy: Co-facilitated weekly DBT skills group composed of 8-12 members 
for one year; met individually with group members for monthly case management 
Process group therapy: Served as process observer in weekly interpersonal process group 
for 8 weeks 
Telecounseling: Provided weekly teletherapy of DBT skills for emotion regulation with a 
child patient living in rural northern Nevada; coordinated care with patient’s teacher, 
parents, and school counselor 
Psychological assessment and testing: Completed comprehensive assessments for 
concerns related to memory, ADHD, and learning disorders; wrote integrated reports and 
provided therapeutic feedback 
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Intake interviews: Completed approximately 20 adult and child therapy intakes; presented 
on intake cases in a weekly multidisciplinary case rounds meeting; provided therapeutic 
feedback of treatment recommendations to patients 
Multidisciplinary teams: Attended weekly case consultation and staff meetings with a 
team of trainees in clinical psychology, school psychology, clinical mental health 
counseling, and social work 
Supervision: Weekly individual supervision, weekly didactic group supervision of group 
therapy  
 
Orientation: Integration of evidence-based interventions, in particular Interpersonal Process Therapy, 
Short-term Psychodynamic Therapy, and Dialectical Behavioral Therapy.  
 
SPECIALIZED CLINICAL TRAINING 
 
August 2020 –   Process Oriented Training Group for Therapists 
Present  Bi-monthly online training meeting for therapists  
   Nate Page, PhD, LP, CGP (Group Therapy Central) 
 
October 2019  DBT Part II: Skills, Skill Training, and Skill Coaching 
   3-day training sponsored by Nevada Psychological Association 
   Armida Fruzzetti, Ph.D. 
 
September 2019 DBT Part I: Theory, Structure, Targets, and Treatment Strategies 
   3-day training sponsored by Nevada Psychological Association 
   Alan E. Fruzzetti, Ph.D. 
 
April 2019  ACT II: Clinical Skills Building Intensive 
   2-day training sponsored by Nevada Psychological Association 
   Steven Hayes, Ph.D. 
 
March 2019  Interprofessional Education and Practice Workshop 
   1-day training sponsored by University of Nevada, Las Vegas IPEP 
 
February 2019  Experiential Institute: Process Group Training 
2-day experiential workshop at American Group Psychotherapy Association 
Annual Conference  
Facilitated by Barbara Finn, Ph.D., CGP, FAGPA 
 
February 2019  Sex Trafficking Identification and Treatment 
½ day training offered through Northern & Southern Nevada Adult Mental 
Health Services 
Shera D. Bradley, Ph.D. 
 
November 2018 Assessment of Competency Certification Training 
1-day training offered through Northern & Southern Nevada Adult Mental Health 
Services 
Shera D. Bradley, Ph.D. 
 
October 2018  ACT I: Introduction to Acceptance and Commitment Therapy 
   2-day training sponsored by Nevada Psychological Association 
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   Steven Hayes, Ph.D. 
 
March 2018  Interprofessional Education and Practice Workshop 
   1-day training sponsored by University of Nevada, Las Vegas IPEP 
 
Fall 2017  Seminar on Integrated Health in Primary Care Settings 
   Semester-course offered at University of Nevada, Las Vegas 
   Sarah Hunt, Ph.D., & Michelle Paul, Ph.D. 
 
September 2017 Doing Business as a Psychologist 
   1-day training offered through Nevada Psychological Association 
   Larry Waldman, Ph.D., ABP 
 
May 2017  Workshop on Linear Regression Using R 
   1-week workshop offered through UNLV Psychology Department 
   Andrew Freeman, Ph.D. 
 
April 2014  Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) 
   2-day training offered through UND Psychology Department 





Descriptive Experience Sampling Lab 
University of Nevada, Las Vegas 
2016 – present 
Role: Graduate Research Assistant 
Supervisor: Russell T. Hurlburt, Ph.D. 
 
Descriptive Experience Sampling (DES) is a method that uses a random beeper to explore inner 
experience.  
 
Activities: Training with the creator of DES in the art of DES interviewing: DES involves hour-
long, repeated interviews aimed at understanding participants’ experiences and describing them 
with fidelity. Projects have focused on exploring the inner experience of: adults in psychotherapy, 
women with premenstrual distress, women with bulimia nervosa, and combat veterans with 
PTSD.  
 
See here for more information: 
http://hurlburt.faculty.unlv.edu/lena/do_I_have_internal_monologue_sampling.html 
 
University of Nevada, Las Vegas 
Fall 2017 – Spring 2020  
Role: Graduate Research Assistant 
Supervisor: Christopher L. Heavey, Ph.D., Senior Vice Provost, UNLV  
 
Activities: Collaborating with Dr. Heavey to review research and prepare and edit chapter drafts 





University of North Dakota Department of Psychology 
Fall 2015   
Role: Undergraduate Research Assistant 
Supervisor: Dmitri Poltavski, Ph.D. 
  
Activities: Trained in use of B-Alert X10 wireless EEG apparatus and software as part of a 
research project examining the effectiveness of Nike Sparq sports vision training for youth 
hockey players.  
 
Te Rū Rangahau Māori Research Laboratory 
University of Canterbury, Christchurch, New Zealand 
Role: Visiting Research Assistant 
Summer 2015    
Supervisor: Angus Macfarlane, Ph.D. 
 
Activities: Studied Dr. Macfarlane’s methods for culturally responsive education and restorative 
justice; Attended workshops, presentations, and cultural events 
 
Addictive Behaviors & Cognitions Lab 
University of North Dakota Department of Psychology  
Spring 2015  
Role: Undergraduate Research Assistant 
Supervisor: Alison Looby, Ph.D. 
 
Activities: Delivered a motivational interviewing intervention as part of a study exploring student 
opinions regarding “study drugs”; Trained in the spirit of motivational interviewing from two 
clinical professionals; Administered questionnaires and led a detailed debriefing for a study 
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interdisciplinary practice in community mental health. May 2018 Association of Psychology 






1. Krumm, A. E. (April, 2019). Motivational interviewing: Basic techniques and how to implement them  
in our setting. One-hour workshop presented to staff at Southern Nevada Adult Mental Health 
Services. Las Vegas, NV.  
 
2. Krumm, A. E. (February, 2019). Does experience cycle with menstruation? Paper presented at the 21st  
annual UNLV Graduate and Professional Student Association Research Forum.  
 
3. Krumm, A. E., & Hurlburt, R. T. (April, 2018). Becoming a Mother: An Account from Everyday Inner  
Experience. Paper presented at the annual conference of the Western Psychological Association, 
Portland, OR. 
 
4. Haugen, A. E. (November, 2015). The child credibility assessment scale: Validity and  
predictability in child sexual and non-sexual abuse cases. Paper presented at the annual Northern 




1. Barchard, K. A., Kaneshiro, C., Krumm, A. E. (February 2020). Evaluating Validity is  
Harmful. Poster presentation at the American Association of Behavioral and Social Sciences, Las 
Vegas, NV.  
 
2. Krumm, A. E., Raymond, N. C., Reger, S. L., Hurlburt, R. T., & Heavey, C. L. (May 2019). The  
Inner Experience of 15 Veterans with PTSD Symptoms as Discovered by Descriptive Experience 





3. Fink-Armold, A., Krumm, A. E., Shope, M. M., & Barchard, K. A. (April 2019). Measuring  
perceptions of the prevalence of workplace sexual harassment. Poster presented at the annual 
conference of the Western Psychological Association, Pasadena, CA.  
 
4. Krumm, A. E., Lapping-Carr, L., Kaneshiro, C., Moynihan, S., Heavey, C. L., & Hurlburt, R. T.  
(May 2018). Subjective experience is not all the same: Private phenomena vs. inferred states. 
Poster presented at the 30th annual meeting of the Association for Psychological Science, San 
Francisco, CA.  
 
5. Kaneshiro, C., Lapping-Carr, L., Krumm, A. E., Moynihan, S., Hurlburt, R.T., & Heavey, C. L. (May  
2018). Can first-person methods reliably apprehend inner experience? Lessons from eyewitness 
testimony. Poster presented at the 30th annual meeting of the Association for Psychological 
Science, San Francisco, CA. 
 
6. Looby, A., Holt, L.J., Engle, D., Heppner, B., Haugen, A., & Ballard, A. (November 2015).  
Efficacy of a group-based motivational interviewing intervention to prevent and reduce 
nonmedical prescription stimulant use among college students. Poster presented at the 49th 
annual meeting of the Association for Behavioral and Cognitive Therapies, Chicago, IL. 
 
7. Haugen, A.E., Ingvalson, B. R., & Ferraro, F. R. (October 2015). Exploring body image and  
body satisfaction among college students with significant autistic traits. Poster presented at the 
Annual Northern Lights Psychology Conference, Grand Forks, ND. 
 
8. Haugen, A. E., Preszler, J.R., Cookman, M.L., & King, A.R. (April 2015). Sibling death and  
adult maladjustment indices: A brief report. Poster presented at the Midwestern Psychological 
Association Conference, Chicago, IL. 
 
9. Haugen, A.E., Preszler, J.R., Cookman, M.L., & King, A.R. (October 2013). Childhood  
bereavement and antisocial tendencies: A brief report. Poster presented at the Annual Northern 
Light Psychology Conference, Grand Forks, ND. 
 
10. Preszler, J.R., Haugen, A.E., Cookman, M.L., & King, A.R. (October 2013). Antisocial  
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Introduction to Statistical Measures (PSY210) 
University of Nevada, Las Vegas 
2016-2017 
Role: Graduate Teaching Assistant 
Supervisor: Russell Hurlburt, Ph.D. 
 
SERVICE & LEADERSHIP 
 
2018 - Present  Contributor/Team Member, Families in Psychology Project  
2018 - 2019 Student Member, The PRACTICE CMH Clinic Advisory Board 
2018 - 2019  Cohort Representative, UNLV Clinical Psychology Student Committee 
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2016 - 2018  Mentor, UNLV Outreach Undergraduate Mentorship Program  
2013 - 2016 Youth Mentor, Grand Forks, ND YMCA Little Brother/Little Sister Program  
2014 - 2015  Volunteer Assistant, Prevent Child Abuse North Dakota  




American Psychological Association (APA), Graduate Student Member (2016-present) 
Nevada Psychological Association (NPA), Student Member (2017-2020) 
American Group Psychotherapy Association, Student Member (2018-present) 
APA Div 29 Society for the Advancement of Psychotherapy, Student Member (2019-present) 
APA Div 24 Society for Theoretical and Philosophical Psychology, Student Reviewer (2017-present) 
 Supervising Reviewer: Dr. Samuel D. Downs, University of South Carolina Salkehatchie 
Association for Psychological Science (APS), Student Affiliate (2016-2018) 
 
RELEVANT WORK EXPERIENCE 
 
Special Events Coordinator 
Global Friends Coalition, Grand Forks, ND 
2016 – 2018 
Supervisor: Cynthia Shabb, Ph.D., Executive Director 
 
Description: Global Friends is a 501 (c) 3 non-profit organization based in Grand Forks, ND. Global 
Friends’ mission is to aid in refugee integration by providing mentorship and educational 
services to refugees and the greater community. The refugees served are primarily from 
Nepal/Bhutan, Somalia, and the Democratic Republic of Congo.  
 
Activities: Consultation regarding grant writing, program design, program evaluation, 
recruitment/marketing strategy 
 
Education & Outreach Coordinator 
Global Friends Coalition, Grand Forks, ND 
2015 – 2016  
Supervisor: Cynthia Shabb, Ph.D., Executive Director   
 
Activities: Researched the educational needs of refugees in the community and designed and 
implemented educational opportunities (e.g., English language classes, healthcare 
workshops, etc.) as well as informative community outreach events; designed evaluation 
measures for classes and events  
 
 
 
 
 
